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"And when your sorrow is comforted ( time soothes all sorrows) you 
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The primary aims of this study were to assess the prevalence of anticipatory nausea 
and vomiting in cancer patients who are receiving their chemotherapy in a setting where 
the new 5-HT3 receptor antagonists are being used for antiemetic therapy, and to identify 
any relationships that may exist between the development of anticipatory symptoms and 
various demographic, clinical and psychological variables. 
Twenty-five patients were followed for an average of five chemotherapy cycles, with 
24% developing anticipatory nausea and 4% developing anticipatory vomiting. The 
average severity of the anticipatory nausea was 'very mild' and there was only one 
episode of 'very mild' anticipatory vomiting. The patients who developed anticipatory 
nausea and vomiting reported significantly higher levels of state anxiety, trait anxiety, 
and depression. The difference in self-reported anxiety and depression was more distinct 
prior to the patients' first three cycles of chemotherapy. Interestingly, the relationship 
between state anxiety, trait anxiety, and the development of anticipatory nausea revealed 
that the incidence of anticipatory nausea and vomiting increased as the levels of anxiety 
and depression decreased. The anticipatory patients also displayed higher expectations 
of experiencing nausea and vomiting as a side effect of their treatment. 
The anticipatory patients were significantly younger than those who did not develop 
anticipatory symptoms. The anticipatory patients also reported more frequent and severe 
posttreatment nausea and vomiting. 
The results of this study indicate that the prevalence of anticipatory nausea and 
vomiting remains relatively high despite the introduction of 5-HT3 receptor antagonists 
as the primary antiemetic in the Christchurch Hospital Oncology Centre. However, the 
results suggest that the severity of the anticipatory nausea and vomiting has decreased 
considerably. The results also provide more support for the classical conditioning model 
of acquisition. It is proposed that it may be possible to identify patients at risk of 
developing anticipatory nausea and vomiting, with the opportunity of implementing 
proven therapeutic strategies which may decrease the incidence of anticipatory 





Cancer is a disease in which cells escape the factors, still largely unknown, that 
regulate normal cell growth. As a consequence, the cells multiply out of control -
crowding out, invading, and destroying other tissues. Cancer is often considered a group 
of diseases rather than a single disease because, with few exceptions, any one of the two 
hundred or more cell types in the human body can become malignant. The behaviour of 
the cells and the prognosis of the illness depend largely on the type of cells affected. 
PREVALENCE 
Cancer is a major disease, with high incidence and mortality rates around the world. 
Every year, more than 15 million people receive a diagnosis of cancer (Bonica, 1979). In 
1988 over 160,000 people died from cancer in the UK (Cancer Research Campaign, 
1989), and in the USA the figure was around 400,000. Worldwide one out of four or 
five people will develop some form of cancer in their lifetime (Hirayama et al., 1980). In 
New Zealand the incidence is relatively high due to our higher than average life-span, 
with about one quarter of all deaths in New Zealand being cancer related (Abdelaal, 
1992). The only cause of death which is greater than cancer in New Zealand is diseases 
of the heart, which accounts for about one third of all deaths. Lung, colorectal, breast 
and stomach cancers form the majority of cancer diagnoses. In Europe the leading cause 
of death in males is lung cancer and the leading cause of death in females is breast 
cancer (Cancer Research Campaign, 1988). The prevalence of cancer is increasing every 
year, as we start to live longer and as the our population becomes older. 
DIAGNOSIS AND ASSESSMENT 
Cancer is usually discovered in one of three ways. Firstly, the patient may have been 
screened for cancer because he or she is seen as being at risk due to their age, gender or 
a pre-existing medical condition. The second way in which cancer may be found is 
when the patient notices an unexplained change in their health, a lump, or a spot on their 
skin. Also, cancer may be discovered while the patient is being examined for an 
unrelated reason, such as a general medical checkup or during an operation. When the 
cancer is found, it may be the primary cancer (at the site of origin) or it may be a 
metastasis (a secondary cancer, relatively distant from the primary site). 
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Usually the general practitioner is the first to detect or suspect cancer; after which, 
assessment by an appropriate specialist is arranged. For example, if a man has a 
testicular lump or suspected prostate cancer he will be referred to a urologist, or a 
woman with a breast lump will most likely see a general surgeon. The specialist may 
suggest additional tests and will usually arrange for a biopsy or removal of all or part of 
the cancer. Following the biopsy, the specialist will tell the patient what was found and a 
plan for further tests and possible treatment is usually discussed. The choices for 
treatment depend on where the cancer is and on its likely behaviour. Many patients will 
also see an oncologist, who specialises in the treatment of cancer, and who has trained 
in radiation and/or chemotherapy treatment. 
TREATMENT 
Despite the connotations of imminent death which accompany the diagnosis of 
cancer, on average 46 percent of women and 35 percent of men with cancer in the UK 
are alive five years after diagnosis (Watson, 1991). At the end of the nineteenth century, 
surgical excision of a tumour was the mainstay of cancer treatment. In the 1920s and 
1930s the advent of radiotherapy greatly increased the options available and more 
recently the use of chemotherapy has also become a treatment option for many cancers . 
Sometimes, major surgery is advised in the hope of removing the cancer entirely. 
This is usually done after it is confirmed that the removal is technically possible and that 
there is no evidence of metastases. Other times, a smaller operation is performed, with 
the hope of removing a majority of the cancer. However, in some cases surgery is not 
possible or the cancer is so advanced that it offers no advantage with respect to cure, 
length of survival, or general well-being. Some surgical operations are delayed until the 
cancer has been reduced in size by either radiotherapy or chemotherapy, so that a 
smaller, less mutilating operation is possible with a high chance of cure. For other 
cancers complete surgical removal is not necessary for a cure and the disease is 
controlled by chemotherapy or radiotherapy. 
In New Zealand, about 70% of all patients with cancer have surgery performed on 
them and in 60% surgery is the sole method of treatment. Radiotherapy is used in about 
25% of all patients and chemotherapy in about 15% of all patients receiving cancer 
treatment, with around half of these receiving radiotherapy or chemotherapy as the sole 
method of treatment (Abdelaal, 1992). 
SUMMARY 
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A diagnosis of cancer is no longer a death sentence, as the public perception of 
cancer would have us believe. There are effective treatments available for many forms 
of this very common disease. With prompt treatment using surgery, radiotherapy, and/or 
chemotherapy, it is now possible to cure some cancers, provide an extended life-
expectancy for others, and improve the quality of life for many more patients. 
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Chemotherapy 
Chemotherapy is the treatment of cancer with drugs which destroy cancer cells. 
Cancer chemotherapy was first developed after it was noticed that soldiers who had 
been exposed to mustard gas died soon after from a complete lack of bone marrow. 
Consequently, it was discovered that the mustard gas affected rapidly dividing cells. So, 
as cancer cells are rapidly dividing by nature there was a concentration of interest in 
trying to modify the mustard gas into a form which could be given to cancer patients. 
From this came the development of the Nitrogen Mustards, including Mustine which is 
still in use today. 
Chemotherapy has an advantage over other treatment modalities in that it is systemic; 
and since the drugs circulate through the whole body, the anatomical site of the tumour 
is less important. Chemotherapy is therefore one of the principal treatments for the 
relatively small population of diseases which are always disseminated (leukemia for 
example), usually disseminated (for example, many lymphomas), usually disseminated 
by the time they are diagnosed (for example, small cell lung cancer), or which are 
disseminated by the time they are diagnosed. 
Specific diseases which may be definitively treated by chemotherapy, using 
chemotherapy as the sole treatment modality, are: Hodgkin's disease, non-Hodgkin's 
lymphoma, acute lymphatic leukaemia, acute myeloid leukaemia, hairy cell leukaemia, 
testicular teratoma (including seminoma), ovarian teratoma, choriocarcinoma, and some 
childhood tumours. Types of cancer in which chemotherapy may be used as neo-
adjuvant treatment, where the chemotherapy is used to reduce the size of bulky tumours 
so that they may be removed or irradiated more easily, are: Squamous carcinomas of the 
head and neck, transitional cell carcinoma of the bladder, bulky mediastinal Hodgkin's 
disease, and some childhood tumours. Diseases in which adjuvant chemotherapy has 
been found to be useful, where the chemotherapy is given after the tumour has been 
removed in order to control distant metastases, are breast cancer and ovarian cancer. 
Diseases in which salvage chemotherapy may be needed, where the initial disease was 
treated and has relapsed, are stage I and II Hodgkin's disease and testicular seminoma. 
Diseases in which palliative chemotherapy frequently produces significant 
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improvements in survival and/or quality of life are ovarian cancer, breast cancer, and 
small cell lung cancer (Calvert & McElwain, 1988). About 10% of all patients treated 
with chemotherapy are cured, about 40% respond to the chemotherapy but are not cured, 
and the remaining 50% do not respond to their chemotherapy (Watson, 1991). 
THE PROCESS OF RECEIVING CHEMOTHERAPY 
Chemotherapeutic drugs may be given in any of several different ways, depending 
upon the dose, the preferences of the medical staff and the patient, and the type of 
cancer. The drugs may be introduced into the body: orally (PO) - pills, capsules, or 
liquids taken by mouth; intravenously (IV) - injection into a vein, either fast (IV push) 
or slow (IV drip or infusion); intramuscularly (IM) - injected into a muscle; 
subcutaneously (SC) - injected underneath the skin; intra-arterially (IA) - injected into 
an artery; intrathecally (IT) - injected into the spinal fluid; intracavitarily (IC) - injected 
into the pleural cavity of the chest or into the abdomen; or topically - applied directly to 
the skin, in the mouth, or into the vagina. Most often chemotherapy is given either orally 
or intravenously, with many protocols combining both methods. Chemotherapy is most 
often injected into veins in the lower arm or hand because they are usually the most 
accessible and convenient, although sometimes these veins are not viable and other 
areas are needed for access. For protocols which involve frequent intravenous infusions 
a 'portacath' is sometimes used, involving the placement of a permanent indwelling 
catheter into a major blood vessel. 
Most intensive chemotherapy regimens, predominantly involving intravenous 
administration, are administered on one day every three or four weeks, although some 
protocols require fortnightly administration (e.g. ABVD) or even weekly treatment (e.g. 
5-FU). Some protocols take only a few minutes to administer, such as the weekly 5-FU 
component for the treatment of colon cancer used in this study, whereas other protocols 
require three or four hours for administration, such as the fortnightly doses of 
adriamycin, bleomycin, vinblastine, and dacarbazine for the treatment of Hodgkin's 
Disease. Most chemotherapy is currently given on an outpatient basis, with inpatient 
chemotherapy reserved for the most toxic regimens (usually those containing cisplatin) 
or for those patients who are considered to be too unwell to be at home. 
MODE OF ACTION AND SIDE EFFECTS 
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The chemotherapy drugs in use today work either by chemically interfering with 
DNA replication at the early stage of cell division or by interfering with protein 
synthesis. Both modes of action impede cell division at a very basic level. Not all cancer 
cells respond to chemotherapy. This may be because only a small percentage of the 
cancer cells are actively dividing and therefore susceptible to chemotherapy. Cancers 
with a large percentage of dividing cells are usually particularly responsive to 
chemotherapy. For example, both cancer of the testes and acute leukaemias generally 
have a high proportion of actively dividing cells and both are potentially curable by 
chemotherapy, even when widespread. 
Some cancers are resistant irrespective of the proportion of dividing cells. The 
malignant cells within a cancer may differ in their ability to respond to drugs. Given 
chemotherapy, the sensitive cells will respond but the resistant cells will slowly 
proliferate and this will result in the progressing cancer being predominantly made up of 
resistant cells. 
Any rapidly dividing cell population is susceptible to the effects of chemotherapy, 
necessarily resulting in losses to normal ceJI populations. Consequently, following the 
administration of the chemotherapy there is a temporary halt in production of blood cells 
in the bone marrow, making the patients susceptible to infection, anaemia, and bruising 
more easily. The cells of the mouth and gut are also affected, resulting in mouth and gut 
ulceration in some cases. Loss of hair and retardation of nail growth are also common. 
Another major side effect of most chemotherapy regimens is nausea and vomiting, 
both acutely (immediately following administration) and in many cases delayed (defined 
as 24+ hours after administration). 
Normal cells usually recover from chemotherapy using inbuilt repair mechanisms, 
whereas cancer cells are generally more primitive and often lack this ability. Therefore, 
chemotherapy is given in repeated doses at time intervals just long enough to allow 
9 
adequate recovery of normal cells but which causes an ongoing reduction in the number 
of cancer cells. This is usually around three to four weeks and is usually judged from 
recovery of the blood cell count. 
No two people experience exactly the same side effects in response to the same drugs 
(Bruning, 1985). Some side effects for some drugs are very common, such as alopecia 
(hair loss) with adriamycin, while other side effects are quite rare. Some side effects 
may be only temporary or intermittent; or they may persist for the duration of the 
treatment, linger after the treatment as a memory, or never go away completely. They 
may be severe or slight, serious or minor, annoying or devastating. It is usually 
impossible to say exactly when side effects will occur and how long they will last. For 
example, nausea and vomiting, extreme tiredness or weakness, dizziness, diarrhoea, and 
constipation typically last a few hours to a few days and then disappear; although 
sometimes one or more of these side effects may persist for some time. 
REDUCTION OF CHEMOTHERAPY SIDE EFFECTS 
Side effects can be kept to a minimum by carefully adjusting the dose of the 
chemotherapy drugs as well as other drugs, such as antiemetics and sedatives. A lot has 
been done in the last ten years to make the side effects easier to bear, but to a certain 
degree the side effects depend upon the attitude and overall health of the patient. A 
positive attitude, full of hope and confidence, can make side effects less noticeable and 
more tolerable. Also, a strong, healthy, young body may withstand the rigours of some 
drugs better than a weakened or older one. 
Nausea and vomiting are managed using a variety of antiemetic drugs prescribed to 
suit individual requirements. The availability and use of antiemetics will be discussed in 
much greater detail in a later section. 
Wigs are often provided before hair loss occurs and normal hair growth usually 
resumes after the treatment is over. Some chemotherapy drugs do not cause hair loss. 
Psychological support may be required in circumstances where the side effects of 
treatment have been excessive. This may involve instruction in more appropriate coping 
strategies, providing emotional support, introducing the patient to other cancer patients 
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in the same situation, or the use of some of the behavioural treatments discussed in more 
detail later. 
LONG-TERM SIDE EFFECTS OF CHEMOTHERAPY 
Due to the way in which some chemotherapy agents interact with and bond to cellular 
DNA, they may lead to adverse effects months or years after treatment. 
Some drugs cause infertility and others may temporarily decrease production of ova 
and sperm, and recovery may take months or years. Some women go on to an early 
menopause. Adequate contraception is important during chemotherapy because of 
uncertainty at any given time whether the patient is fertile or not. Chemotherapy drugs 
may, but not always, have some effects on the developing foetus. Sperm banking is 
sometimes an option for young men likely to be rendered infertile by curative 
chemotherapy. 
Another problem is the development of a second, new cancer. Very intensive 
chemotherapy, particularly with certain drugs, places the patient at greater risk of 
developing a new malignancy. This risk may be slightly increased if radiation treatment 
is also given. However, the risk is still much less than the risk of recurrence of the first 
cancer, or of death had the first cancer not been successfully treated. It is especially 
important to consider this risk when planning for curative treatment. 
CHEMOTHERAPY DRUGS 
There are approximately twenty drugs commonly used in the treatment of cancers 
today, although fewer than ten are used very often. They are usually classified according 
to their chemistry and the way in which they act on cancer cells. 
Better responses are gained from the use of combinations of three or four drugs and 
where possible, drugs with different toxicities are chosen. However, drugs may exhibit 
different side effects when given in combination. 
Recently there has been a focus on the development of slightly modified forms of 
older drugs (analogues) which retain the activity of the parent drug but which have 
fewer side effects. 
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Drug Emetogenicity 
No chemotherapy drug causes nausea and vomiting in every patient it is administered 
to. In an effort to assess how emetogenic the chemotherapy protocols used on the 
patients in this study are, a 'Chemotherapy Drug Toxicity' questionnaire (Appendix 1) 
was constructed and circulated throughout the oncology department at Christchurch 
Hospital. Twelve questionnaires were completed by the medical staff, who had, on 
average, been working in oncology for more than nine years. The results of this 
questionnaire were compared to other reports on the emetogenicity of chemotherapy 
drugs. 
Table 1 shows how the medical staff of the oncology department at Christchurch 
Hospital rated the individual drugs used in the protocols of the patients in this study; 
including the perceived frequency with which the chemotherapy drugs induce nausea 
and/or vomiting and the perceived severity of the nausea and/or vomiting which they 
induce. The most emetogenic drugs are at the top of the table and the least emetogenic 
drugs are nearest the bottom. 
Cisplatin is the drug perceived to be the most emetogenic and is believed to almost 
always cause severe nausea and/or vomiting. All other reports on the emetogenicity of 
chemotherapy drugs have described the nausea and vomiting associated with cisplatin as 
severe and common (Calvert & McElwain, 1988; Cohen, 1982; Chabner & Myers, 
1989). Dacarbazine (DTIC) is believed to frequently cause severe nausea and/or 
vomiting. The nausea and vomiting associated with DTIC has previously been described 
as frequent, common, and marked (Calvert & McElwain, 1988; Cohen, 1982; Chabner 
& Myers, 1989). Adriamycin is perceived to frequently cause moderate nausea and/or 
vomiting - a view supported by other literature (Calvert & McElwain, 1988; Cohen, 
1982; Chabner & Myers, 1989). Carboplatin and Cyclophosphamide are perceived to 
cause moderate nausea and/or vomiting on about half of the occasions in which they are 
administered. This view of the emetogenicity of carboplatin is supported by Calvert and 
McElwain (1988) but is described as mild by Chabner and Myers (1989). Etoposide is 
perceived to be causing mild nausea and/or vomiting about half the time; a perception 
supported by other literature (Calvert & McElwain, 1988; Cohen, 1982; Chabner & 
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Myers, 1989). Vinblastine, 5-FU, Procarbazine, Chlorambucil, Bleomycin, Vincristine, 
and Levamisole are all perceived to rarely cause mild nausea and/or vomiting. These 
perceptions are supported by other literature in the case of vinblastine, 5-FU, 
chlorambucil, bleomycin, and vjncristine (Calvert & McElwain, 1988; Cohen, 1982; 
Chabner & Myers, 1989) but procarbazine is said to cause nausea and/or vomiting more 
often than this by Calvert and McElwain (1988) and Cohen (1982). Levamisole is not 
reported in any of the literature mentioned. Prednisone is believed to never induce any 
nausea and/or vomiting, but this drug also gets no mention in any of the literature. 
In order to estimate the emetogenicity of the drug combinations used on the patients 
in this study, two estimates were derived from the toxicity questionnaire results: one is 
calculated using the most emetogenic drug in the protocol and the other is calculated 
using the average emetogenicity of all of the drugs in the protocol. Table 2 shows the 
two expected emetogenicity estimates for each of the protocols used in this study. When 
the most emetogenic drug in the protocol is used to determine the emetogenicity of the 
entire protocol, BEP is the most emetogenic protocol; followed by ABVD; then CHOP , 
Adriamycin (single agent), and CAP; Carboplatin (single agent); Cyclophosphamide 
(single agent), CMF, and CHOP (without adriamycin); ChlVPP; and the least 
emetogenic protocol is 5-FU plus levamisole. When the emetogenicity of a protocol is 
estimated using the average of the emetogenicity ratings of all of the drugs in a protocol, 
adriamycin (single agent) is the most emetogenic, followed in order by carboplatin 
(single agent), ABVD, BEP, Cyclophosphamide (single agent), CAP, CHOP, CHOP 
with methotrexate IT, CMF, CHOP without adriamycin, ChlVPP, and the least 
emetogenic protocol is 5-FU plus levamisole. 
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Table 1. 
Individual Drug Emetogenicity 
Toxicity Questionnaire Ratings 
Frequency Severity Emetogenicity 
Cisplatin 3.7 2.9 Always, Severe 
Dacarbazine (DTIC) 3.3 2.5 Frequently, Severe 
Adriamycin 3 2.4 Frequently, Moderate 
Carboplatin 2.3 1.7 Half of the time, Moderate 
Cyclophosphamide 2 1.5 Half of the time, Moderate 
Etoposide 1.6 1.3 Half of the time, Mild 
Vinblastine 1.2 1.2 Rarely, Mild 
5-Flourouracil 1 1.1 Rarely, Mild 
Procarbazine 0.7 Rarely, Mild 
Chlorambucil 0.9 0.9 Rarely, Mild 
Methotrexate 0.9 0.9 Rarely, Mild 
Bleomycin 0.9 0.8 Rarely, Mild 
Vincristine 0.8 0.8 Rarely, Mild 
Levamisole 0.5 0.5 Rarely, Mild 
Prednisone 0.3 0.2 Never 
Table 2. 
Expected Emetogenicity of the Protocols Used in this Study 
Most Emetic Substance Average Emetogenicity 
Frequency Severity Frequency Severity 
CHOP 3 2.4 1.525 1.225 
CHOP+Methotrexate IT 3 2.4 1.4 1.16 
Adriamycin 3 2.4 3 2.4 
CMF 2 1.5 1.3 1.17 
CAP 3 2.4 1.77 1.37 
ABVD 3.3 2.5 2.1 1.725 
BEP 3.7 2.9 2.07 1.67 
Cyclophosphamide 2 1.5 2 1.5 
5-FU+Levamisole 1.1 0.75 0.8 
CHOP without Adriamycin 2 1.5 1.175 0.95 
Carhop la tin 2.3 1.7 2.3 1.7 
ChlVPP 1.2 1.2 0.85 0.75 
END POINTS: RESPONSE, REMISSION & CURE 
It is important to consider whether the benefits of treatment outweigh the 
disadvantages. Definite treatment end points or goals must be specified, such as cure or 
symptom palliation, and treatment effectiveness must be balanced against side effects. 
Cure means that the expectation or probability of survival is the same as it would 
have been had the cancer not occurred. 
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Complete remission means that all evidence of cancer in the body has disappeared 
after treatment. This does not always mean cure as a tumour has to have over one 
million cells before it is detectable. Therefore, chemotherapy should be continued after 
all detectable tumour has disappeared, to destroy the remaining cells. Complete 
remission is essential for cure. 
Partial remission means that the tumour has decreased by more than half of its 
original size, which often improves the patient's quality of life and sometimes prolongs 
it. The cancer usually grows again or relapses at a later date. 
QUALITY OR QUANTITY? 
Sometimes the side effects of chemotherapy are so severe and distressing that the 
patient needs to have their dosage reduced or may want to stop the treatment entirely. 
Aggressive chemotherapy regimens may produce side effects which lead some patients 
to think that the treatment is worse than the disease. This loss of treatment often means 
that the patient's life expectancy is shortened considerably. The choice of whether to 
endure the side effects is entirely up to the patient and often comes down to a decision 
about whether to have quality of life, with no chemotherapy, or quantity of life, with 
chemotherapy. 
Most patients are undoubtedly prepared to tolerate great discomfort in order to 
achieve a remission or cure (Slevin et al., 1989), but where no significant survival 
advantage can be observed between treatments, other aspects of the treatment become 
important to consider, such as the effects on quality of life. One of the main issues in 
cancer treatment currently, is the cost at which cancer treatment is achieved in terms of 
its effects on quality of life. 
THE GROWTH OF PSYCHOSOCIAL ONCOLOGY 
Concern for the psychological well-being of cancer patients is not new, but 
psychosocial oncology as a subspeciality of oncology is a recent arrival in the health 
arena. It has primarily grown from research aimed at understanding and alleviating the 
emotional and social impact of cancer and its treatment. Essentially, clinical practice in 
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psychosocial oncology covers the detection of psychological, psychiatric, and social 
morbidity, the diagnosis of this morbidity, and the provision of treatments designed to 
alleviate it (Watson, 1992). It is a multidisciplinary area and the skills may be practised 
by nurses, oncologists, psychologists, psychiatrists, social workers, and a wide range of 
other professional groups. 
SUMMARY 
Cancer chemotherapy has been in use for over fifty years and is now used as the 
definitive treatment for a number of previously untreatable diseases and as an adjuvant 
treatment for many other diseases. Its main advantage is its ability to treat metastases 
and its main disadvantage is its toxicity to normal cells in the body. Presently, 
chemotherapy has the ability to cure some cancers and provide remission to many 
others, but many still remain resistant to the currently available drugs. Most of the side 
effects of chemotherapy are controlled by adjusting the drug dosage and by providing 
support services to the patients when required. When considering the use of 
chemotherapy it is important to specify the treatment goals and to make sure that the 
extra duration of life gained from chemotherapy outweighs the physiological and 
psychological consequences of the treatment. Of special interest to this study is the 
nausea and vomiting associated with some chemotherapy drugs. 
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Chemotherapy-Induced Nausea and Vomiting 
Nausea and vomiting are the most distressing of all the side effects of chemotherapy 
(Boakes et al., 1993). The prevalence of posttreatment nausea and vomiting in cancer 
chemotherapy has decreased over the past fifteen years. A 1980 study by Martin-
Jimenez reported that 79% of the patients experienced some degree of vomiting after 
their first cycle of chemotherapy. Leventhal et al. ( 1986) reported that 86% of their 
sample of breast cancer patients experienced some degree of nausea and 47% 
experienced vomiting to some degree during their treatment. Lindley et al. (1989) 
reported that 50% of their outpatient chemotherapy patients experienced posttreatment 
nausea and 27% experienced posttreatment vomiting. It has been reported that over 90% 
of patients receiving high dose cisplatin experience some degree of nausea and/or 
vomiting, and that this often occurs more than 24 hours, and lasting up to 120 hours, 
after the chemotherapy has been administered (Lindley & Hirsch, 1992). 
ETIOLOGY 
The nausea and vomiting associated with cancer chemotherapy are caused by many 
different pathologies and in view of this multitude of aetiologies, it seems unlikely that 
they are governed by a common mechanism. There do, however, appear to be three 
general components which hold true. Firstly, afferent pathways relay the emetic signal to 
the central nervous system. Secondly, there is a central reception, recognition and 
processing area or areas which integrates the emetic signal. Thirdly, the efferent 
pathways coordinate the respiratory, gastrointestinal and abdominal movements which 
accompany nausea and emesis. 
AFFERENT PATHWAYS 
1) Gastrointestinal Tract 
Stimulation of vagus nerve branches supplying the stomach elicits vomiting in 
animal experiments. Chemical irritation of the gastric mucosa by nitrogen mustard or 
copper sulphate also produces vomiting. Cutting the gastric branches of the vagus nerve 
abolishes this vomiting response. In vomiting resulting from intestinal obstruction, 
.i' 
biliary colic and cardiac pain, the stimulus appears to be transmitted via sympathetic 
pathways. 
2) Chemoreceptor Trigger Zone (CTZ) 
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Borison and Wang (1953) identified an area separate from the vomiting centre, 
situated in the floor of the fourth ventricle within the area postrema. It is not part of the 
brain and has direct contact with both the cerebrospinal fluid and with circulating blood, 
thus existing outside the blood-brain barrier. Very little is known about the 
chemoreceptor trigger zone. This area is known to be sensitive to apomorphine; and 
ablation of the area in dogs abolishes the vomiting response to apomorphine while the 
intragastric response to copper sulphate remains intact. The area responds to a very wide 
range of chemical substances. Over seventeen probable neurotransmitters have been 
identified in or near the CTZ and hence the mechanisms involved are likely to be 
extremely complex. 
3) Labyrinth 
Motion sickness and the vomiting associated with labyrinthitis are mediated via 
impulses from the labyrinth along the vestibular nerve to the lateral medulla (Reason & 
Brand, 1975). 
4) Other Afferents 
Electrical stimulation of the hypothalamus in the cat sometimes induces vomiting and 
this vomiting may be delayed. Higher centres also have input to the vomiting centre. 
VOMITING CENTRE 
Borison and Wang (1949) and Borison (1959) were the first to identify the 
importance of certain sites of the dorsolateral reticular formation of the medulla. Since 
its function is that of coordinating the multiple physiological reactions in vomiting it 
may actually be a number of adjacent, closely inter-related sites rather than a single 
zone. This theory is supported by some electrical stimulation experiments by Miller and 
Wilson (1983) which failed to localise a single vomiting centre. 
There are at least three major inputs into the vomiting centre. Firstly, there is input 
from the vestibular system, and this is thought to be involved in the development and 
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expression of nausea and vomiting due to motion (Reason & Brand, 1975). Secondly, 
input comes from the area postrema, which is thought to be influenced by chemical 
challenges such as food poisoning and chemotherapy. The third input is from cortical 
areas from the limbic system and the cerebrum. There are fibre tracts from areas in the 
limbic system associated with the expression of emotion and associated with memory 
that connect to the vomiting centre. This provides the neurologic substrate which makes 
possible the involvement of psychological phenomenon in the expression of nausea and 
vomiting (Morrow & Dobkin, 1988). Thus, nausea and vomiting may be elicited by 
diverse circumstances such as the sight of blood or other injury, the sight of another 
person vomiting, or even the thought of a food or situation that has previously been 
associated with nausea or vomiting (Andrykowski, 1990). 
EFFERENT PATHWAYS 
This involves the transmission of signals from the lateral medulla via somatic 
efferent pathways controlling respiratory and abdominal muscles and visceral efferent 
components, modifying gastric tone and motility, and also autonomic efferents 
producing salivation, pallor and sweating. 
DIFFERING EMETIC PROBLEMS 
There are three types of nausea and vomiting which may occur as a result of 
chemotherapy: 1) acute chemotherapy induced emesis, 2) delayed emesis, and 3) 
anticipatory emesis. Patients may also have nausea and vomiting not directly related to 
their chemotherapy. This may be caused by other medications or by tumour-related 
complications such as intestinal obstruction or raised intracranial pressure. There are a 
large number of important factors to consider when deciding what type of antiemetic 
cover to provide. 
IMPORTANT FACTORS IN PLANNING ANTIEMETIC THERAPY: 
1) Patient characteristics 
- emesis control during prior chemotherapy 




- emetic potential of chemotherapy drugs 
- dosage and schedule 
- rate of administration 
- time of onset of emesis 
- consideration of the effects of combining different drugs 
3) Antiemetics 
- dosage and schedule 
- rate of administration 
- combination regimens 
Patient Characteristics 
Patients who have previously experienced poor emetic control are more likely to 
experience bad control during subsequent treatment. Oralla and colleagues ( 1981) found 
that control of emesis was three times more likely if the patient had no previous 
chemotherapy. The patient's history of alcohol intake is also of importance, with 
histories of excessive and/or prolonged alcohol intake (>lOOg/day, or about 5 mixed 
drinks) making the occurrence of posttreatment nausea and vomiting less likely 
(D'Acquisto et al., 1986; Sulivan, Leyden & Bell, 1983). However, this does not imply 
that alcohol is an antiemetic or that antiemetic therapy is not needed in patients with 
prior heavy alcohol use. It may indicate that some of the receptor sites involved in 
nausea and vomiting are less sensitive in patients with such a history. The age of the 
patient may also influence the choice of antiemetics, as there is an increased incidence 
of acute dystonic reactions (muscle spasms in the neck, mouth or face due to the effects 
of phenothiazines) in younger patients given antiemetics that act by blocking dopamine 
receptors. This makes the use of 5-HT3 receptor blockers a more attractive option in 
younger patients. 
Chemotherapy Drugs and Emesis 
The chemotherapy agents which are most often associated with nausea and vomiting 
also induce the most severe nausea and vomiting. In patients who have not previously 
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received chemotherapy, emesis typically begins 1-2 hours after the chemotherapy has 
started. There are exceptions to this, with high dose cyclophosphamide producing 
emesis which may be delayed for 9-18 hours after the chemotherapy has begun (Petting, 
Grochow, Folstein, et al., 1982). An antiemetic regimen must consider the individual 
pattern and potential for causing emesis of each chemotherapy drug and when 
combination chemotherapy is used, the emetic pattern and potential of the drugs in 
combination must be considered. 
Antiemetic Agents 
No single antiemetic agent is ideal for the control of chemotherapy induced nausea 
and vomiting. An appropriate combination can often be more useful than a single drug. 
A more extensive description of the antiemetic agents available is provided in the 
section on the pharmacological treatment of nausea and vomiting. 
SUMMARY 
Posttreatment nausea and vomiting is one of the most frequently reported side effects 
of chemotherapy. The nausea and vomiting associated with cancer chemotherapy is the 
result of a complex, and largely unknown, physiological and psychological process. The 
tolerance level of each patient varies greatly, both between and within individuals. Some 
can tolerate four or five hours of nausea and vomiting, whereas others would 
discontinue their treatment under these conditions. Some experience the same level of 
nausea and vomiting during all of their treatments, while others have an increase or 
decrease in their level of nausea and vomiting. Also, some may become more tolerant as 
their treatments progress, while others become less tolerant. The substantial individual 
differences in ability or willingness to tolerate chemotherapy side effects suggest that 
psychological factors play a critical role in translating drug side effects into emotional 
distress, disruption of life activities, and refusal to continue treatment (Nerenz et al., 
1984). 
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Anticipatory Nausea and Vomiting 
As if the pharmacological side effects of chemotherapy are not enough, there has 
been a constant stream of reports in recent years of the frequent development of 
anticipatory nausea and vomiting (ANV) associated with chemotherapy, where the 
patient experiences nausea and vomiting before the emetic chemotherapy drugs have 
been administered (Redd & Andrykowski, 1982). There are, however, definitional 
problems that have emerged in the literature. These have resulted in a large amount of 
variance between studies, with many patients who would have been counted as having 
developed ANV being left out and many who may not have had ANV being labelled as 
having ANV. This issue is discussed below and a solution is proposed. 
ANV is typically conceptualised in terms of a classical conditioning paradigm, where 
the patient initially responds to the chemotherapy drugs (unconditioned stimuli) with 
posttreatment nausea and/or vomiting (unconditioned responses). When the 
chemotherapy is delivered there are usually other things present (conditioned stimuli) 
that come to be associated with the chemotherapy drugs and the posttreatment nausea 
and vomiting, and after a number of pairings they may come to elicit anticipatory nausea 
and/or vomiting (conditioned responses) in the absence of the chemotherapy drugs. The 
evidence for this theory is discussed below and a number of other theories of aetiology 
are mentioned. 
Much research has been conducted with respect to the factors that are related to the 
acquisition of this response (Dobkin, Zeichner, & Dickson-Parnell, 1985; Cohen et al., 
1986; Andrykowski, Redd & Hatfield, 1985). Many factors have been implicated, with a 
few appearing in the majority of the literature, and their role in the acquisition of ANV 
will be discussed in more detail later. 
The treatment of ANV using behavioural techniques has been less than adequately 
pursued or documented, despite evidence which shows that methods such as hypnosis, 
progressive relaxation training, systematic desensitisation, and a variety of other 
techniques are very effective in reducing anticipatory nausea and vomiting, 
posttreatment nausea and vomiting, and the anxiety and depression associated with 
treatment - generally making the experience a lot less stressful (Morrow & Dobkin, 
1988; Burish & Carey, 1986; Redd & Andrykowski, 1982). The use of behavioural 
treatments is discussed later, and their mode of action is considered. 
DEFINITION & ASSESSMENT 
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Most research has been less than rigorous with respect to defining exactly what ANV 
is (Andrykowski, 1986). Some researchers have even failed to specify how they defined 
ANV. When specified, there are three basic classes of definition: nausea and/or 
vomiting prior to or during the chemotherapy infusion; nausea and/or vomiting prior to 
the infusion; and either of the above two, with some qualifying statement added, such as 
'without another cause for such' or 'associated with some treatment-related stimulus'. 
There are problems with all three of these definitions, in that they will often pick up 
episodes of nausea and/or vomiting that are attributable to physiological or 
pharmacological factors. 
The first definition, which includes nausea and/or vomiting prior to or during the 
infusion, may pick up a lot of 'false positives' due to the posttreatment nausea and 
vomiting starting while the infusion is still being administered. This is especially 
problematic if the chemotherapy protocol involves lengthy infusions of two hours or 
more (Andrykowski, 1986). Both the first definition and the second, which includes 
nausea and/or vomiting prior to the infusion, may pick up 'false positives' if the 
chemotherapy protocol includes oral medication taken over a long period of time, as 
these drugs may be responsible for the nausea and/or vomiting prior to the infusion 
(Andrykowski, 1986). The third definition, although narrowing the range of responses 
that can be characterised as ANV, still has the same inherent problems as the other two 
definitions. Andrykowski (1986) has offered a definition that restricts the definition of 
ANV to reports of nausea and/or vomiting prior to a treatment on day one of a 
chemotherapy cycle. This usually ensures that the patient has not received any emetic 
drugs for at least a week. It therefore greatly reduces the likelihood that the observed 
nausea and vomiting is the result of physiological or pharmacological factors, producing 
a more homogeneous criterion group of patients with ANV. Burish and Carey (1986) 
have suggested a modification of Andrykowski's definition, preferring to use two 
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operational criteria for identifying ANV: the symptoms should be measured a) before 
the chemotherapy drugs are infused and b) after the assumption can reasonably be 
made, based on the pharmacological properties of the drugs, that any previously 
administered medications have cleared the system. For the purpose of this study, 
anticipatory nausea and vomiting will be defined as, and restricted to, reports of nausea 
and/or vomiting in the 48 hours prior to treatment on day one of a chemotherapy cycle. 
PREVALENCE 
There have been a large number of prevalence rates found with respect to ANV, 
ranging from 18% (Nicholas, 1982) to 63% (Cella et al., 1984) of patients receiving 
cancer chemotherapy. The prevalence rates generally range from 20-40% (Bernstein, 
1991). This variance is due to at least four factors: definitional problems, variability in 
treatment protocols, difference in time of assessment, and methodological variance 
(Burish & Carey, 1986). The definitional problems have already been discussed and the 
remaining three factors will be discussed below. 
Most studies present data from patients receiving extremely varying types of 
chemotherapy and also different antiemetic agents are commonly presented together. 
Thus, because ANV is closely related to the presence of posttreatment nausea and/or 
vomiting, which in turn is affected by the emetogenicity of the chemotherapy and the 
success or failure of the antiemetic agents, there is considerable variance in the 
prevalence of ANV across patients on different chemotherapy protocols as well as 
between patients on the same protocol (Burish & Carey, 1986). 
There is also substantial variability between studies in the number of treatments the 
patient has received prior to being assessed for the presence of ANV. For example, 
Wilcox et al. (1982) assessed their subjects prior to the tenth chemotherapy cycle 
whereas Morrow et al. (1982) assessed their subjects prior to the fourth cycle. This may 
account for much of the variability, due to the relationship that has been established 
between the number of treatments completed and the development of ANV. 
Much of the variance in prevalence is probably the result of methodological variance 
between studies (Burish & Carey, 1986). A wide variety of measures have been used to 
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assess nausea and vomiting. For example, several investigators have used a visual 
analogue scale to assess how nauseated their subjects were (Olafsdottir et al., 1986; 
Ahles, 1984; Adrykowski, Redd & Hatfield, 1985); others have used self-report 
questionnaires (Dobkin et al., 1985; Weddington, Miller & Sweet, 1984); while others 
have used the Morrow Assessment of Nausea and Emesis (MANE) self-report scale to 
measure the frequency, duration, and peak intensity of anticipatory nausea and vomiting, 
and posttreatment nausea and vomiting (Morrow, 1984; Cohen et al., 1986). Another 
measurement inconsistency that has contributed to the variance in prevalence rates is the 
amount of recall required of patients (Burish & Carey, 1986). This is a problem, as a 
report by Stunkard et al. ( 1985) revealed a significant difference between concurrent and 
retrospective recall, with the retrospective data exaggerating vomiting frequency -
suggesting that the use of concurrent reporting will produce more accurate prevalence 
rates. Overall, there is not yet a widely used and convincingly validated instrument or 
procedure for measuring nausea and vomiting (Burish & Carey, 1986). It is believed that 
these four factors, including definitional problems, variability in protocols, difference in 
the time of assessment, and methodological variability, could account for about 10 of 
the 40 percent prevalence rate reported (Morrow & Dobkin, 1988). 
If all of the studies are taken into account and combined to achieve an estimated 
prevalence rate for ANV, about 32% of patients receiving chemotherapy report ANV 
(Burish & Carey, 1986). If only the prospective, longitudinal studies are considered (i.e., 
Andrykowski et al., 1985; Jacobson et al., 1985; Love et al., 1985), the prevalence rate 
is about 45%. A more recent study by Boakes et al. (1993) reports that 41 % of their 
patients developed at least 'mild' anticipatory nausea and that 24% developed 'moderate 
to severe' anticipatory nausea. 
CORRELATES & PREDICTORS 
Univariate Correlates 
There are three groups of variables that have been shown to correlate significantly 
with the presence of ANV. These are demographic variables, clinical variables and 
psychological variables. 
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(1) Demographic Variables- Age is the only demographic variable that has been 
consistently shown to have any predictive value, with younger (under 50) patients 
showing an increased incidence of ANV (Morrow & Dobkin, 1988; Burish & Carey, 
1986). The reason for this is not known but there are a number of theories, including one 
that uses evidence from classical conditioning. Novel stimuli are more easily 
· conditioned, and since young people are more likely to be encountering novel stimuli 
during their treatment, conditioning of ANV in young people is more likely. Another 
theory is that younger people get more noxious tumours than older people and there is 
some evidence to support this as well (Redd & Andrykowski, 1982). 
Only two studies, out of a possible eleven looking at gender have found a significant 
correlation, with an increased likelihood of developing ANV in females (Petting et al., 
1983; Wilson et al., 1986). Ethnicity, education level, socioeconomic and marital status 
have all demonstrated no significant or consistent relationship with ANV (Morrow & 
Dobkin, 1988; Andrykowski, 1986; Burish & Carey, 1986). 
(2) Clinical Variables - The length of treatment, or the number of treatments 
completed, is significantly and consistently correlated with a higher incidence of ANV; 
as is more lengthy and intense posttreatment nausea and vomiting (Morrow & Dobkin, 
1988). Another clinical variable that has been associated with a higher incidence of 
ANV is a susceptibility to motion sickness, with those who are susceptible to motion 
sickness having significantly more side effects from the chemotherapy drugs, 
significantly more posttreatment nausea and vomiting, and significantly more ANV 
(Morrow, 1984; 1985; Leventhal et al. 1988). 
(3) Psychological Variables - Increased anxiety, both state and trait anxiety, is the 
most consistent psychological variable which correlates with ANV (Burish & Carey, 
1986; Morrow & Dobkin, 1988). Depression, hostility and coping styles have also been 
studied in chemotherapy patients, with two studies out of a possible four finding a 
relationship between elevated levels of depression and ANV (Cohen, 1982; van Komen 
& Redd, 1985), one study out of three finding a relationship between increased hostility 
and ANV (Ingle et al., 1984), and one study out of three finding a significant 
relationship between more coping attempts made and ANV (Ingle et al., 1984). It is 
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possible however, that the variability in the findings from studies on these factors is due 
to measurement variance rather than actual differences in response (Morrow & Dobkin, 
1988). 
Multivariate Correlates 
Many of the recent studies on ANV point to the role of interactive relationships 
among the demographic, clinical and psychological variables mentioned above which 
might be associated with the development of ANV. Morrow (1982) found that he could 
get an 80% accurate retrospective classification of ANV by using a combination of age, 
and the severity and duration of posttreatment nausea and vomiting, whereas Ingle et al. 
(1984) found that they could get a 71 % accurate classification by using age, 
posttreatment nausea and vomiting, anxiety and coping success. Cohen (1982) found 
that 80% of the variance between subjects could be accounted for by anxiety, noxious 
sensations (tastes and odours), age, and the frequency of posttreatment nausea and 
vomiting. It has also been found that 24% of the variance could be accounted for by the 
level of posttreatment nausea alone, and that a significant portion of the remaining 
variance could be accounted for by state anxiety (anxiety in response to the treatment), 
and the length of time it takes to administer the drugs (Andrykowski, Redd & Hatfield, 
1985). 
Morrow (1984) stated that patients with ANV were significantly more likely to have 
four or more of the following features: 
a) Less than 50 years of age. 
b) Nausea and/or vomiting after their last treatment. 
c) Described their nausea after the last treatment as 'moderate, severe, or intolerable'. 
d) Described their vomiting after the last treatment as 'moderate, severe, or 
intolerable'. 
e) Report the side effect, 'warm or hot all over', after the last treatment. 
f) Susceptible to motion sickness. 
g) Experienced 'sweating' after the last treatment. 
h) Experienced 'generalised weakness' after the last treatment. 
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To summarise this section, the variables that have been found to correlate with ANV 
in many studies are: high levels of posttreatment nausea and/or vomiting; age (younger); 
higher doses, greater amounts or more emetogenic drugs; and higher levels of anxiety or 
general distress (especially state anxiety). The variables that have been found to 
correlate with ANV in only one study or by only one group of investigators are: more 
coping strategies tried (Ingle et al., 1984); inhibitive rather than facilitative coping style 
(Altmaier, Ross & Moore, 1982); prior history of motion sickness; parents with high 
anxiety levels (paediatric patients only); long infusions rather than short (Andrykowski, 
Redd & Hatfield, 1985); large group treatment room rather than a private room (van 
Kamen & Redd, 1985); itching, taste and smell sensations during treatment (Nicholas, 
1982; Nerenz, Leventhal & Love, 1982 respectively); and being unmarried (Petting et 
al., 1983). 
ETIOLOGY 
There have been seven different models of aetiology proposed for the development of 
ANV in chemotherapy patients: physiological, autonomic reactivity, psychodynamic, 
coping, anxiety, taste aversion, and learning models. Below is a brief discussion of these 
models, with most of the attention focused on the learning model, as this seems to be the 
most widely accepted model of aetiology (Morrow & Dobkin, 1988; Bernstein, 1991; 
Burish & Carey, 1986). 
Physiological Model 
The physiological view is that anticipatory symptoms may be produced by brain 
metastasis or local cancer involvement of the gastrointestinal tract (Chang, 1981). This 
model is opposed by at least two findings: the first is that the metastatic spread of cancer 
to the brain or gastrointestinal tract is much less prevalent than ANV; and secondly, 
there seems to be no association between metastatic disease and ANV (Morrow & 
Dobkin, 1988). 
Autonomic Reactivity Model 
This model proposes that increased autonomic reactivity is an accurate individual 
marker for ANV susceptibility (Kvale et al., 1991). There is evidence to support this, in 
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that patients who have been shown to have high levels of autonomic reactivity, as 
measured by heart rate and peripheral vascular changes in response to auditory stimuli, 
have been more likely to develop ANV (ibid., 1991). This model is closely related to the 
learned model, in that it is based on the relationship between reactivity and the 
conditioning process. It has been shown that spontaneously high reactive individuals 
show conditioned responses to phobic scenes more easily (Hugdahl, Fredrikson, & 
Ohman, 1977), and also that autonomic reactivity is predictive of both acquisition and 
extinction of conditioned responses (Ohman & Bohlin, 1973). 
Psychodynamic Model 
According to this view,-nausea and vomiting 'are not always direct side effects of 
chemotherapy, but rather may be surfacing manifestations of underlying psychological 
readjustment problems associated with life-threatening illness' (Chang, 1981). This 
model suggests that these side effects may be caused by psychological mechanisms, 
including anger, anxiety, and frustration. There is no direct empirical support for this 
model, although increased levels of anxiety have been measured in patients with ANV 
(Morrow & Dobkin, 1988; Redd, Burish & Andrykowski, 1985). 
Coping Model 
This model suggests that patients who develop ANV may be deficient in their ability 
to adjust to, or cope with, the physical and emotional challenges associated with their 
chemotherapy treatments. The increased levels of anxiety shown in patients with ANV 
may be seen as a failure to cope effectively (Morrow & Dobkin, 1988). It has been 
reported that patients with ANV demonstrate significantly less desire and ability to cope 
than patients without ANV (Altmaier et al., 1982), although these researchers' method 
of assessing coping has never been validated or replicated. Ingle et al. (1984) found a 
positive correlation between the number of ways the patient had tried to cope with 
having cancer and the development of ANV - in that their initial coping strategies may 
have been inadequate or deficient. However, the methodology of this study was also 
questionable, using retrospective self-report measures of nausea and vomiting, so these 
findings must be treated with caution. 
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An alternative coping model recognises a three-way interaction between physical and 
psychological demands of the medical situation and the coping resources of the 
individual (Gil, 1984). This theory identifies three channels of responses: overt 
behavioural, physiological, and cognitive. So, any difference in physical, psychological 
or coping ability will lead to a different response to the chemotherapy situation. The 
physical and psychological factors might include the administration of toxic chemicals, 
symptoms of the disease, concern about prognosis, fear of injections, etc; and the coping 
resources may include overt behavioural control, cognitive control, or physiological 
control (Morrow & Dobkin, 1988). 
Anxiety Model 
Houts et al. (1984) have proposed four potential ways that anxiety might relate to 
ANY: 1) anticipatory nausea may cause pretreatment anxiety; 2) pretreatment anxiety 
may cause anticipatory nausea; 3) anticipatory nausea and pretreatment anxiety may 
both be caused by posttreatment nausea; or 4) pretreatment anxiety may facilitate the 
conditioning process of ANY. There is some data to support all of these potential 
explanations so it is unclear if any of them are correct, or maybe there are a variety of 
different ways in which anxiety interacts with ANY in different people (Morrow & 
Dobkin, 1988). 
Andrykowski et al. ( 1985) showed that elevated levels of state anxiety may precede 
the initial occurrence of ANV, although they stress that the relationship between anxiety 
and ANV may not be a strictly causal one. Their data does support the view that 
heightened anxiety following a treatment may increase posttreatment nausea and/or 
vomiting, which in turn may increase the susceptibility to conditioning on the next 
treatment - facilitating and promoting a conditioning process rather than serving as a 
direct cause. This would support the explanation that anxiety is involved in some form 
in the conditioning of side effects (Morrow & Dobkin, 1988). 
Taste Aversion Model 
In the taste aversion model animals use the taste and smell of particular substances as 
cues for avoiding substances that have made them ill in the past and there is evidence 
that these tastes and smells have become aversive or noxious. This learning may occur 
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very rapidly; often requiring only a single episode. Bernstein and Webster (1980) 
demonstrated that human subjects could acquire learned taste aversions in a single trial 
when consumption of food (a novel-favoured icecream) was followed by nausea and 
vomiting induced by chemotherapy. Taste aversion experiments have revealed that the 
mammalian learning mechanisms do not operate randomly, associating stimuli and 
reinforcers only as a function of recency, frequency and intensity. Mammals associate 
gustatory and olfactory cues with internal malaise even when these stimuli are separated 
by long time periods (Garcia, Ervin & Koelling, 1966). 
Lorenz et al. (1986) and Petting et al. (1983) reported that patients who noticed a 
taste of drugs during chemotherapy injection were more likely to develop anticipatory 
nausea and vomiting than patients who did not notice a taste. However, more recent 
studies have been unable to replicate this finding (Andrykowski, 1987; Morrow, 1989). 
Learned Model 
This model states that ANV is acquired through a classical conditioning process in 
which environmental cues become associated with drug delivery and later act to trigger 
responses similar to those which are elicited by the drugs (Bernstein, 1991). An operant 
learning model does not seem to be appropriate for the development of ANV, as this 
model would state that the patient receives some form of reward and/or avoids or 
escapes from some noxious consequence. Although the patient may receive increased 
attention from their nurses, doctors, friends and family, it is difficult to imagine how this 
would be reinforcing enough to encourage further nausea and vomiting (Morrow & 
Dobkin, 1988). 
According to the classical conditioning model the probability of developing ANV 
increases with the number of chemotherapy treatments and with the severity of 
posttreatment symptoms of nausea and vomiting. Posttreatment nausea and/or vomiting 
are necessary for the development of ANV under this model; a fact which is supported 
by most research (Redd & Andrykowski, 1982). In the classical conditioning model, the 
intensity and novelty of the conditionable stimulus influence the ease with which that 
conditionable stimulus may become conditioned. Therefore, a more intense and/or novel 
stimulus has the potential to become a stronger conditioned stimulus with fewer pairings 
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needed to establish the conditioning. Also of interest in classical conditioning is the 
concept of biological preparedness, where it may only take one pairing of a certain type 
of food with the sickness reflex to condition a strong negative response to that food in 
the future. This phenomenon has lead to the study of taste aversion as a subtype of 
classical conditioning. 
A classical conditioning explanation of how ANV might develop is outlined in 
Figure 1 below (Morrow & Dobkin, 1988). An unconditioned response (posttreatment 
nausea and/or vomiting) which follows an unconditioned stimulus (the chemotherapy 
drugs administered) in the context of potentially conditionable stimuli (sensations, 
thoughts, images of the clinic and/or nurse, etc) will, after a number of repeated trials 
(chemotherapy treatments), give rise to a conditioned stimulus (such as the 
chemotherapy nurse) eliciting a conditioned response (anticipatory nausea and 
vomiting). 
The First Few Chemotherapy Treatments: 
Conditioned Stimulus------- No Response 
(e.g. Nurse) 
Unconditioned Stimulus------- Unconditioned Response 
(Chemotherapy Drugs) (Nausea, Vomiting) 
After Several Chemotherapy Treatments: 
Conditioned Stimulus------- Conditioned Response 
(e.g. Nurse) (Nausea, Vomiting) 
Figure 1. Classical Condition Model for the Acquisition of ANV. 
Support for this view comes from many different observations that conform to the 
classical conditioning paradigm, including the course of development, stimulus 
generalisation, correspondence between unconditioned and conditioned responses, the 
intensity of the unconditioned response, and higher order conditioning (Morrow & 
Dobkin, 1988). 
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Course of Development: ANV develops only after a number of administrations of 
chemotherapy drugs have been given (Morrow et al., 1982). ln fact, ANY is virtually 
never seen before a number of administrations have been given. The percentage of 
patients with ANY increases with the number of treatments given (Morrow, 1982; 
Olafsdottir, Sjoden & Westling, 1986). This observation is consistent with the 
development of a learned response where the strength of that response (ANY) increases 
with the number of conditioning trials (treatments). 
Stimulus Generalisation: The learning phenomenon of stimulus generalisation, where 
there is a response to a stimulus similar to the original conditioned stimulus, fits the 
available clinical data on ANY. It has been observed that the patients ANY may be 
elicited by an increasing range of stimuli and situations as the treatment progresses 
(Redd & Andrykowski, 1982). Nausea may even be induced by mental images of the 
chemotherapy setting (Redd et al., 1993). 
Correspondence Between Unconditioned and Conditioned Responses: Many studies 
have shown that there is a relationship between the occurrence of posttreatment nausea 
and/or vomiting and the likelihood of an individual developing ANV (Morrow & 
Dobkin, 1988). There has been no reported case of ANV without some degree of 
posttreatment nausea and/or vomiting. Also, the anticipatory nausea and vomiting (CR) 
closely resembles the posttreatment nausea and vomiting (UCR), fitting in with the 
classical conditioning model. 
Intensity of Unconditioned Response: The intensity of the posttreatment nausea and 
vomiting affects the development of ANV, with greater posttreatment nausea and 
vomiting leading to a higher incidence of ANV (Morrow & Dobkin, 1988). 
Higher-Order Conditioning: Through higher-order conditioning, neutral stimuli can 
come to elicit a conditioned response by being paired with a prior conditioned stimulus, 
rather than an unconditioned stimulus as in first-order conditioning. Generally, a higher-
order conditioned stimulus does not elicit a conditioned response as strong as a first-
order conditioned stimulus. This all fits in quite well with ANV, as the patient will often 
get increasing ANY as he/she gets closer to the treatment setting, the first-order 
conditioned stimulus (Olafsdottir et al., 1986; Nicholas, 1982). 
Critique of the Learning Model 
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There are at least two characteristics of ANY that do not fit comfortably within the 
learning model outlined above. Firstly, in conventional classical conditioning the UCS-
UCR interval is typically only a few seconds or possibly minutes and the shorter the 
interval, the better the conditioning. When we look at the UCS-UCR interval in 
chemotherapy treatment, the time between receiving the drugs and experiencing the 
posttreatment nausea and/or vomiting, is usually measured in hours rather than seconds 
or minutes. However, this may not be a problem if we look at the evidence from taste-
aversion experiments which shows that conditioning involving the gastrointestinal 
system (as nausea and vomiting do) can occur with intervals up to 8 or 9 hours 
(Robertson & Garcia, 1985). The learned taste-aversion model would further predict 
that the patient does not have to be aware of the nausea (UCR) for conditioning to 
occur; so in cases where the patient is medicated below the threshold of conscious 
awareness, ANY could still develop (Morrow & Dobkin, 1988). Whether this is true has 
yet to be proven. 
Secondly, the conditioned response in classical conditioning usually occurs following 
each presentation of the conditioned stimulus, but the conditioned response of ANY is 
often not present prior to every treatment after ANY has initially been conditioned 
(Morrow & Dobkin, 1988). One explanation for this may be that the conditioned 
stimulus is not present prior to each chemotherapy treatment. For example, if the 
treatment room has become part of the conditioned stimulus, the patient may not be 
treated in the same room during each treatment. There is no data to support or reject this 
hypothesis as yet. 
SUMMARY 
Anticipatory nausea and vomiting is a phenomenon which has received much 
attention recently. For this study ANY is defined as, and restricted to, reports of nausea 
and/or vomiting in the 48 hours prior to treatment on day one of a chemotherapy cycle. 
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A wide range of prevalence rates have been reported, from 18% (Nicholas, 1982) up to 
63% (Cella et al., 1984); with the prevalence rates generally ranging from 20-40% 
(Bernstein, 1991). Age is the only demographic variable that has been consistently 
shown to have any prediction value, with younger (under 50) patients showing an 
increased incidence of ANV. The length of treatment, or the number of treatments 
completed, more lengthy and intense posttreatment nausea and vomiting, and 
susceptibility to motion sickness have all been shown to have a significant correlation 
with ANV. Increased anxiety in those who develop ANV, both state and trait anxiety, is 
the most consistent psychological variable which correlates with ANV. Depression, 
hostility and coping styles have also been studied in chemotherapy patients with no 
consistent relationship shown between these variables and ANV. Many models of 
acquisition have been proposed, with the classical conditioning model receiving the 
most support, although there is also some support for the taste aversion model and the 
anxiety model of aetiology - perhaps indicating that the acquisition of ANV does not 
follow one specific model but can develop as a result of several different processes. 
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Management of Posttreatment and Pretreatment 
Nausea and Vomiting 
There are seven different types of treatment that have been used for ANV: 
pharmacological agents and six behavioural treatments - including progressive muscle 
relaxation, hypnosis, systematic desensitisation, EMG biofeedback, stimulus control, 
and stress inoculation training. 
PHARMACOLOGICAL TREATMENT 
Over half of the patients who undergo cancer chemotherapy experience significant 
posttreatment nausea and vomiting (Redd et al., 1993). It has been widely accepted that 
the use of traditional antiemetic drugs (i.e. phenothiazines) for nausea and vomiting 
associated with chemotherapy is not effective for a large proportion of patients, so it is 
not surprising that traditional pharmacological treatments do little to alleviate ANV 
(Redd & Andrykowski, 1982). As well as being ineffective, many are disliked due to 
their severe sedative effects and the fact that many of them cause muscle tremors, 
rigidity or fatigue (particularly in the young and elderly). There are, however, new 
methods for the use of antiemetic drugs which involve the use of multiple agents well 
before the treatment begins rather than the traditional method of administering the drugs 
just prior to, or even after, the emetic agents have been given (Andrykowski & Redd, 
1987). There is also a new class of antiemetic available, the 5-HT3 receptor antagonists, 
which have demonstrated greater antiemetic efficacy against chemotherapy induced 
nausea and vomiting than the other antiemetics available today. If an effective 
pharmacological treatment could be found then it could theoretically prevent, or at least 
postpone the development of ANV, as a weaker unconditioned response (nausea and 
vomiting) would lead to weaker conditioning or delayed conditioning. 
5-HT~ Receptor Antagonists 
The development of highly selective and specific antagonists of neuronally located 5-
HT receptors allowed a detailed characterisation of the recognition site which was 
classified as the 5-HT3 receptor (Bradely et al., 1986). The possibility that 5-HT3 
receptor antagonists might control chemotherapy-induced nausea and vomiting came 
with the realisation that intravenous administration of high doses of metoclopramide 
provided the most effective antiemetic treatment (Gralla, 1983), and it is known that 
metoclopramide inhibits the effects of 5-HT (Fozard & Mwaluko, 1976). 
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Ondansetron (Zofran) is the most extensively investigated 5-HT3 receptor antagonist 
and is currently in clinical use around the world, including the oncology department 
where this study was conducted. Another 5-HT3 receptor antagonist, granisetron 
(Kytril), was also available for use during this study. Ondansetron and granisetron have 
comparable efficacy, and are each reported to provide complete control in 65-70% of 
those patients receiving cisplatin-containing regimens and complete control in around 
86% of those receiving non-cisplatin regimens (Bleiberg, 1992; Plosker & Goa, 1991 ). 
The side effects of ondansetron are headaches and constipation in less than 15% of 
patients and an insignificant liver enzyme increase on rare occasions (Bleiberg, 1992). 
The side effects of granisetron are headaches in 10-15 % of patients, constipation, 
diarrhoea and somnolence on rare occasions, and transient changes in blood pressure 
(Plosker & Goa, 1991). 
Ondansetron was used primarily in oral form, with 8mg being taken just before 
receiving the chemotherapy drugs and again eight and sixteen hours after the first 
administration. This dose of ondansetron has an active period of around eight hours, so 
the three doses provided cover for the twenty-four hours after the chemotherapy. 
Granisetron was given intravenously in a 3mg dose just before receiving the 
chemotherapy drugs. The single 3mg dose of granisetron also provided twenty-four 
hours of antiemetic cover, with granisetron being the antiemetic used in cases where the 
chemotherapy regimen involved infusions over a few days, such as the BEP treatment 
for testis cancer. 
Substituted Benzamides 
Metoclopramide is the most popular drug of this class. Metoclopramide increases 
lower oesophageal pressure and enhances gastric emptying, although other central 
effects contribute to its antiemetic activity. Standard doses of metoclopramide (10-20 
mg) are not as effective as high dose metoclopramide (1-2 mg/kg or approximately 
100mg) in the treatment of chemotherapy induced nausea and vomiting. High dose 
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metoclopramide has been shown to be superior, or at least equivalent, to all other 
antiemetic agents, except 5-HT3 antagonists, against cisplatin-induced emesis and has 
demonstrated good antiemetic activity against the emesis associated with a wide range 
of chemotherapeutic agents (Gralla, 1982). High doses of metoclopramide have been 
found to be highly effective, with about half of those studied achieving complete emetic 
control and about two thirds having a 'major response' to the drug (Garnick, 1983; 
Anthony et al., 1986). The side effects associated with metoclopramide are: mild 
sedation, akathisia (restlessness), acute dystonic reactions ( age-related), and diarrhoea. 
The dystonic reactions may be controlled by diphenhydramine or lorazepam (Cadman, 
1977). Dexamethasone increases the efficacy of metoclopramide and reduces the 
diarrhoea associated with it. Metoclopramide (Maxolon) was used in standard doses of 
10-20mg, both intravenously and orally, in this study. 
Phenothiazines 
Prior to the introduction of high dose metoclopramide, phenothiazines were the most 
commonly used antiemetics in chemotherapy patients. They work by disrupting 
dopamine transmission in the chemoreceptor trigger zone. Phenothiazines do not work 
well with the more emetic chemotherapy agents; being less active than high dose 
metoclopramide (Gralla et al., 1981) and dexamethasone (Markman et al., 1984), and 
equivalent to or less active than THC (Frytak et al., 1979). The side effects of the 
phenothiazines include orthostatic blood pressure changes, extrapyramidal effects 
(restlessness), and sedation. The extrapyramidal effects can be prevented or controlled 
with diphenhydramine. 
Butyrophenones 
Haloperidol (oral) and Droperidol (intravenous) are the more commonly used drugs 
in this class. They also work by interrupting dopamine transmission in the 
chemoreceptor trigger zone. There is no substantial difference in efficacy between 
haloperidol and droperidol, so haloperidol is used more often due to its more convenient 
route of administration. The butyrophenones are not as effective as metoclopramide in 
the prevention of chemotherapy induced nausea and vomiting (Grunberg et al., 1984). 
The side effects associated with the butyrophenones are sedation, dystonic reactions, 
akathisia, and occasionally hypotension. 
Cannabinoids 
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Sallan and colleagues (1975) were the first to publish reports from patients who 
described less nausea and vomiting from their chemotherapy while being 'high' after 
smoking marijuana. Consequently it was discovered that the active agent in marijuana, 
delta-9-tetrahyrocannabinol (THC), possessed antiemetic properties. Two types of 
cannabinoids are available for clinical use; THC, and a synthetic cannabinoid. 
Cannabinoids have been found to be equivalent or superior to oral prochlorperazine 
(Frytak et al., 1979). However, there are many side effects associated with the 
cannabinoids; including sedation, dizziness, dry mouth, euphoria, dysphoria, paranoid 
ideation, orthostatic hypotension, and ataxia. Metoclopramide and dexamethasone are 
more effective and have far fewer side effects (Mitchell, 1992). 
Corticosteroids 
Many studies have confirmed the utility of corticosteroids as antiemetics although the 
mechanism of action of the corticosteroids remains unknown (Gralla, 1982). 
Dexamethasone and methylprednisone are the best studied agents in this class, with 
dexamethasone being the more popular of the two. They have been found to be 
especially useful when combined with other antiemetic agents (Rosel et al., 1985). The 
side effects associated with these drugs are minimal with short-term use, but with long-
term use there may be mood changes and a potential for gastric ulceration. 
Dexamethasone was used in doses of 8-16mg, intravenously and orally, in this study. 
Benzadiazapines 
These drugs make useful additions to antiemetic regimens rather than acting on their 
own (Gralla, 1982). Lorazepam is the most studied drug in this class. The major side 
effect of this drug is sedation. 
Summary of Available Antiemetics 
Until the early 1980s it was widely believed among medical practitioners that 
chemotherapy induced nausea and vomiting were a minor problem of cytotoxic 
treatment (Martin, 1992). The introduction of the highly emetogenic chemotherapy drug 
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cisplatin was the main force behind the search for more effective antiemetics. The first 
major step was the introduction of high-dose metoclopramide, which was shown to 
provide complete emetic control for the twenty-four hours following chemotherapy 
infusion in approximately one-third of patients treated with cisplatin-based regimens 
(Oralla et al., 1981). High-dose metoclopramide became the cornerstone of antiemetic 
treatment in cisplatin-treated patients during the 1980s and also demonstrated its 
superiority over other antiemetics with patients receiving non-cisplatin regimens (Tyson 
et al., 1982; Allan et al., 1986). In the early 1990s the 5-HT3 antagonists ondansetron 
and granisetron became available, and proved to be more efficacious and less toxic than 
high-dose metoclopramide with both cisplatin-based and non-cisplatin regimens (Marty 
et al., 1990; Bonneterre et al., 1990). It is now possible to provide complete emetic 
control for approximately 65-85% of all patients receiving chemotherapy (Bleiberg, 
1992). 
PSYCHOLOGICAL TREATMENTS 
Progressive Relaxation Training (PRT) 
Progressive muscle relaxation training is a commonly used behavioural technique 
which involves learning how to relax by actively tensing and relaxing various muscle 
groups in a progressive manner (Masters et al., 1987). The procedure typically involves 
being taught by a therapist, where a training tape is made, and the individual is told to 
practice at home using the training tape in order to acquire the ability to relax whenever 
it is necessary. PRT has been used by cancer chemotherapy patients to reduce side 
effects, such as posttreatment nausea and vomiting, depression, and anxiety; but its 
effect on ANY has yet to be investigated. 
Lyles et al. (1982) found that relaxation training, with guided imagery, resulted in 
less nausea and vomiting both during and after the patient's chemotherapy infusion, less 
anxiety, less physiological arousal, and less depression following the treatment. Burish 
et al. (1987) investigated whether PRT could be used to prevent or at least lessen 
chemotherapy side effects through early intervention. The patients who received PRT 
reported less nausea during and following chemotherapy, as well as less vomiting, lower 
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physiological arousal, less depression, and a progressive reduction in posttreatment 
nausea and vomiting over time - with only 10% of the PRT patients experiencing 
posttreatment nausea compared to 54% of the control patients. Relaxation training does 
appear to provide symptom relief to chemotherapy patients during and after the 
administration of the drugs (Morrow & Dobkin, 1988). 
Hy_pnosis 
Hypnosis could be described as a state of intensified attention and receptiveness, and 
an increased responsiveness to an idea or set of ideas (Erickson, 1959). Most of the 
studies that have used hypnosis to treat ANY have been carried out with paediatric 
patients as children are more readily hypnotised than adults (Morrow & Dobkin, 1988). 
Three controlled studies have examined the use of hypnotherapy with patients 
experiencing ANV. Redd and colleagues ( 1982) individually instructed each patient in 
focusing attention, achieving deep muscle relaxation, and imagining pleasant scenes. 
Most of the subjects, who were all females, showed a decrease in posttreatment nausea 
and vomiting, and elimination of ANV. Cotanch et al. ( 1985) trained children who were 
experiencing particularly troublesome nausea and vomiting in self-hypnosis, involving a 
combination of relaxation training and hypnosis. Consequently, there was a significant 
reduction in nausea and vomiting, and a significant increase in oral intake of food. 
Zeltzer, LeBaron and Zeltzer (1988) compared hypnotherapy to supportive counselling 
and found that both groups of children reported reductions in nausea and vomiting, and 
rated chemotherapy as less noxious following intervention with no significant difference 
in outcome between the two groups. It has been suggested that nonspecific therapy 
effects, such as demand characteristics and/or extra attention given, may contribute to 
the effects of treatment (Morrow & Dobkin, 1988). It may also be argued that it is the 
induction of relaxation which provides the therapeutic results observed with the use of 
hypnosis, although there has been no study which has used hypnosis without a 
relaxation component. 
Systematic Desensitisation (SD) 
Systematic desensitisation is a widely used behaviour therapy treatment for anxieties, 
fears and phobias. It involves the substitution of one response, generally muscle 
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relaxation, for the unwanted behaviour. During the systematic desensitisation treatment 
that has been used in cancer patients, patients imagine scenes from a hierarchy of events 
related to chemotherapy treatment while remaining deeply relaxed. In this way, 
treatment stimuli become associated with relaxation so that when the patient encounters 
stimuli, such as the treatment room, they respond with relaxation rather than ANV 
(Morrow & Dobkin, 1988). 
Morrow and Morrell (1982) found that SD produced a significant reduction in the 
frequency, severity, and duration of ANV. Morrow (1986) found that SD was 
significantly better than counselling, relaxation alone, or no treatment in the reduction of 
ANY, both in severity and duration. Dobkin (1987) showed that SD could be used to 
reduce, or maybe even prevent, posttreatment nausea and vomiting. 
EMG Biofeedback 
Biofeedback refers to a number of procedures that provide information to a subject 
about one or more biological responses (Masters et al., 1987). Electromyographic 
(EMG) biofeedback is often used as a general relaxation technique. Most EMG 
biofeedback procedures involve attaching three small electrodes to the forehead to 
measure tension levels primarily from the muscles in the upper facial area. The general 
purpose of biofeedback is to teach a person to use the feedback to gain conscious control 
of a biological response over which the subject previously had little or no control. 
Burish, Shartner and Lyles (1981) used EMG biofeedback combined with relaxation 
to treat a 44 year old female cancer patient with both ANV and posttreatment nausea 
and vomiting. After ten training sessions the patient was able to reduce her 
physiological arousal (EMG, pulse rate, and blood pressure) and reported feeling less 
nauseated. 
Stimulus Control 
The conditioning model of ANV suggests that stimulus control might be an effective 
treatment. Manipulations that disrupt the predictive relationship between the 
conditioned stimulus and the unconditioned stimulus should allow the conditioned 
nausea and vomiting to extinguish, and it should also be possible to eliminate ANV by 
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removing or significantly altering the stimuli assumed to elicit the conditioned response 
(Greene & Seime, 1987). 
Greene and Seime ( 1987) employed a stimulus control technique on a 61 year old 
female with intraductal breast cancer, using a masking stimulus (lemon juice) to obscure 
taste sensations thought to function as a conditioned stimulus. A decrease in ANV was 
observed across the course of six chemotherapy treatments. 
Stress Inoculation Training 
Stress inoculation is aimed at helping clients cope with aversive states by enhancing 
their self-control skills. Stress inoculation training involves three relatively discrete 
phases: education, acquisition ( often including PRT), and application (Masters et al., 
1987). There is evidence that stress inoculation training is useful in dealing with phobic 
reactions (Meichenbaum & Cameron, 1972), general states of chronic overarousal, and 
stress (Long, 1985; Lustman & Sowa, 1983). 
Moore and Altmaier ( 1981) used a stress inoculation training package, involving 
cognitive behaviour modification combined with PRT and education, to treat nine 
cancer patients. Consequently, three patients reported feeling less anxious prior to 
treatment, having learned effective coping skills. 
Mode ofAction 
Four hypotheses have been proposed to explain how and why behaviour therapy is 
effective for treating both anticipatory and posttreatment nausea and vomiting in cancer 
chemotherapy patients: 
(1) Nonspecific Factors - Factors such as attention received from a therapist, demand 
characteristics, expectation for success, or other 'placebo' effects may be involved in the 
effectiveness of behaviour therapy. From the available evidence, however, it seems that, 
although these factors may play a role, other treatment components are necessary for the 
therapy to be effective (Morrow, 1982; Morrow & Dobkin, 1988). 
(2) Cognitive Diversion - This hypothesis states that behaviour therapy diverts the 
patient's attention away from the chemotherapy treatments so that the conditioning no 
longer occurs - removing the conditioned stimuli prevents the occurrence of the 
conditioned response. The cognitive diversion hypothesis is also inconsistent with the 
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available evidence, in that the availability of distracting stimuli (e.g. television, friends 
and family) has failed to reduce the side effects of chemotherapy. It should also be noted 
that systematic desensitisation actually focuses attention on these stimuli but still has the 
ability to reduce the side effects as much as hypnosis and progressive relaxation training 
(Morrow & Dobkin, 1988). 
(3) Self-Control - This proposes that behavioural techniques change the patient's self-
perceived sense of control over their disease. As their psychological state improves 
their subjective feeling of helplessness diminishes, resulting in less nausea and vomiting 
as they feel they are 'in control' of their cancer and its treatment. As yet there is no 
empirical evidence to support this hypothesis and only one study that provides any 
evidence against it (Morrow & Morrell, 1982). 
( 4) Relaxation - It has been suggested that the key ingredient in all of the behavioural 
techniques is the induction of a relaxed state - which consequently leads to a reduction 
in anxiety and physiological arousal (Burish & Carey, 1984; Redd & Andrykowski, 
1982). Morrow (1986) suggests that relaxation may be a necessary but not sufficient 
treatment component for reducing ANV. This study also suggests that 
counterconditioning is a necessary element in the treatment package. 
Counterconditioning involves the pairing of a conditioned stimulus with an 
unconditioned stimulus or conditioned stimulus that elicits a different or incompatible 
response to the one which it is currently conditioned with, counteracting the effects of 
the original conditioning process. 
The Therapist's Role 
The amount of therapist time needed to carry out the treatments described above is 
quite large, and is a major consideration when deciding whether a patient should receive 
behaviour therapy to reduce or prevent ANV. The possible use of audio tapes to reduce 
the necessary professional time required to administer treatments such as hypnosis and 
systematic desensitisation has been investigated, but it has been found that the voice on 
the tape has become a conditioned stimulus, eliciting nausea (Morrow, 1984; Redd, 
Rosenberger & Hendler, 1983). Another possible way of reducing the therapist time 
required is to instruct other health professionals (nurses and physicians) in the 
44 
administration of behaviour therapy. There is some evidence to support this solution, 
showing that behaviour therapy techniques can be taught to a variety of health 
professionals and still be effective, and that physicians and nurses may be as credible as 
psychologists in the use of these procedures (Morrow & Dobkin, 1987). 
Summary ofthe Psychological Treatments 
All of the psychological treatment methods appear to provide control of, and/or 
protection from, the development of anticipatory symptoms. It is unclear exactly how 
these treatments work, although relaxation and cognitive diversion appear to be the two 
most important components. The use of these psychological treatments is not limited to 
trained therapists and it is possible for them to be taught to and used effectively by a 
variety of health professional without losing their effectiveness. 
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Aims of This Study 
The main aims of this study are to assess the prevalence of anticipatory nausea and 
vomiting in a setting where 5-HT3 receptor antagonists are widely used; to confirm any 
relationships there may be between the development of anticipatory symptoms and 
various demographic, clinical, and psychological variables; and to uncover any other 
factors which may increase the likelihood of a cancer chemotherapy patient developing 
anticipatory nausea and vomiting. 
Assuming that the learning model for the development of ANV is correct, a reduction 
in posttreatment nausea and vomiting should prevent or delay the acquisition of 
anticipatory symptoms. Therefore, given that 5-HT3 receptor antagonists are currently 
the most effective pharmacological treatments for chemotherapy induced emesis, it is 
hypothesised that the prevalence of anticipatory nausea and vomiting should be lower 
than the prevalence rates reported in studies where 5-HT3 receptor antagonists have not 
been used. As there have been no studies reporting the prevalence of anticipatory nausea 
and vomiting where 5-HT3 receptor antagonists have been used as the main antiemetic, 
the prevalence rates from all other studies on anticipatory nausea and vomiting may be 
used as a comparison. The prevalence of ANV in this study should therefore be less 
than, or at least at the lower end of the range of prevalence rates reported previously, 
which is generally 20-40% (Bernstein, 1991). 
Another important part of the study is the examination of the relationships which 
have been shown to exist between ANV and various demographic, clinical, and 
psychological variables. The demographic factors of gender and age will be examined, 
with age having shown a consistent relationship with ANV in the past and gender 
having only shown a significant relationship in a small percentage of studies. The 
younger patients, under 50 years old, are expected to have a higher incidence of ANV 
(Morrow & Dobkin, 1988; Burish & Carey, 1986). If there is a relationship between 
gender and the development of ANV, previous research would suggest that the females 
in the study should experience a higher incidence of ANV than the males (Petting et al., 
1983; Wilson et al., 1986). 
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The clinical variables which will be examined are the frequency and severity of 
posttreatment nausea and vomiting, the patients current susceptibility and history of 
motion sickness, and the emetogenicity of the chemotherapy protocols. It is 
hypothesised that those patients who experience more severe and frequent posttreatment 
nausea and vomiting will be more likely to develop ANY than those patients who 
experience only mild and occasional posttreatment nausea and vomiting (Morrow & 
Dobkin, 1988). Those patients who are susceptible to motion sickness are expected to 
experience more posttreatment nausea and vomiting and therefore will be more likely to 
develop ANY (Morrow, 1984; 1985; Leventhal et al., 1988). Also related to 
posttreatment nausea and vomiting is the hypothesis that those patients who are 
receiving the most emetogenic chemotherapy regimens will experience more 
posttreatment nausea and vomiting and will have a high prevalence of ANY. 
The accuracy of the emetogenicity predictions will be tested by comparing the 
predicted nausea and vomiting with the actual nausea and vomiting which accompanies 
the chemotherapy protocols in this study. This will provide some indication of how 
accurate the medical staffs' perception of the nausea and vomiting associated with 
chemotherapy is, and may also give an indication of how effective the new antiemetics 
are in controlling the expected nausea and vomiting. The results of this investigation 
should also provide some guidelines for the estimation of the emetogenicity of 
chemotherapy protocols - providing information for the selection of appropriate 
antiemetic cover. 
The psychological variables which will be measured and examined in this study are: 
state anxiety, trait anxiety, and depression levels before receiving each cycle of 
chemotherapy; and the patient's expectations about the side effects which he or she may 
encounter as a result of his or her chemotherapy. 
State anxiety has almost always been shown to have a positive relationship with 
ANV (Morrow & Dobkin, 1988), so it is expected to be higher in the patients who 
develop ANV. The results should reveal whether higher levels of state anxiety are 
present before the development of ANY and posttreatment nausea and vomiting, or if 
state anxiety increases after the development of ANY and posttreatment nausea and 
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vomiting. The relationship between trait anxiety and ANV has never produced any 
consistent results in the past, although when a significant relationship has been reported 
it has always been that trait anxiety is higher in patients who develop ANV. Also of 
interest is whether state anxiety and trait anxiety remain stable over time. 
Some level of depression in cancer patients is expected (Cavanaugh & Wettstein, 
1989), but there have been reports that higher than normal levels of depression are 
related to the development of ANV (Morrow & Dobkin, 1988). This study aims to 
provide some information about the relationship which exists between depression and 
ANV. The change in the levels of depression over time will also be of interest. 
The patients' expectations about the side effects which may accompany their 
chemotherapy will also be measured. This should reveal whether the patients' 
expectations have any influence on the development of ANV and posttreatment nausea 
and vomiting. Currently there has been no consistent relationship found between ANV 
and the expectations of the patient, although one study has reported that higher 
expectations are correlated with a higher incidence of ANV and posttreatment nausea 





SELECTION CRITERIA AND PROCEDURES 
Potential participants for this study were recruited from the Oncology Department at 
Christchurch Hospital between the 26th of April and the 13th of September, 1993. Each 
new patient who fitted the following criteria for inclusion was approached to obtain 
informed consent to participate. 
Criteria for Inclusion: 
1) Eighteen years or older. 
2) Receiving cyclical chemotherapy. 
3) No previous chemotherapy. 
4) No pre-existing nausea or vomiting due to brain metastases or gastrointestinal 
involvement by cancer. 
5) Able to give informed consent. 
Each patient was given an information sheet (Appendix 2) which outlined the aims 
and procedures of the study and any questions that the patient had about the study were 
answered before consent to participate was obtained. 
This study received ethical approval from the University of Canterbury and 
Christchurch Hospital before any patients were approached. 
Procedures 
ENVIRONMENT 
The oncology department at Christchurch Hospital services a large portion of the 
South Island of New Zealand. The outpatient department had a chemotherapy suite 
situated on the first floor, which contained four recliner chairs and two hospital beds. 
The chemotherapy is usually administered by one of two specialist nurses who staff this 
suite on a regular basis. The oncology department is associated with an oncology ward 
located in the main hospital, which is about five minutes walk from the oncology 
department. This ward is staffed by nurses who have a great deal of experience in 
administering chemotherapy. Whenever possible, those patients who are receiving very 
emetic chemotherapy regimens are placed in one of the single rooms available in this 
ward. 
50 
The majority of the interviewing for those receiving their chemotherapy as 
outpatients in this study was conducted in a consultation room near the chemotherapy 
suite. The interview room contained a desk, some chairs, a hand-basin, an x-ray light, a 
white board and a large cupboard. The three patients who were instructed in progressive 
muscle relaxation training were taken through the procedure in an examination room 
adjoining the interview room. The relaxation training room contained a bed, wardrobe, 
chair and bedside cabinet. 
Most of the interviewing for those receiving their treatment as inpatients was 
conducted in the oncology ward, at the bedside. This was often in a four or five-bed 
room with other patients around at the time of the interview. Some patients were 
assigned to single rooms and were interviewed in this much more private environment. 
INITIAL INTERVIEW 
Most of the initial interviews, before the patient had received his/her first cycle of 
chemotherapy, were conducted in the interview room in the oncology department; and 
the balance were conducted in the oncology ward. Each patient completed the 
questionnaires in the initial interview under supervision and with assistance from the 
investigator. The questionnaires for this initial interview were completed in the 
following order for each patient: 1) Side Effect Expectancy Questionnaire, 2) 
Susceptibility to motion sickness, 3) Anxiety and Depression Visual Analogue Scales, 
4) State-Trait Anxiety Inventory, and 5) Beck Depression Inventory. Three patients, 
numbers 002, 019 and 022, did not want to complete the Side Effect Expectancy 
Questionnaire as they did not want to think they were starting their treatment with 
expectations about any side effects which they may or may not experience. Two patients 
(001 and 002) did not complete the visual analogue scale questionnaire during their 
initial interview as this questionnaire was not available at the time of their interviews. 
The timing of this initial interview was always planned so that it was completed 
within the three hours preceding their first chemotherapy treatment. These interviews 
typically lasted approximately thirty minutes, but in some cases where the patient was 
extremely unwell or tired the interview lasted for up to one hour from start to finish. 
This extra time was necessary as these patients often needed to take a break during the 




Each patient was required to complete three questionnaires before day one of each of 
their chemotherapy cycles. The questionnaires were always completed in the following 
order: 1) Anxiety and Depression Visual Analogue Scales, 2) State-Trait Anxiety 
Inventory and 3) Beck Depression Inventory. Most patients preferred to complete the 
questionnaires themselves after being guided through them for the first one or two 
cycles, although some patients preferred to complete all of their questionnaires under 
supervision. The pretreatment interviews typically lasted about twenty minutes for those 
who required supervision and only a few minutes for those who preferred to complete 
the questionnaires themselves; after which they would take the questionnaires away to 
complete while waiting for their chemotherapy. 
POSTTREATMENT ASSESSMENT 
The Morrow Assessment of Nausea and Emesis was completed at least seven days, 
but never more than twenty-eight days, after the patients had completed each cycle of 
chemotherapy. Most of these assessments were completed in telephone interviews, 
although sometimes they were completed while the patient was back at the hospital 
between treatments (for example, during radiotherapy appointments for those patients 
being treated for breast cancer). For the patients who were receiving weekly or two-
weekly infusions, the nausea and vomiting assessments were conducted prior to the 
pretreatment interview for their next cycle of chemotherapy. 
REVIEWING OF PATIENT NOTES 
While they were participating in the study, each patient's medical and oncology notes 
were periodically reviewed to obtain information regarding their medical status, 
antiemetic cover, and general well-being. The investigator was also in regular contact 
with the patients' oncologists and other medical staff who dealt with the patients. 
PROGRESSIVE MUSCLE RELAXATION TRAINING (PMRT) 
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The progressive muscle relaxation training method used in this study closely 
followed Cormier and Cormier's (1979) procedure. PMRT involves learning how to 
relax by actively tensing and relaxing various muscle groups in a progressive manner. 
This relaxation training procedure requires that the subject be as comfortable as possible 
- preferably wearing comfortable clothing and in a comfortable environment. The ideal 
situation would be a small room with a recliner chair for the subject to lie back in, but 
for the purposes of this study a small clinical examination room adjoining the interview 
room was used. The patient was asked to lay on the bed in this room and to get as 
comfortable as possible before starting the relaxation training procedure. The initial 
training session lasted 30-45 minutes and all other training sessions took about 20 
minutes. 
PMRT was offered to all patients who had experienced anticipatory nausea or 
vomiting on two consecutive cycles (Patients 001, 002, 004, and 007), apart from the 
two patients being treated for testis cancer who developed anticipatory nausea (Patients 
014 and 018), as they had finished their treatment by the time they had experienced two 
consecutive cycles of anticipatory nausea. Of the four patients who were offered PMRT, 
only patient 007 thought that her anticipatory symptoms were bad enough to try using 
relaxation training. 
Overall, three patients in this study were instructed in progressive muscle relaxation 
training. Patient 007 developed severe anticipatory nausea before the second half of her 
third cycle and was offered PMRT before receiving her next cycle of chemotherapy. She 
was guided through the procedure for cycles four and the first half of cycle five, after 
which her anticipatory symptoms were no longer present and she thought it was no 
longer necessary to go through the relaxation procedure before her next cycles. Patient 
017 was told about the relaxation training which was being offered to those patients who 
developed anticipatory nausea and vomiting, and consequently wanted to be shown the 
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procedure before she started her first cycle of chemotherapy. She was instructed in 
PMRT for her first two cycles but then discontinued the training due to personal 
problems and a back complaint which made the exercises uncomfortable. Patient 020 
also requested to be shown PMRT before cycle one and also acquired a relaxation tape 
from another source before starting treatment. He was instructed in PMRT for his first 
two cycles and then continued to use his relaxation tape for the remainder of his 
chemotherapy cycles. The results of the relaxation training are provided in Appendix 3, 
as this was not a major part of the study. 
Measures 
BECK DEPRESSION INVENTORY (BDI) 
The Beck Depression Inventory (BDI) was first introduced in 1961 (Beck et al., 
1961). The revised version of the BDI was developed in 1971 and copyrighted in 1978 
(Beck et al., 1979). It has become one of the most widely used instruments for assessing 
the intensity of depression in psychiatric patients and also for detecting depression in 
normal populations (Beck, Steer & Garbin, 1988). 
The Beck Depression Inventory was used in this study to provide a measure of the 
level of depression prior to each chemotherapy cycle. It was chosen over other tools, 
such as the Hospital Anxiety and Depression Scale, as it provides two measures - the 
first thirteen items cover the affective/cognitive symptoms of depression and the 
remaining eight items cover the physiological symptoms of depression. 
Description 
The content of the BDI was derived from clinical observations about the attitudes and 
symptoms displayed frequently by depressed psychiatric patients and infrequently by 
non-depressed psychiatric patients (Beck et al., 1961). These clinical observations were 
consolidated into twenty-one symptoms and attitudes which could be rated from zero to 
three in terms of intensity. The twenty-one items are: l)Mood, 2)Pessimism, 3)Sense of 
Failure, 4 )Lack of Satisfaction, 5)Guilt Feelings, 6)Sense of Punishment, ?)Self-dislike, 
8)Self-accusation, 9)Suicidal Wishes, lO)Crying, 1 l)Irritability, 12)Social Withdrawal, 
13)Indecisiveness, 14)Distortion of Body Image, 15)Work Inhibition, 16)Sleep 
Disturbance, l 7)Fatigability, 18)Loss of Appetite, 19)Weight Loss, 20)Somatic 
Preoccupation, 21 )and Loss of Libido. 
Forms 
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The BDI was originally intended for clinical administration but a card form is now 
available (May, Urquhart & Tarran, 1969), as are several computerised forms which 
have been developed to join the original paper-and-pencil self-administered form. There 
have been no direct comparisons among these forms to estimate whether or not the 
format affects its reliability and validity. There is also a short form of the BDI (Beck & 
Beck, 1972), but although the long and short forms are highly correlated there is 
evidence that the short form may represent one cognitively oriented symptom 
dimension, where as the long form represents non-cognitive symptom clusters also 
(Beck, Steer & Garbin, 1988). The long form was used in this study as it essentially 
contains two measures, one being the affective and cognitive symptoms of depression 
and the other being the physiological symptoms of depression. 
Versions 
There have been two major versions developed: 
1) Beck, Ward ,Mendelson, Mack and Erbaugh (1961) 
2) Beck, Rush, Shaw and Emery (1979) 
It is notable that many researchers seem unaware that there are two versions of the 
BDI, with many publications not stating which version was used or only mentioning one 
version when in fact it was the other version which they used. The two versions are 
considered to be highly correlated (Lightfoot & Oliver, 1985). It was the later version 
which was used in this study. 
Administration 
It appears to make no difference in the respondents' scores as to whether or not the 
BDI is administered publicly or privately (King & Buchwald, 1982). However, the 
gender of the administrator may influence the responses, with same-gender 
administrators leading to scores which are likely to be one point higher (King & 
Buchwald, 1982). However, Bryson and Pilon (1984) reported no gender difference. The 
BDI was administered both publicly and privately in the current study, and the 
investigator was a 23 year old male psychology masters student. 
Scoring 
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The BDI is scored by adding the scores for each of the 21 items to obtain a total score 
and also a score for the affective/cognitive symptoms (items 1-13) and the physiological 
symptoms (items 14-21). The maximum total score is 63, with a maximum of 39 for the 
affective/cognitive items and 24 for the physiological items. 
Reliability and Validity 
The BDI has been shown to have high internal consistency (Beck, Steer, & Garbin, 
1988) and stability (Beck, 1967). It also has high content validity, reflecting six of the 
nine DSM-III criteria satisfactorily (Moran & Lambert, 1983); and also high concurrent 
validity with clinical ratings, the Hamilton Psychiatric Rating Scale for Depression, the 
Zung Self-Reported Depression Scale, the MMPI Depression Scale, and the Multiple 
Affect Adjective Checklist Depression Scale (Beck, Steer, & Garbin, 1988). The BDI 
has also demonstrated high discriminant validity, with the ability to differentiate 
depressed and alcoholic patients from normals (Conde & Esteban, 1976), psychiatric 
patients from normals (Akiskal et al., 1982), and also the ability to detect depression in 
medical patients (Rhodes, 1981; Sullivan, 1979; Turner & Romano, 1984). The items in 
the BDI have demonstrated good construct validity, with BDI scores being related to 
biological indicators of depression such as REM latency (Akiskal et al., 1982) and 
plasma 11-hydroxycorticosteroids (Brooksbank & Coppen, 1967). 
Demographic Correlates 
1) Gender - there is conflicting evidence about the correlation between the gender of 
the respondent and their BDI score. However, more studies have reported that women 
have higher BDI scores than men, although several other studies have reported no 
significant relationship between gender and BDI scores. 
2) Age - Adolescents have been reported to score higher than adults (Levine, 1982; 
Teri, 1982) and the elderly tend to score higher than younger respondents (Schnurr et al., 
1976). 
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3) Education - Educational attainment has been shown to be inversely related to BDI 
scores (Beck, 1967; Dorus & Senay, 1980). 
4) Race - there is no clear relationship between race and BDI scores. 
Norms and Clinical Cut-offs 
The Center for Cognitive Therapy has distributed the following guidelines for BDI 
cut-off scores: none or minimal depression = < 1 0; mild to moderate depression = 10-18; 
moderate to severe depression= 19-29; and severe depression= 30-63. Beck and 
Beamesderfer (1974) stated that scores of 13-20 indicate mild depression, 21-30 indicate 
moderate depression, and 31 or greater indicate severe depression. Norris et al. ( 1987) 
used a cut-off score of 17 to detect major depression in medical outpatients. Also, 
Craven et al. (1988) used a cut-off score of 14/15 to detect minor depression in renal 
dialysis patients, and a cut-off score of 12/13 was found to be 79% sensitive and 77% 
specific by Neilson and Williams ( 1980) to define the lower limits of depression in a 
medical population. 
A mean BDI score of 13.9 (S.D. 8.2) was reported for cancer patients compared to a 
significantly lower mean score of 11.1 (S.D. 9.0) for patients with other medical 
disorders (Cavanaugh & Wettstein, 1989). Cavanaugh and Wettstein (1989) also report 
that cancer patients have significantly higher scores on the physiological symptoms of 
the BDI, with a mean score of 5.8 (S.D. 5.7) on the affective/cognitive symptoms and a 
mean score of 8.1 (S.D. 4.0) on the physiological symptoms. The same study also 
reports that 51.2% of the cancer patients recorded BDI scores ~13 and 15.6% recorded 
BDI scores ~21. For the purposes of determining clinical significance in this study, the 
cut-off scores provided by the Center for Cognitive Therapy will be used to determine 
the level of clinical depression for each BDI score. 
Use of the BDI in Medical Populations 
The BDI has been used extensively in medical populations in a wide variety of 
studies and is reported to be as good at detecting depression in these patients as any 
other self-report screening method (Meakin, 1992). Zich et al. (1990) suggest that the 
BDI might assist physicians in reliably detecting depression in medical patients as they 
demonstrated a high level of agreement between the BDI and the DSM-III diagnosis of a 
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major depressive episode. A comparison among various medical populations shows that 
patients with gastrointestinal disease, cancer, bone and connective tissue disease, 
neurological disease, and respiratory disease have the greatest amount of depressive 
symptomatology (Cavanaugh & Wettstein, 1989; Cavanaugh, 1986). It has also been 
demonstrated that the BDI works equally as well with medical patients as it does with 
psychiatric patients (Emmons, Petting, & Zonderman, 1987). So although the BDI has 
not previously been used to measure levels of depression in anticipatory nausea and 
vomiting studies, there is no reason why its use here should be questioned. 
SPEILBERGER STATE-TRAIT ANXIETY INVENTORY (STAI) 
The construction of the STAI began in 1964 in an attempt to develop a single set of 
items that could be administered with different instructions to provide objective 
measures of state and trait anxiety. 
Trait anxiety refers to relatively stable individual differences in anxiety proneness, 
that is, to differences between people in the tendency to perceive stressful situations as 
dangerous or threatening and to respond to such situations with elevations in the 
intensity of their state anxiety. Trait anxiety may also reflect individual differences in 
the frequency and intensity with which anxiety states have been manifested in the past, 
and in the probability that state anxiety will be experienced in the future. The stronger 
the trait anxiety, the more probable that the individual will experience more intense 
elevations in state anxiety in a threatening situation. 
The State-Trait Anxiety Inventory was used in this study to provide a measure of the 
level of state and trait anxiety before each chemotherapy cycle. It was used in preference 
to other measures of anxiety as it provides measures for both state and trait anxiety and 
it has been used extensively in similar research. 
Description 
The ST AI (Speilberger et al., 1983) was designed to measure state and trait anxiety in 
college and high school students and has since been used extensively in research and 
clinical practice. The inventory consists of twenty statements that evaluate how 
respondents feel 'right now' (Form Y-1 ), and twenty statements that assess how 
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respondents 'generally' feel (Form Y-2), yielding separate scores for state and trait 
anxiety respectively. The twenty items of the STAI-Sare: 1) Calm, 2) Secure, 3)Tense, 
4)Strained, 5)At ease, 6)Upset, ?)Worrying over possible misfortunes, 8)Satisfied, 
9)Frightened, lO)Comfortable, l l)Self-confident, 12)Nervous, 13)Jittery, 14)Indecisive, 
15)Relaxed, 16)Content, 17)Worried, 18)Confused, 19)Steady, 20)Pleasant. The twenty 
items of the STAI-Tare: 21)Pleasant, 22)Nervous and restless, 23)Satisfied with self, 
24)Wish could be as happy as others seem to be, 25)Feel like a failure, 26)Rested, 
27)Calm, cool, and collected, 28)Difficulties piling up and cannot overcome them, 
29)Worry too much over something that really doesn't matter, 30)Happy, 3l)Disturbing 
thoughts, 32)Lack self-confidence, 33)Secure, 34)Make decisions easily, 35)Feel 
inadequate, 36)Content, 37)Unimportant thoughts rnn through mind, 38)Take 
disappointments so keenly that can't put them out of mind, 39)Steady, 40)Get in state of 
tension or turmoil as think over recent concerns and interests. 
Scoring 
Each item in the STAI is given a weighted score of I to 4. A rating of 4 indicates the 
presence of a high level of anxiety for ten state anxiety items and eleven trait anxiety 
items. A high rating indicates the relative absence of anxiety for the remaining ten state 
anxiety items and nine trait anxiety items. The scoring weights for the anxiety-present 
items are the same as the numbers on the test form (i.e. items 1, 2, 5, 8, 10, 15, 16, 19, 
20, 21, 23, 26, 27, 30, 33, 34, 36, 39) whereas the scoring weights for the remaining 
anxiety-absent items are the reverse of the numbers on the test form (i.e. 1, 2, 3, 4 are 
scored as 4, 3, 2, 1). To obtain the scores for state anxiety and trait anxiety, you add the 
weighted scores for the first twenty items to obtain the state anxiety score and add the 
weighted scores for the other twenty items to obtain the trait anxiety score. Scores for 
both the state anxiety and trait anxiety scales can vary from a minimum of 20 to a 
maximum of 80. 
Reliability: Stability and Internal Consistency 
A median test-retest correlation coefficient for the trait anxiety scale when used with 
college and high school students has been reported as 0.765 and 0.695 respectively 
(Speilberger et al., 1983). The state anxiety scale has inherently low test-retest stability, 
as a valid measure of state anxiety should reflect the influence of unique situational 
factors that exist at the time of testing and which result in fluctuations in respondents' 
test scores over time. The state anxiety scale does, however, exhibit high internal 
consistency with a median alpha coefficient of 0.93 being reported (Speilberger et al., 
1983) . A median alpha coefficient of 0.90 has been reported for the trait anxiety scale 
(Speilberger et al., 1983). 
Validity 
1) Contrasted Groups - There is evidence to show that the STAI-T score can 
discriminate between normals and psychiatric patients, with psychiatric patients 
demonstrating significantly higher trait anxiety scores (Speilberger et al., 1983). 
Evidence of construct validity comes from the observation that the scores of military 
recruits tested shortly after beginning highly stressful training programs were much 
higher than those of college and high school students of about the same age who were 
tested under relatively non-stressful conditions (Speilberger et al., 1983). 
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2) Correlations Between the State Anxiety and Trait Anxiety Scales - Persons high in 
trait anxiety tend to be higher in state anxiety, even in relatively neutral situations. This 
correlation is decreased under stressful conditions and increased under conditions that 
pose some threat to self-esteem (Speilberger et al., 1983). 
Norms 
The norms provided in the STAI manual are not always appropriate, being based on a 
large sample of college undergraduates and high school students in the United States, 
and smaller groups of male psychiatric patients, general medical and surgical patients, 
and young prisoners, also from the United States. Therefore, Knight, Waal-Manning and 
Spears ( 1983) conducted a study on 1173 subjects from a small town in the South Island 
of New Zealand. The average state anxiety score was 30.19 (S.D:7.31) for males and 
33.51 (S.D:8.61) for females; whereas the average trait anxiety score was 33.11 
(S.D:7.80) for the males and 36.85 (S.D:8.89) for the females. There is some trend for 
both the state anxiety and trait anxiety scores to correlate with age, with the younger 
subjects recording higher scores (Knight et al., 1983). 
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The Use of the STAI in Medical Populations 
The ST AI has been used extensively in much of the research on anticipatory nausea 
and vomiting (e.g. van Komen & Redd, 1985; Andrykowski et al., 1985, 1987; 
Andrykowski, 1988), an~ also in a recent study on anticipatory anxiety in cancer 
chemotherapy patients (Jacobsen, Bovjberg, & Redd, 1993). 
MORROW ASSESSMENT OF NAUSEA AND EMESIS (MANE) 
The MANE was designed by Morrow ( 1982) in an attempt to provide a reliable and 
valid tool for the assessment of chemotherapy treatment-related nausea and vomiting. 
Currently the MANE is the most comprehensive and widely used measure of treatment-
related nausea and vomiting (Carnrike et al., 1988). 
Description 
The MANE is a brief 16-item questionnaire which assesses the frequency, severity 
and duration of pretreatment and posttreatment nausea and vomiting associated with 
previous chemotherapy. The first eight items on the questionnaire assess the duration 
and severity of posttreatment nausea and vomiting as well as assessing when the nausea 
and vomiting were at their worst. The next six items assess the severity of pretreatment 
nausea and vomiting and also how long before the treatment it first occurred. The last 
two items on the questionnaire assess how useful the patient thought his/her medication 
was in controlling the nausea and vomiting. 
Reliability and Validity 
The MANE has been found to have a high degree of reliability on the severity and 
duration of treatment-related nausea and vomiting (Morrow, 1984). It has also 
demonstrated a moderate degree of test-retest reliability, although it appears to be more 
reliable with respect to nausea than vomiting (Carnrike et al., 1988). Carnrike et al. 
(1988) also report that the MANE has a moderate degree of concurrent validity, 
although they also report a nonsignificant level of discriminant validity. This 
nonsignificant level of discriminant validity relates to the high correlation between items 
within the MANE. 
The MANE was used in this study as it is currently the most reliable and valid tool 
for assessing both posttreatment and pretreatment nausea and vomiting. 
SIDE EFFECT EXPECTANCY QUESTIONNAIRE (SEEQ) 
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The Side Effect Expectancy Questionnaire was developed specifically to assess 
patient expectations for experiencing each of 16 side effects associated with 
chemotherapy (Appendix 4; Andrykowski & Redd, 1987). For each side effect, patients 
indicated their expectations on a 5-point categorical scale. The patients were told before 
they were shown the SEEQ that it contained a list of the side effects associated with all 
of the different chemotherapy drugs and that it was not a list of the side effects 
associated with their chemotherapy in particular. The sixteen side effects which it lists 
are: nausea, vomiting, tiredness, hair loss, nervousness, change in taste or appetite, 
weight loss, weight gain, skin itching, pain, weakness, diarrhoea, sleep problems, chills, 
problems with sex, and constipation. It takes about five minutes to complete. The SEEQ 
is scored by adding the scores for each of the sixteen side effects to obtain a total, with a 
possible maximum score of 80. 
The SEEQ has been used in studies on anticipatory nausea and vomiting in cancer 
chemotherapy patients (Andrykowski & Redd, 1987); and a similar questionnaire, with 
only thirteen side effects, was used recently in a study looking at anticipatory anxiety 
associated with cancer chemotherapy (Jacobsen, Bovbjerg, & Redd, 1993). The SEEQ 
was used in this study to determine whether there is a relationship between the amount 
of side effects the patient is expecting and the level of posttreatment and pretreatment 
nausea and vomiting which that patient experiences. 
SUSCEPTIBILITY TO MOTION SICKNESS 
The patients were assessed as to their history of motion sickness during the initial 
interview and the results from this were recorded by the interviewer in the space 
provided at the bottom of the SEEQ (Appendix 4). Information was obtained as to their 
current susceptibility to motion sickness and how sensitive they were, as well as a 
general history of their susceptibility to motion sickness. 
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DEPRESSION & ANXIETY I0CM VISUAL ANALOGUE SCALES 
In order to provide some sort of verification of the levels of anxiety and depression 
being reported on the Beck Depression Inventory and the State-Trait Anxiety Inventory, 
a very brief, three item questionnaire was constrncted (Appendix 5). Ten centimetre 
visual analogue scales have been used to measure pretreatment anxiety (Jacobsen, 
Bovbjerg, & Redd, 1993) and depression in cancer chemotherapy patients previously. 
Description 
On the one page questionnaire there are three 10cm visual analogue scales; one each 
for state anxiety, trait anxiety and depression. The patients were instrncted to make a 
mark along each of the 10cm lines. For the first item, they were instrncted to place a 
mark on the line which corresponded to the level of anxiety that they were experiencing 
'now'. The second item was to indicate how anxious the patient is 'generally', and the 
third item was answered as to how depressed the patient was feeling with no reference 
to any time period. The entire questionnaire took approximately one minute to complete 
each time, although it often took five or ten minutes to explain how to complete the 
questionnaire during the initial interview. 
Scoring 
The answers were scored by measuring from the left-hand end of the lines to the 
patients' marks, yielding a score in millimetres. 
e.g. A mark at this point on the visual analogue scale would yield a score of 45mm. 
Statistical Analysis 
For the purposes of analysing the data, the patients were divided into two groups, one 
being the patients who developed anticipatory nausea and/or vomiting (ANV group) and 
the other containing the patients who did not experience anticipatory nausea and/or 
vomiting (non-ANV group). 
Averages were obtained for each patient at each cycle and population standard 
deviations were used to compare these averages. Student t-tests (two-tailed, for 
independent means) were used to test for any significant differences between the two 
groups on all of the variables measured. No other tests of statistical significance were 
used due to the low number of subjects and the correspondingly low level of power 
which they would have. The relationship between variables was tested using Pearson 
product-moment correlation coefficients and the trend of the data was tested using 







Of the thirty-six patients who fitted the criteria for inclusion in the study, twenty-six 
(72%) were approached and successfully enlisted; six (17%) were deemed unsuitable by 
their oncologist, either because they were only expected to receive one or two treatments 
or due to their emotional state; three (8%) refused to participate; and one (3%) was 
missed due to confusion about when she was to start her treatment. Patient 012 died 
soon after receiving his first cycle of chemotherapy and was consequently excluded 
from all statistical analyses. 
Table 3. 
Demographics for Individual Patients 
Pat. No. Age Gender Diagnosis Extent 
1 36 m Sarcoma Metastatic 
2 40 f CA Breast Stage II 
3 58 m NHL Invaded distal spermatic cord 
4 53 f CA Breast Metastatic 
5 61 f NHL Stage Illa 
6 67 m NHL Intermediate grade, diffuse large cell 
7 20 f HD Nodular sclerosing 
8 51 f Ovarian Stage II-III 
9 69 f Ovarian Stage II 
10 67 f Adeno.Colon Dukes C 
11 41 f CA Breast Stage I 
12 65 m Myeloma Kidney metastases 
13 54 m Adeno.Colon Dukes C2 
14 34 m Teratoma Testis Stage I 
15 44 m Seminoma Testis Large retroperitoneal mass 
16 69 m Adeno.Colon Dukes C 
17 39 f CA Breast Stage II 
18 28 m Teratoma Testis Stage II 
19 59 m HD Stage Illb 
20 25 m HD Stage lb 
21 42 m Germ Cell Testis Stage I 
22 55 f Myeloma 
23 41 m HD Stage II 
24 40 m NHL Stage II 
25 65 m Adeno.Colon Dukes C 
26 46 f CA Breast Stage III 
HD=Hodgkin's Disease, Adeno.Colon=Adenocarcinoma of the Colon, NHL=Non-Hodgkin's Lymphoma, CA=Carcinoma. 
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GENDER 
As Table 3 shows, fourteen ( 56%) of the patients analysed in this study were male 
and eleven ( 44%) were female. Of the six (24%) patients who developed ANY, three 
(50%) were male and three (50%) were female. In the non-ANY group which contained 
nineteen patients, eleven (58%) were male and eight (42%) were female. 
AGE 
The average age of all of the participants was 43.72 (SD: 14.2). The average age of 
those patients who went on to develop ANY was 35.17 (SD: 11.2), significantly lower 
than the average age of those who did not develop ANY, 52.26 (SD:12.6; t(23)=-2.9661, 
P<0.01). Table 4 shows that the patients with Hodgkin's Disease, Testis, and Breast 
Carcinoma were younger than those with non-Hodgkin's lymphoma, myeloma, colon 
and ovarian cancer. The average ages for the different diagnostic groups are generally 




Diagnosis and Age of the Patients Analysed 
Number Mean Age (s.d) Number(%) With ANV 
Sarcoma 36 1 (100%) 
Adeno.Colon 4 63.75 (6.70) 0 (0%) 
CA Breast 4 43.80 (5.81) 2 (50%) 
NHL 4 56.50 ( 11.62) 0 (0%) 
HD 4 36.25 (17.61) 1 (25%) 
Myelorna 2 60.00 (7 .07) 0 (0%) 
Ovarian 2 60.00 (12.73) 0 (0%) 
Testis 4 37.00 (7.39) 2 (50%) 
Total 25* 43.72 (14.2) 6 (24%) 
*Patient number 012 died Qfter cycle one, so only twenty five patients were analysed 
Table 3 shows the demographics for all of the patients in the study and Table 4 shows 
the average age of patients in the different diagnostic groups. Four patients were treated 
for non-Hodgkin's lymphoma; three males and one female, with an average age of 56.50 
(SD: 11.62). Five patients were treated for carcinoma of the breast; all female, with an 
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average age of 43.80 (SD:5.81). Four patients were treated for Hodgkin's Disease; three 
males and one female, with an average age of 36.25 (SD: 17 .61 ). Four males were 
treated for testis cancer; with an average age of 37 .00 (SD:7 .39). Four patients were 
treated for colon cancer; three males and one female, with an average age of 63.75 
(SD:6.70). Two females, one 52 years old and the other 69 years old, were treated for 
ovarian cancer. Two patients, a 65 year old male and a 56 year old female, were treated 
for myeloma. One 37 year old male was treated for sarcoma. 
CHEMOTHERAPY PROTOCOLS 
Of the five patients treated for carcinoma of the breast, one received six cycles of 
intravenous Cyclophosphamide and Adriamycin, and oral Prednisone (CAP), and the 
other four patients received either six or eight cycles of intravenous Cyclophosphamide, 
Methotrexate, and 5-FU (CMF). All five patients had their chemotherapy recycled every 
four weeks. 
Two of the four patients treated for non-Hodgkin's lymphoma received intravenous 
Cyclophosphamide, Adriamycin and Vincristine, and oral Prednisone (CHOP), plus 
intra-thecal Methotrexate. One of these patients received four cycles and the other six 
cycles. The patient who received four cycles had his dose reduced to 75% of his initial 
dose for cycles three and four. One of the remaining two lymphoma patients received 
six cycles of intravenous Cyclophosphamide, Etoposide and Vincristine, and oral 
Prednisone ( CHOP with the adriamycin replaced by etoposide due to the patient's 
cardiac history); and the other received six cycles of CHOP. All four of the patients with 
non-Hodgkin's lymphoma had their chemotherapy recycled every four weeks. 
Two of the Hodgkin's Disease patients received six cycles of intravenous 
Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD). This protocol involved 
receiving ABVD on day one and fifteen of each cycle, and having their treatment 
recycled on day 28. One received only two cycles of ABVD before being changed to 
oral Chlorambucil, intravenous Vinblastine, oral Procarbazine, and oral Prednisone 
(ChlVPP) for the remaining four cycles due to a pre-existing heart problem which made 
the continued use of Adriamycin inadvisable. The remaining HD patient received six 
cycles of ChlVPP. The patients receiving ChlVPP had their chemotherapy recycled 
every four weeks. 
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All four of the patients with testis cancer received four cycles of intravenous 
Bleomycin, Etoposide, and Cisplatin (BEP), although the bleomycin was removed from 
the last couple of cycles in most of these patients due to its effects on their respiratory 
functioning. The testis cancer patients had their chemotherapy recycled every three 
weeks. 
The four patients with colon cancer all received five consecutive days of intravenous 
5-FU followed by six months of weekly intravenous 5-FU plus fortnightly oral 
Levamisole. 
Both of the patients with ovarian cancer were treated with intravenous Carboplatin 
every four weeks. One received three cycles and the other received four cycles before 
their diseases were found to have progressed and one had her treatment changed to 
Taxol and the other had her treatment discontinued. 
Two patients with myeloma received intravenous Cyclophosphamide every four 
weeks. 
One patient with sarcoma received intravenous Adriamycin on two consecutive days, 
every three weeks. The dose was spread over two days due to its cardiotoxicity. 
A detailed list of the chemotherapy protocols used on the patients in this study is 
provided in appendix 6. 
ANTIEMETIC COVER 
The antiemetic cover provided for each patient during each of their chemotherapy 
cycles is listed in Table 5. Sixteen (64%) of the twenty-five patients were given 5-HT3 
receptor antagonists at cycle one, with eighteen (72%) patients receiving either 
ondansetron or granisetron for the majority of their chemotherapy cycles. All but one 
(83%) of the ANV patients received 5-HT3 receptor antagonists throughout their 
chemotherapy, and the remaining patient received ondansetron from her second cycle 
onwards. Most of the patients receiving 5-HT3 antagonists, and some who were 
receiving metoclopramide, were prescribed dexamethasone as well as ondansetron or 
granisetron. One patient was part of a study looking at the efficacy of providing five 
days cover with ondansetron, but was returned to the standard dose schedule after her 
second cycle of chemotherapy. The patients who did not receive 5-HT3 receptor 




Table 6 shows the number of cycles for which each of the twenty-six patients were 
followed. Twenty-four patients were followed for at least four cycles of their 
chemotherapy. Patient number 012 died two days after receiving his first cycle of 
chemotherapy due to complications from his kidney disease and patient number 008 was 
followed for only three cycles, at which point her disease was found to have progressed 
and her chemotherapy was discontinued. For the purposes of conducting an analysis of 
the results, the data from patient 008 was included but the data collected from patient 
012 was not included in any statistical analyses. 
Of the twenty-four patients who were followed for four cycles or more, thirteen were 
followed for four cycles, one was followed for five cycles, eight for six cycles, one for 
seven, and one for eight cycles of their chemotherapy. 
The average number of cycles for which a patient was followed and assessed was 
5.06 (range 3-8); 5.33 (range 4-6) for those who developed ANY and 4.79 (range 3-8) 
for the non-ANV patients (t(23)=0.9220, ns). 
Table 5. 
Antiemetic Cover Provided During Each Chemotherapy Cycle ( C) 
Patient Antiemetic Cover 
1 Cl: Ondansetron, C2-6: Ondansetron+Dexamethasone 
2 C 1-2: Ondansetron+Dexamethasone, C3-4: Granisetron, C5-6: Granisetron+Dexamethasone 
3 C 1-6: Ondansetron+Dexamethasone 
4 Cl: Metoclopramide+Dexamethasone, C2-6: Ondansetron+Dexamethasone 
5 C 1-6: Ondansetron+Dexamethasone 
6 Cl: Metoclopramide+Dexamethasone, C2-4: Ondansetron+Dexamethasone 
7 Cl-6: Ondansetron+Dexamethasone 
8 Cl-3: Ondansetron 
9 Cl-4: Metoclopramide+Dexamethasone 
10 Cl-8: Metoclopramide 
Table 5. (Contd) 
Patient Antiemetic Cover 
11 Cl-3: Ondansetron+Dexamethasone, C3-6: Granisetron+Dexamethasone 
13 Cl-5: Metoclopramide 
14 Cl: Granisetron, C2-4: Granisetron+Dexamethasone 
15 Cl-4: Granisetron+Dexamethasone 
16 Cl-7: Metoclopramide 
17 Cl-2: Ondansetron, C3: Ondansetron+Dexamethasone, C4-6: Granisetron+Dexamethasone 
18 Cl-4: Granisetron+Dexamethasone 
19 Cl-4: Metoclopramide 
20 Cl-4: Ondansetron+Dexamethasone 
21 Cl-4: Granisetron+Dexamethasone 
22 Cl-4: Metoclopramide 
23 C 1-4: Ondansetron 
24 Cl-4: Ondansetron+Dexamethasone 
25 Cl-4: Metoclopramide 
26 Cl-2: Ondansetron 5 Day Trial*, C3-4: Ondansetron 
*This patient received a five day supply of ondansetron for her first two cycles of chemotherapy. 
Ondansetron=Zofran 8mgPOx3 
Granisetron=Kytril 3mgIVxl 
Metoclopramide=Maxolon l0-20mgIV or PO 
Dexamethasone=8- l 6mgIV or PO 
SUSCEPTIBILITY TO MOTION SICKNESS 
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Table 6 shows that fifteen (60%) of the twenty-five patients who were included in the 
statistical analyses did not presently suffer from motion sickness, four ( 16%) suffered 
only from sea sickness, and six (24%) suffered from motion sickness in general. Four 
(16%) of these patients did not presently suffer from motion sickness but reported 
experiencing motion sickness earlier in their lives. 
Of the ANV patients, four (66%) did not presently suffer from motion sickness, one 
(17%) suffered from sea sickness, and one (17%) suffered from motion sickness in 
general. One ( 17%) of the ANV patients did not presently suffer from motion sickness 
but reported experiencing motion sickness as a child. In the non-ANV group, twelve 
(58%) did not presently suffer from motion sickness, three (16%) suffered from sea 
sickness, and five (26%) suffered from motiori sickness in general. Three (15%) of the 
non-ANV patients did not presently suffer from motion sickness but reported 
experiencing it in the past. These similar percentages for both groups indicate that there 
was no clear relationship between the patients' susceptibility to motion sickness and the 
development of ANV. 
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Table 6. 
Cy__cles Followed and Motion Sickness History 
Patient Number No. of Cycles Followed Motion Sickness 
1 6 No 
2 6 No 
3 6 No 
4 6 Childhood 
5 6 Pregnancy 
6 4 No 
7 6 No 
8 3 Sea 
9 4 Yes 
10 8 20 yrs ago 
11 6 Yes 
13 5 No 
14 4 Sea 
15 4 Childhood 
16 7 No 
17 6 Yes 
18 4 Yes 
19 4 No 
20 4 Yes 
21 4 No 
22 4 No 
23 4 Sea 
24 4 No 
25 4 Sea 
26 4 Yes 
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Posttreatment Nausea and Vomiting 
Posttreatment nausea and vomiting were assessed using the Morrow Assessment of 
Nausea and Emesis. Separate severity ratings, from 1-6 (Very Mild-Intolerable), were 
obtained for posttreatment nausea and posttreatment vomiting. The frequency of the 
posttreatment nausea and vomiting was obtained by calculating the percentage of cycles 
in which nausea and vomiting were reported on the MANE for each patient. 
POSTTREATMENT NAUSEA AND VOMITING SEVERITY 
Table 7 shows the average severity of posttreatment nausea experienced by all of the 
patients analysed, as well as showing the ANV patients and non-ANV patients 
separately. 
Table 7. 
Posttreatment Nausea Severity 
All Patients ANV Non-ANV 
Cycle 1 1.62 2.67 (n=6) 1.29 (n=19) 
Cycle 2 1.74 2.92 (n=6) 1.37 (n=19) 
Cycle 3 1.46 3.08 (n=6) 0.95 (n=19) 
Cycle4 1.77 3.67 (n=6) 1.14 (n=18) 
Cycle 5 0.77 1.38 (n=4) 0.43 (n=7) 
Cycle 6 1.85 2.88 (n=4) 1.17 (n=6) 
Cycle 7 0.50 * 0.50 (n=2) 
Cycle 8 2.00 * 2.00 (n=l) 
Average 1.58 2.97 1.14 
S.D. 1.47 1.49 1.16 
Highest 2.50 4.25 1.95 
Lowest 0.78 1.92 0.42 
*no patients who developed ANY were followed for more than six cycles. 
The average severity level of posttreatment nausea in the ANV group was 2.97 
(SD: 1.49; 'Moderate' on the MANE), which is significantly higher than the average of 
1.14 (SD:1.16; 'Very mild' on the MANE) for the patients in the non-ANV group 
(t(23)=3.8062, P<0.01). The ANV group had a higher average level of posttreatment 
nausea for all six of the cycles comparable - significantly higher on all but the fifth 
cycle. The ANV group were 0.94 standard deviations higher after cycle one 
(t(23)=2.3 l 90, P<0.05), 1.05 SDs higher after cycle two (t(23)=2.4005, P<0.05), 1.45 
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SDs higher after cycle three (t(23)=3.2552, P<0.01), 1.72 SDs higher after cycle four 
(t(22)=4.3627, P<0.01), and 1.16 SDs higher after cycle six (t(8)=2.6431, P<0.05); but 
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Figure 2. Posttreatment Nausea Severity 
The most severe posttreatment nausea was reported by the ANV group, and was 
126% higher than that reported by the non-ANV group on average (t(23)=3.7847, 
P<0.01), and the lowest levels reported by the non-ANV group were 79% lower than 
those reported by the patients in the ANV group (t(23)=3.2049, P<0.01). 
Figure 2 shows that the severity of posttreatment nausea in the ANV group reached a 
peak following cycles three and four, whereas the non-ANV group remained relatively 
stable over the first six cycles. The regression lines and corresponding correlation 
coefficients indicate that the relationship between posttreatment nausea severity and the 
cycle number is nonlinear, with a relatively flat regression lines (ANV group: slope=-
0.09, Non-ANV group: slope=0.01) and low levels of correlation (ANV group: r=-0.21, 
Non-ANV group: r=0.03). It appears that the level of posttreatment nausea in the ANV 
group increased gradually over the first four cycles, but then dropped sharply for the 
fifth cycle before increasing again after the sixth cycle. 
Table 8. 
Posttreatment Vomiting Severity 
All Patients ANV 
Cyclel 0.58 1.92 (n=6) 
Cycle2 0.68 1.67 (n=6) 
Cycle3 1.22 2.58 (n=6) 
Cycle4 1.13 2.83 (n=6) 
Cycle5 0.64 1.00 (n=4) 
Cycle6 1.00 1.50 (n=4) 
Cycle7 0.00 * 
Cycle8 0.00 * 
Average 0.86 2.14 
S.D. 1.33 1.57 
Highest l.78 3.75 
Lowest 0.24 0.83 
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Figure 3. Posttreatment Vomiting Severity 
Similarly, the average posttreatment vomiting severity level reported by those in the 
ANV group of 2.14 (SD: 1.57; Mild on the MANE), was significantly higher than the 
average level of 0.46 (SD:0.95; less than Very mild on the MANE) reported by those in 
the non-ANV group (t(23)=4.5672, P<0.01). Table 8 shows that the ANV group 
consistently rated their posttreatment nausea higher than the patients in the non-ANV 
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group, being significantly higher after the first four cycles; 1.32 standard deviations 
higher at cycle one (t(23)=4.1613, P<0.01), 0.95 SDs higher at cycle two (t(23)=2.8506, 
P<0.01), 1.35 SDs higher at cycle three (t(23)=2.7581, P<0.05) and 1.71 SDs higher at 
cycle four (t(22)=4.3393, P<0.01). The difference was not significant for the fifth and 
sixth cycles; being only 0.43 SDs higher at cycle five (t(9)=0.6900, ns) and 0.62 SDs 
higher at cycle six (t(S)=0.9035, ns). The highest average levels of the ANV group were 
217% higher than those of the non-ANV group (t(23)=4.2291, P<0.01), and the lowest 
average levels of the non-ANV group were 87% lower than those of the ANV group 
(t(23)=2.5565, P<0.05). 
Figure 3 shows that the severity of posttreatment vomiting in the two groups reached 
a peak following cycles three and four. The regression lines and corresponding 
correlation coefficients indicate that the relationship between posttreatment vomiting 
severity and the cycle number is nonlinear, with a relatively flat regression lines (ANV 
group: slope=0.11, Non-ANV group: slope=-0.04) and low levels of correlation (ANV 
group: r=-0.30, Non-ANV group: r=-0.34). Figure 3 also shows that both groups 
demonstrated the same pattern - starting out with less severe vomiting, developing their 
worst vomiting after cycles three and four, and then experiencing less severe 
posttreatment vomiting after cycles five and six. 
POSTTREATMENT NAUSEA AND VOMITING FREQUENCY 
As Figure 4 shows, the patients in the ANV group reported posttreatment nausea 
94% of the time whereas the patients in the 11011-ANV group reported posttreatment 
nausea 56% of the time (t(23)=2.4043, P<0.05). Table 10 shows that four (21 % ) patients 
in the non-ANV group experienced no nausea at all but there were no patients in the 
ANV group who experienced complete control of their posttreatment nausea. Those 
patients in the non-ANV group who did not have complete control of their posttreatment 
nausea experienced it 72% of the time. 
Figure 4 also shows that the patients who developed ANV reported posttreatment 
vomiting 69% of the time whereas those who did not develop ANV reported 
posttreatment vomiting 23% of the time (t(23)=3.2167, P<0.01). Table 10 shows that 
ten of the patients in the non-ANV group did not experience any vomiting at all but 
there were no patients in the ANV group who experienced complete control of their 
posttreatment vomiting. Those patients in the non-ANY group who did not have 
complete control of their posttreatment vomiting experienced posttreatment vomiting 
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Figure 4. Frequency of Posttreatment Nausea and Vomiting 
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As Figure 5 shows, age demonstrated a large negative relationship with posttreatment 
nausea (r=-0.58), indicating that younger patients experienced more posttreatment 
nausea than older patients. This relationship was not as strong with posttreatment 
vomiting (r=0.25). There was a very strong correlation between posttreatment nausea 
severity and posttreatment nausea frequency (r=0.84), as well as a strong correlation 
between posttreatment vomiting severity and posttreatment vomiting frequency 
(r=0.93). This means that a higher frequency of posttreatment nausea and vomiting 
corresponded to a higher severity of posttreatment nausea and vomiting, so that the 
patients who experienced posttreatment nausea and vomiting more often were also the 
patients who experienced the most severe nausea and vomiting. Also, there was a high 
correlation between posttreatment nausea severity and posttreatment vomiting severity 
(r=0.62), and between posttreatment nausea frequency and posttreatment vomiting 
frequency (r=0.41). This shows that the patients who experienced more severe nausea 
also experienced more severe vomiting, and that patients who experienced posttreatment 
nausea more often also experienced posttreatment vomiting more often. Table 9 shows 
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that there were no large differences in the severity of posttreatment nausea and vomiting 
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Figure 5. Posttreatment and Pretreatment Nausea and Vomiting for Three Age Groups 
Table 9. 
Posttreatment and Pretreatment Voniiting Severity for Males and Females 
Male (n=14) Female (n=l 1) 
Posttreatment Nausea 1.60 1.60 
Posttreatment Vomiting 0.83 1.13 
Pretreatment Nausea 0.20 0.27 
Pretreatment Vomiting 0 0.02 
Table 10. 
Frequency of Posttreatment Nausea and Vomiting 
Patient Posttreatment Nausea Frequency 

















Posttreatment Vomiting Frequency 

















Table 10. (Contd) 
Patient Posttreatment Nausea Frequency 
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EXPECTED VERSUS ACTUAL NAUSEA AND VOMITING 
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Tables 11 and 12 show the expected frequency and severity of nausea and vomiting 
for all of the patients in the study. The actual posttreatment nausea and vomiting 
severity scores (PNS and PVS) are the average nausea and vomiting ratings from the 
MANE, which yields a severity rating from 1-6 (Very Mild-Intolerable). The actual 
posttreatment nausea and vomiting frequency ratings (PNF and PVF) were calculated 
using the percentages from Table 10, giving a frequency rating from 0-4 (Never-
Always). For example, patient 001 experienced posttreatment nausea after 67% of his 
chemotherapy cycles, so his frequency rating is 67% of 4, or 2.67. The expected nausea 
and vomiting, frequency and severity ratings, were obtained from the results of the 
'Toxicity Questionnaire' mentioned in the introduction. Unfortunately, in comparing the 
actual nausea and vomiting versus the expected nausea and vomiting it is not possible to 
make a direct comparison as they are on different scales, although they are both 
measuring the same variable in a similar manner. The expected nausea and vomiting 
ratings are in two groups, one being the expected nausea and vomiting where the most 
emetic substance (Max) in the protocol is used to calculate the emetogenicity of the 
entire protocol, and the other being the expected nausea and vomiting where the average 
emetogenicity (Mean) of all of the components in the protocol are used. 
Tables 11 and 12 show that the patients who developed ANY were expected, on 
average, to experience nausea and vomiting more often and more severe than the 
patients who did not develop ANV, and that this was true for both methods of 
estimating protocol emetogenicity (Max:t(23)=2.0999, P<0.05; Mean:t(23)=2.1441, 
P<0.05). The ANV group were also expected to experience more severe nausea and 
vomiting as a result of their chemotherapy, and this was also consistent using both 
methods of estimation (Max:t(23)=2.1593, P<0.05; Mean:t(23)=2.3730, P<0.05). 
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Reasonably good correlations existed between posttreatment nausea severity and 
expected severity estimated using the most emetic substance (r=0.49), and between 
posttreatment nausea frequency and expected frequency estimated using the most emetic 
substance (r=0.49). The correlations between the estimates using the average 
emetogenicity and the actual nausea and vomiting were comparatively low. This shows 
that the most accurate estimate of the emetogenicity of the chemotherapy protocols was 
obtained using the most emetic substance as the basis for the estimation and not the 
average emetogenicity of all of the drugs in the protocol. 
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Table 11. 
Expected Versus Actual Posttreatment Nausea 
Patient Actual Actual Expected Expected Expected Expected 
PNS* PNF* Frequency Severity Frequency Severity 
(1-6) (0-4) (Max) (Max) (Mean) (Mean) 
{0-4) {1-3) (0-4) (1-3) 
1 1.50 2.67 3 2.4 3 2.4 
2 2.83 4 2 1.5 1.3 1.17 
3 0 0 2 1.5 1.175 0.95 
4 1.67 4 3 2.4 1.77 1.37 
5 1.00 3.33 3 2.4 1.525 1.225 
6 3.25 4 3 2.4 1.4 1.16 
7 3.83 4 3.3 2.5 2.1 1.725 
8 0.33 1.33 2.3 1.7 2.3 1.7 
9 1.00 2 2.3 1.7 2.3 1.7 
10 1.25 2.5 1 1.1 0.75 0.8 
11 2.17 4 2 1.5 1.3 1.17 
13 1.40 2.4 1.1 0.75 0.8 
14 4.75 4 3.7 2.9 2.07 1.67 
15 0.50 1 3.7 2.9 2.07 1.67 
16 0 0 1.1 0.75 0.8 
17 1.80 3.2 2 1.5 1.3 1.17 
18 3.25 4 3.7 2.9 2.07 1.67 
19 0.50 2 1.2 1.2 0.85 0.75 
20 1.50 3 3.3 2.5 2.1 1.725 
21 0.50 2 3.7 2.9 2.07 1.67 
22 0 0 2 1.5 2 1.5 
23 2.50 4 3.3 2.5 2.1 1.725 
24 2.25 4 3 2.4 1.4 1.16 
25 0 0 1 1.1 0.75 0.8 
26 1.75 4 2 1.5 1.3 1.17 
All 1.58 2.62 2.46 1.97 1.61 1.34 
ANV 2.97 3.78 3.12 2.43 2.05 1.67 
Non-ANV 1.14 2.25 2.25 1.82 1.48 1.24 
*PNS=Posttreatment Nausea Severity, PNF=Posttreatment Nausea Frequency 
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Table 12. 
Exp_ected vs Actual Posttreatment Vomiting 
Patient Actual Actual Expected Expected Expected Expected 
PVS* PVF* Frequency Severity Frequency Severity 
(1-6) (0-4) (Max) (Max) (Average) (Average) 
(0-4) (1-3) (0-4) (1-3) 
1 2.00 4 3 2.4 3 2.4 
2 0.67 0.67 2 1.5 l.3 1.17 
3 0 0 2 1.5 1.175 0.95 
4 2.67 3.33 3 2.4 1.77 1.37 
5 0.50 1.33 3 2.4 1.525 1.225 
6 2.25 3 3 2.4 1.4 1.16 
7 1.00 1.33 3.3 2.5 2.1 1.725 
8 0 0 2.3 1.7 2.3 1.7 
9 0.75 2 2.3 1.7 2.3 1.7 
10 0.38 0.5 1 1.1 0.75 0.8 
11 0.83 2 2 1.5 1.3 1.17 
13 0 0 1 1.1 0.75 0.8 
14 3.50 4 3.7 2.9 2.07 1.67 
15 0 0 3.7 2.9 2.07 1.67 
16 0 0 l 1.1 0.75 0.8 
17 1.60 4 2 1.5 l.3 1.17 
18 3.00 4 3.7 2.9 2.07 1.67 
19 0 0 1.2 1.2 0.85 0.75 
20 0 0 3.3 2.5 2.1 1.725 
21 0 0 3.7 2.9 2.07 1.67 
22 1.50 2 2 1.5 2 1.5 
23 0 0 3.3 2.5 2.1 1.725 
24 0 0 3 2.4 1.4 1.16 
25 0.25 1 1 1.1 0.75 0.8 
26 0.75 2 2 1.5 1.3 1.17 
All 0.87 1.41 2.46 1.97 1.61 1.34 
ANV 2.14 2.89 3.12 2.43 2.05 1.67 
Non~ANV 0.46 0.94 2.25 1.82 1.48 1.24 
*PVS=Posttreatment Vomiting Severity, PVF=Posttreatment Vomiting Frequency 
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Anticipatory Nausea and Vomiting 
Six (24%) of the twenty-five patients developed ANV while they were participating 
in this study. Five (83%) of the ANV patients developed anticipatory nausea and one 
(17%) experienced both anticipatory nausea and anticipatory vomiting. Two patients 
(011 and 0 17) experienced anticipatory anxiety and loss of appetite but did not report 
anticipatory nausea or vomiting. 
A severity rating from 1-6 (Very Mild-Intolerable) was obtained for anticipatory 
nausea and anticipatory vomiting. The frequency of the anticipatory nausea and 
vomiting was obtained by calculating the percentage of cycles in which anticipatory 
nausea and vomiting were reported for each patient and translating that percentage into a 
rating from 0-4 (Never-Always). 
PRETREATMENT NAUSEA AND VOMITING SEVERITY 
Table 13 shows that the average severity of the anticipatory nausea experienced by 
the six patients who developed ANV was 0.93 (SD: 1.13), which corresponds to 'mild' 
on the MANE. There was only one episode of 'very mild' anticipatory vomiting, 
experienced by patient 004, before her fourth cycle of chemotherapy. As Figure 6 
shows, the worst anticipatory nausea was experienced prior to cycles three and four, 
with considerably higher levels of AN reported before these cycles. The highest level of 
AN reported was 'moderate' and was reported at some stage by five out of the six 
patients who developed ANV. There was little or no anticipatory nausea reported prior 
to cycles five and six. 
There was a reasonably good negative correlation between the severity of the 
anticipatory nausea and the age of the patient (r=-0.46), so that the younger patients 
experienced more anticipatory nausea than the older patients. Also, posttreatment 
nausea severity was shown to have a reasonable correlation with anticipatory nausea 
severity (r=0.44), showing that more severe posttreatment nausea is associated with 
more severe anticipatory nausea. 
Table 13. 
Pretreatment Nausea and Vomiting Severity 
Cycle 1 (n=6) 
Cycle 2 (n=6) 
Cycle 3 (n=6) 
Cycle 4 (n=6) 
Cycle 5 (n=4) 
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Figure 6. Pretreatment Nausea and Vomiting Severity 
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PRETREATMENT NAUSEA AND VOMITING FREQUENCY 
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One ( 17%) of the ANV patients experienced AN prior to receiving her first 
treatment, two (33%) developed ANV prior to their second cycles of chemotherapy, two 
(33%) experience AN for the first time prior to their third cycles, and one ( 17%) 
developed AN prior to receiving his fourth cycle of chemotherapy. The patient who 
experienced anticipatory nausea before her first treatment had received radiotherapy for 
her breast cancer about four years prior to this and had experienced a great deal of 
nausea and vomiting during that treatment, consequently making her very anxious about 
starting chemotherapy. 
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Table 14 shows the percentage of cycles in which the six ANV patients experienced 
anticipatory nausea and vomiting. Patient 001 experienced anticipatory nausea for the 
last three of his six cycles of Adriamycin; patient 002 experienced anticipatory nausea 
prior to cycles two and three but not again during her six cycles of CMF chemotherapy; 
patient 004 experienced anticipatory nausea prior to receiving her first four treatments of 
CAP chemotherapy and also reported 'very mild' anticipatory vomiting prior to her 
fourth cycle; patient 007 reported experiencing anticipatory nausea prior to her second, 
third and fourth cycles of ABVD; and patients 014 and 018 experienced anticipatory 
nausea before their last two out of four cycles of BEP. On average, the patients who 
experienced anticipatory nausea reported it before 47% of their treatments. Three 
patients reported anticipatory nausea before half of their treatments, two reported it 
before one third of their treatments, and one patient reported it before two thirds of her 
treatments. 
Posttreatment nausea severity was shown to have a positive relationship with 
anticipatory nausea frequency (r=0.54), showing that more severe posttreatment nausea 
is associated with more frequent episodes of anticipatory nausea. There was a very 
strong correlation between anticipatory nausea severity and anticipatory nausea 
frequency (r=0.90), which shows that more severe anticipatory nausea is very closely 
linked with more frequent episodes of anticipatory nausea. This means that the patients 
who experience the most severe anticipatory nausea also experience anticipatory nausea 
more often. Also, there were reasonably strong correlations between anticipatory nausea 
severity and expected severity using the most emetic substance (r=0.44), and also 
between anticipatory nausea frequency and expected frequency using the same method 
of estimation (r=0.43). This demonstrates that the expected emetogenicity of the 
protocols (using the most emetic substance) was a reasonably good predictor of the 
severity and frequency of anticipatory nausea. 
Table 14. 

































A) STAI-S Scores 
The STAI-State anxiety scores for those who developed ANV and those who did not 
develop ANV were compared. On average, the patients who developed ANV scored 
significantly higher on this measure of state anxiety (t(23)=3.1065, P<0.01). The 
average score for the ANV group over the entire follow-up period was 37 (SD:9.58), 
28% higher than the average score for the non-ANV group of 29 (SD:7.03). Table 15 
shows that the average STAI-S scores of the ANV group were consistently higher than 
those of the non-ANV group and were significantly higher on the first three cycles; 1 .40 
standard deviations higher at cycle one (t(23)=3.1921, P<0.01), 0.94 SDs higher at cycle 
two (t(23)=2.5886, P<0.05) and 1.22 SDs higher at cycle three (t(23)=2.5902, P<0.05). 
There was no significant difference for the last three cycles; only 0.67 SDs higher at 
cycle four (t(22)=1.4132, ns), 0.92 SDs higher at cycle five (t(9)=1.8173, ns) and 0.10 
SDs higher at cycle six (t(8)=0.1969, ns). On average the ANV group recorded 
maximum scores 31 % higher than patients in the non-ANV group (t(23)=3.1267, 
P<0.01), whereas the non-ANV groups' lowest scores were 19% less than those in the 
ANV group (t(23)=2.0293, ns). 
The regression lines in Figure 7 show that there is a large downward trend for the 
ANV group (slope=-2.60) and that this line accurately reflects the pattern of results (r=-
0.89). So, as the patients proceeded through their chemotherapy they reported a 
decreasing level of state anxiety before each cycle. The non-ANV group did not 
demonstrate this general decline in state anxiety - remaining relatively stable throughout 
their chemotherapy (slope=0.17), although the flat line does not accurately represent the 
pattern of results (r=0.17). 
The younger patients tended to report higher levels of state anxiety (r=-0.44). 
Overall, there was a strong correlation between the STAI-State scores and the STAI-
Trait scores (r=0.72), although the relationship was stronger in the non-ANV patients 
(r=0.70) compared to the ANV patients (r=0.54). This correlation shows that the STAI-
Trait anxiety scores were influenced by the STAI-State scores and vice versa, so that a 
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higher state anxiety score was correlated with a high trait anxiety score. There was a 
reasonable correlation between the STAI-S scores and the state anxiety mm scores 
overall (r=0.48), but there was only a good correlation among the ANV group. This 
shows that the visual analogue scale state anxiety scores provided a good validation of 
the state anxiety scores measured using the STAI, but only in the ANV group. There 
were strong correlations between the STAI-S scores and posttreatment nausea (r=0.65) 
and vomiting (r=0.64) severity, and also between STAI-S scores and posttreatment 
nausea (r=0.63) and vomiting (r=0.53) frequency. This means that high state anxiety 
score were associated with more severe and frequent posttreatment nausea and 
vomiting. The STAI-S scores were also closely related to anticipatory nausea severity 
(r=0.63) and frequency (r=0.61), showing that high levels of state anxiety were 
associated with more severe and frequent anticipatory nausea .. 
STAI-State scores were also shown to be highly predictive of the occurrence of 
anticipatory nausea in consequent cycles. STAI-S scores at cycle one were highly 
correlated with anticipatory nausea severity before cycle two (r=0.84) and cycle three 
(r=0.85). So, the patients who had high levels of state anxiety at cycle one were likely to 
have more severe anticipatory nausea before cycles two and three. There was an 
opposite relationship between STAI-S scores at cycle two and anticipatory nausea 
severity at cycle three (r=-0.70), but a positive relationship between STAI-S scores at 
cycle two and anticipatory nausea severity at cycle four (r=0.51 ). This means that the 
patients with high state anxiety at cycle two experienced less severe anticipatory nausea 
at cycle three and more anticipatory at cycle four. There was a very high positive 
correlation between STAI-S scores at cycle three and anticipatory nausea severity at 
cycle four (r=0.91), with patients who having high state anxiety at cycle three 
experiencing high levels of anticipatory nausea at cycle four. 
In comparison to the norms for the STAI-S reported by Knight, Waal-Manning and 
Spears (1983) of 30.19 (S.D:7.31) for males and 33.51 (S.D:8.61) for females, the 
average for the males was 31.15 (SD:8.47) and the average for the females was 31.14 
(SD:8.48). 
Table 15. 
State-Trait Anxiety Inventory, State Anxiety Averages 
All Patients ANV Non-ANV 
Cycle 1 34.98 43.92 (n=6) 32.16 (n=19) 
Cycle 2 30.26 36.25 (n=6) 28.37 (n=19) 
Cycle 3 31.38 39.17 (n=6) 28.92 (n=19) 
Cycle 4 30.19 34.42 (n=6) 28.78 (n=l8) 
Cycle 5 29.68 34.63 (n=4) 26.86 (n=7) 
Cycle 6 27.15 27.63 (n=4) 26.83 (n=6) 
Cycle 7 33.00 * 33.00 (n=2) 
Cycle 8 32.00 * 32.00 (n=l) 
Average 31.15 37.36 29.19 
S.D. 8.41 9.58 7.03 
Highest 38.32 46.75 35.66 
Lowest 25.50 29.75 24.16 
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Figure 7. STAI-State Anxiety Averages 
B) STAI-S Profiles 
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Although the ANV patients scored higher on average on the STAI-S than non-ANV 
patients, they did not score significantly higher on all of the STAI-S items. Figure 8 and 
Table 16 show that the ANV patients, on average, scored significantly higher on nine of 
the twenty items. The items which were significantly higher in the ANV group were 
items 2 (Secure; t(23)=2.5125, P,0.05), 3 (Tense; t(23)=2.2845, P<0.05), 5 (At ease; 
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t(23)=2.2150, P,0.05), 13 (Jittery; t(23)=2.9258, P<0.01), 15 (Relaxed; t(23)=2.1993, 
p<0.05), 16 (Content; t(23)=2.3187, P<0.05), 18 (Confused; t(23)=2.6104, P<0.05), 19 
(Steady; t(23)=3.6596, P<0.01), and 20 (Pleasant; t(23)=2.3695, P<0.05). The items 
which were not significantly different were 1 (Calm), 4 (Strained), 6 (Upset), 7 (Worried 
about possible misfortunes), 8 (Satisfied), 9 (Frightened), 10 (Comfortable), 11 (Self-
confident), 12 (Nervous), 14 (Indecisive), and 17 (Worried). The patients who 
developed ANV were less secure, more tense, less at ease, more jittery, less relaxed, less 
content, more confused, less steady, and feeling less pleasant than those patients who 
did not develop ANV. 
Table 16. 
State-Trait Anxiety Inventory - State Anxiety Individual Item Averages 
Item Average All Pats AverageANV Average Non ANV 
1 1.72 1.90 1.66 
2 1.46 1.81 1.35 
3 1.49 1.79 1.40 
4 1.48 1.71 1.41 
5 1.72 2.13 1.60 
6 1.19 1.32 1.15 
7 1.37 1.44 1.34 
8 1.78 2.19 1.65 
9 1.31 1.51 1.25 
10 1.74 2.19 1.59 
11 1.64 1.88 1.57 
12 1.55 1.81 1.47 
13 1.28 1.64 1.17 
14 1.27 1.33 1.25 
15 1.84 2.22 1.72 
16 1.87 2.38 1.71 
17 1.53 1.79 1.44 
18 1.16 1.36 1.10 
19 1.66 2.26 1.47 
20 1.90 2.50 1.71 
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Figure 8. STAI-State Anxiety Individual Item Averages 
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C) State Anxiety mm Scores 
Where state anxiety was measured using a 10cm visual analogue scale, the patients 
who developed ANV rated their anxiety greater than those who did not go on to develop 
ANV although this difference was not statistically significant (t(23)=1.9204, ns). The 
average score, as measured in millimetres, were 26 (SD:21.27) for the ANV group and 
14 (SD: 16.02) for those in the non-ANV group - 86% higher in the ANV group. Table 
17 shows that the average state anxiety mm scores were higher for those in the ANY 
group in five out of the six cycles available to compare, with only cycle one being 
significantly different. The ANV group scored 1.14 standard deviations higher at cycle 
one (t(21)=2.6429, P<0.05), 0.81 SDs higher at cycle two (t(23)=1.5937, ns), 0.62 SDs 
higher at cycle three (t(23)=1.2782, ns), 0.93 SDs higher at cycle four (t(22)=2.0728, 
ns), 0.27 SDs higher at cycle five (t(9)=0.5284, ns), but 0.28 SDs lower than the non-
ANV group at cycle six (t(8)=-0.5300, ns). The highest scores recorded by ANV 
patients were 92% higher than the highest state anxiety mm scores recorded by non-
ANV patient on average (t(23)=2.9809, P<0.01). On the other hand, the lowest scores 
on average were from the patients in the non-ANV group, 61 % lower than those in the 
ANV group, although this was not significant (t(23)=1.4777, ns). 
The regression lines in Figure 9 show a very strong downward trend in the state 
anxiety mm scores for the ANY group (slope=-6.50, r=-0.96). Although the non-ANV 
group has an upward trend overall (slope= 1.68), there is a downward trend for the first 
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six cycles (slope=-2.22). Cycles seven and eight include only two and one observations 
respectively, so the sharp increase in state mm scores for these cycles is probably just a 
result of this reduction in patient numbers. 
Table 17. 
State Anxiety 10cm Visual Analogue Scale Averages 
All Patients ANV Non-ANV 
Cycle 1 24.28 41.13 (n=6) 20.74 (n=l9) 
Cycle 2 18.92 29.92 (n=6) 15.45 (n=l9) 
Cycle 3 16.86 25.25 (n=6) 14.21 (n=l9) 
Cycle 4 14.46 27.00 (n=6) 10.28 (n=18) 
Cycle 5 11.36 14.50 (n=4) 9.57 (n=7) 
Cycle6 7.50 4.50 (n=4) 9.50 (n=6) 
Cycle 7 29.50 * 29.50 (n=2) 
Cycle 8 33.00 * 33.00 (n=l) 
Average 17.11 26.30 14.21 
S.D. 17.95 21.27 16.02 
Highest 32.10 50.58 26.26 
Lowest 7.00 13.00 5.11 














r = -0.956615 
0 
2 3 4 5 6 7 8 
Cycle 
~ ANVGroup ___...,_ Non-ANV Group 
Figure 9. State Anxiety Visual Analogue Scale Averages 
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TRAIT ANXIETY 
A) STAI-T Scores 
The two groups also scored differently on the twenty items in the STAI-Trait 
subscale. The average score for those who developed ANY was 37 (SD:9.05), 23% 
higher than the average recorded by those who did not develop ANY of 30 (SD:7.96; 
t(23)=2.1344, P<0.05). Table 18 shows that the ANY group scored significantly higher 
on the first three cycles; scoring 1.05 standard deviations higher at cycle one 
(t(23)=2.1371, P<0.05), 1.34 SDs higher at cycle two (t(23)=3.1473, P<0.01) and 1.00 
SDs higher at cycle three (t(23)=2.2522, P<0.05). However, there was not a significant 
difference between the ANY patients and non-ANY patients for the last three cycles; 
only 0.63 SDs higher at cycle four (t(22)=1.4072, ns), 0.50 SDs higher at cycle five 
(t(9)=2.l 190, ns) and 0.52 SDs higher at cycle six (t(8)=1.4663, ns). On average, the 
highest scores of the patients in the ANY group were 37% higher than those in the non-
ANY group (t(23)=2.9318, P<0.01), and the lowest scores of the patients in the non-
ANY group were 15% lower than those in the ANY group (t(23)=1.3464, ns). So, the 
highest scores of the ANY group were significantly higher than the highest scores of the 
non-ANV group, but the lowest scores of the two groups were not significantly 
different. 
Figure 10 shows that there was a downward trend in the STAI-T scores for both 
groups (ANV: slope=-3.01, non-ANV: slope=-0.64) and that these downward sloping 
regression lines are an accurate description of the relationship between the STAI-T 
scores and the cycle number (ANY: r=-0.94, non-ANY: r=-0.96). So, there was a 
tendency for the patients to report less trait anxiety as their chemotherapy progressed. 
Age was shown to have a fairly strong correlation with STAI-T scores (r=-0.56), with 
younger patients recording higher scores. Overall, there was a strong positive correlation 
between the STAI-T scores and the BDI scores (r=0.60), although this was not as strong 
in the ANY patients. This correlation shows that, generally, higher levels of trait anxiety 
were associated with higher levels of depression. There was a reasonable correlation 
between the STAI-T scores and the trait anxiety mm scores (r=0.49), with a stronger 
correlation in the ANY group (r=0.69), showing that the visual analogue scale for trait 
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anxiety provided good validation of the STAI-T scores. STAI-T scores were also highly 
correlated with posttreatment nausea severity (r=0.72) and frequency (r=0.70), but not 
very strong for posttreatment vomiting severity and frequency. This demonstrates that 
high trait anxiety was associated with more severe and frequent posttreatment nausea 
but not vomiting. There were good positive relationships between STAI-T scores and 
anticipatory nausea severity (r=0.69) and frequency (r=0.44) in the ANV group, showing 
that high trait anxiety was associated with more severe and frequent anticipatory nausea. 
STAI-Trait scores at cycle one were correlated with anticipatory nausea severity 
before cycles three (r=0.62) and four (r=0.61), so that patients with high state anxiety 
scores at cycle one experiencing higher levels of anticipatory nausea at before cycles 
three and four. There was no strong relationship between cycle two STAI-T scores and 
consequent anticipatory nausea severity, but there was a strong positive relationship 
between ST AI-T scores at cycle three and anticipatory nausea severity at cycle four 
(r=0.71). This means that the patients who recorded higher levels of trait anxiety at cycle 
three also experienced higher levels of anticipatory nausea at cycle four. 
In comparison to the norms for the STAI-T reported by Knight, Waal-Manning and 
Spears(l983) of 33.11 (S.D:7.80) for the males and 36.85 (S.D:8.89) for the females, the 
males in this study had an average score of 32.35 (SD:8.67) and the females had an 
average score of 30.52 (SD:9.20). 
Table 18. 
State-Trait Anxiety Inventory - Trait Anxiety Averages 
All Patients ANV Non-ANV 
Cycle 1 33.82 40.92 (n=6) 31.58 (n=19) 
Cycle 2 32.70 41.75 (n=6) 29.84 (n=19) 
Cycle 3 32.28 39.00 (n=6) 30.16 (n=l9) 
Cycle 4 30.75 34.92 (n=6) 29.36 (n=18) 
Cycles 25.73 28.25 (n=4) 24.29 (n=7) 
Cycle 6 26.00 28.75 (n=4) 24.17 (n=6) 
Cycle 7 22.50 * 22.50 (n=2) 
Cycle 8 21.00 * 21.00 (n=l) 
Average 31.54 37.32 29.72 
S.D. 8.87 9.05 7.96 
Highest 36.56 45.92 33.61 
Lowest 27.82 31.50 26.66 
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Figure 10. STAI-Trait Anxiety Score Averages 
B) STAI-T Profiles 
The ANV group, on average, scored significantly higher on six of the twenty ST AI-T 
items. As Table 19 and Figure 11 show, the items on which the patients who developed 
ANV scored significantly higher were items 27 (Calm, cool, and collected; 
t(23)=3.8279, P<0.01), 28 (Difficulties piling up; t(23)=2.2410, P<0.05), 30 (Happy; 
t(23)=2.1870, P<0.05), 33 (Secure; t(23)=2.8374, P<0.01), 38 (Take disappointments 
keenly and can not forget them; t(23)=2.2467, P<0.05), and 39 (Steady; t(23)=4.0571, 
P<0.01). The items on which there was not a significant difference were items 21 (Feel 
pleasant), 22 (Nervous and restless), 23 (Satisfied with self), 24 (Wish could be as 
happy as others seem), 25 (Feel like failure), 26 (Rested), 29 (Worry over unimportant 
matters), 31 (Disturbing thoughts), 32 (Lack self-confidence), 34 (Make decisions 
easily), 35 (Feel inadequate), 36 (Content), 37 (Bothered by unimportant things), and 40 
(Tension and turmoil as think over recent concerns and interests). The patients who 
developed ANV on average saw themselves as being less 'cool, calm, and collected', 
more susceptible to having difficulties piling up which they are unable to overcome, less 
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happy, less secure, more likely to take disappointments so keenly that they are unable to 
put them out of their minds, and less steady than the patients who did not develop ANV. 
Table 19. 
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Figure 11. STAI-Trait Anxiety Individual Item Averages 
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C) Trait Anxiety mm Scores 
Self-reported trait anxiety as measured by the 10cm visual analogue scale also 
revealed differences between those who developed ANV and those who did not. The 
average trait anxiety mm score was higher in the group who developed ANV than in the 
group who did not develop ANV, although this difference was not statistically 
significant (t(23)=1.8758, ns). 
The average trait anxiety mm score among those patients who developed ANV was 
27 (SD:21.43), 93% higher than the average score of 14 (SD: 16.43) among those who 
did not develop ANV. Table 20 shows that the ANV group scored higher on average in 
each of the cycles comparable, but only demonstrated significant differences on cycles 
three and four; 1.01 SDs higher at cycle three (t(23)=2.8606, P<0.01) and 0.82 SDs 
higher at cycle four (t(22)=3.3037, P<0.01), but only 0.91 standard deviations higher at 
cycle one (t(21)=1.2412, ns), 0.91 SDs higher at cycle two (t(23)=1.6804, ns), 0.26 SDs 
higher at cycle five (t(9)=0.7400, ns), and 0.34 SDs higher at cycle six (t(8)=0.8601, ns). 
The highest scores of those in the ANV group were 53% higher than those of patients in 
the non-ANV group, although this was not a statistically significant difference 
(t(23)=1.2715); whereas the lowest scores of the patients in the non-ANV group were 
71 % lower than those in the ANV group, which was a significant difference 
(t(23)=2.5388, P<0.05). So, the ANV group did not have high scores significantly 
higher than the non-ANV group, but the non-ANV group had low scores significantly 
lower than the ANV group. 
The linear regression lines in Figure 12 show that there was a downward trend in the 
trait anxiety mm scores for both groups (ANV: slope=-5.40, non-ANV: slope=-1.78) 
and that these lines are accurate representations of the relationship between the state 
anxiety mm scores and the cycle number (ANV: r=-0.97, non-ANV: r=-0.75). So, this 




Trait Anxiety 10cm Visual Analogue Scale Averages 
All Patients ANV Non-ANV 
Cycle 1 26.33 40.38 (n=6) 23.37 (n=l9) 
Cycle 2 22.66 35.50 (n=6) 18.61 {n=l9) 
Cycle3 14.98 29.25 (n=6) 10.47 (n= 19) 
Cycle4 10.50 21.92 {n=6) 6.69 {n=l8) 
Cycle 5 11.91 15.00 (n=4) 10.14 (n=7) 
Cycle6 12.55 16.38 (n=4) 10.00 (n=6) 
Cycle7 7.00 * 7.00 (n=2) 
Cycle8 10.00 * 10.00 (n=l) 
Average 17.39 27.19 14.30 
S.D. 18.65 21.43 16.43 
Highest 30.80 41.83 27.32 
Lowest 7.08 15.25 4.50 
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Figure 12. Trait Anxiety Visual Analogue Scale Averages 
DEPRESSION 
A) BDI Total Scores 
The severity of depression recorded by the Beck Depression Inventory revealed 
similar differences between the ANY and non-ANY groups as were demonstrated by the 
state anxiety and trait anxiety measures. On average, the ANY group scored 
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significantly higher than the non-ANV group (t(23)=2.3155, P<0.05), with the ANV 
group having an average score of 10 (SD:5.53), 67% higher than the average score of 6 
(SD:4.63) in the non-ANV group. Table 21 shows that the ANV group scored higher on 
all six cycles compared, although the difference was significant only on the first three 
cycles. The ANV group scored 1.10 standard deviations higher at cycle one 
(t(23)=3.5975, P<0.01), 1.12 SDs higher at cycle two (t(23)=2.8360, P<0.01) and 0.99 
SDs higher at cycle three (t(23)=2.2424, P<0.05). There was not a significant difference 
between the two groups for the last three cycles; being only 0.60 SDs higher at cycle 
four (t(22)=1.0217, ns), 0.67 SDs higher at cycle five (t(9)=1.7026, ns) and 0.63 SDs 
higher at cycle six (t(S)=l.6323, ns). The highest scores on average were scored by the 
ANV group, 82% higher than those scored by the non-ANV group (t(23)=2.5988, 
P<0.05). The lowest scores on average were scored by the non-ANV group, 51 % lower 
than those scored by the ANV group (t(23)=1.8257, ns). So, the highest scores of the 
ANV group were significantly higher than the highest scores of the non-ANV group, but 
the lowest scores of the two groups were not significantly different. 
Figure 13 shows that there was tendency for patients to report less depression as their 
chemotherapy progressed. The downward sloping regression lines (ANV: slope=-0.98, 
non-ANV: slope=-0.64) are an accurate representation of the relationship between the 
BDI total scores and the cycle number (ANV: r=-0.96, non-ANV: r=-0.87). 
The BDI-Total scores were highly correlated with the depression mm scores (r=0.70), 
showing that the visual analogue scale for depression provided good validation for the 
BDI. There were also good overall correlations between the BDI-Total scores and 
posttreatment nausea (r=0.55) and vomiting (r=0.65) severity, although the ANV group 
demonstrated a relatively strong negative correlation between the BDI-Total scores and 
posttreatment nausea severity (r=-0.48). This means that overall there was a tendency 
for the patients with the higher BDI scores to experience more severe posttreatment 
nausea and vomiting, but in the ANV group there was a tendency for the patients with 
the lower BDI scores to experience more severe posttreatment nausea. There was also an 
opposite correlation between the BDI-Total scores and posttreatment nausea frequency 
(ANV r=-0.73, Non-ANV r=0.55), showing that lower BDI scores in the ANV group 
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were associated with more frequent posttreatment nausea whereas higher BDI scores in 
the non-ANV group were associated with more frequent posttreatment nausea. There 
were consistently high correlations between the BDI-Total scores and posttreatment 
vomiting frequency (r=0.64 overall), showing that higher BDI scores were associated 
with more frequent posttreatment vomiting in both groups. There was a very strong 
correlation between the BDI-Total scores and SEEQ-Total scores in the ANV group 
(r=0.87) but not in the non-ANV group (r=0.24). This means that the patients in the 
ANV group with high BDI scores were also likely to have high SEEQ-Total scores, and 
that those with the high scores were expecting more side effects from their treatment 
than those with lower scores. 
There were no strong relationships between BDI scores and consequent levels of 
anticipatory nausea, although most of the relatively small correlations calculated were 
negative, meaning there was a tendency for those who scored higher on the BDI to 
experience less severe anticipatory nausea. 
Table 21. 
Beck Depression Inventory Total Score Averages 
All Patients ANV Non-ANV 
Cycle 1 7.50 12.42 (n=6) 6.52 (n=l9) 
Cycle 2 6.14 10.92 (n=6) 4.67 (n=l9) 
Cycle3 6.98 11.42 (n=6) 6.10 (n=l9) 
Cycle4 6.52 8.92 (n=6) 5.75 (n=l8) 
Cycle5 5.55 8.25 (n=4) 4.67 (n=7) 
Cycle6 5.45 7.63 (n=4) 4.25 (n=6) 
Cycle7 3.00 * 3.00 (n=2) 
Cycle 8 1.00 * 1.00 (n=l) 
Average 6.45 10.06 5.54 
S.D. 5.36 5.53 4.63 
Highest 9.82 14.92 8.21 
Lowest 3.48 5.67 2.79 
*no patients who developed ANY were followed for more than six cycles. 
The Center for Cognitive Therapy has distributed the following guidelines for BDI 
cut-off scores: none or minimal depression= <10; mild to moderate depression= 10-18; 
moderate to severe depression= 19-29; and severe depression= 30-63. Table 22 shows 
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Figure 13. Beck Depression Inventory Total Score Averages 
As can be seen in Table 22, on average the patients who developed ANV reported 
symptoms of depression on the BDI which equate to mild to moderate levels of 
depression, whereas the patients who did not develop ANV recorded none or minimal 
levels of depression on average. Three (50%) of the ANV patients had average BDI 
scores in the mild to moderate range of depression whereas only one (5%) of the non-
ANV patients had an average BDI score in the mild to moderate range, with the 
remainder of both groups having average scores in the none to minimal range, except 
one non-ANV patient with an average score in the moderate to severe range. Table 22 
also shows that only two of the ANV patients never had BDI scores above the none or 
minimal level, whereas two had scores in the mild to moderate range and two had 
maximum scores in the moderate to severe range. 
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Table 22. 
Clinical Ratings for the Average EDI Scores 
Patient Average BDI Score Clinical Rating Most Severe (Rating) 
1 16.33 Mild-Moderate 21 (Moderate-Severe) 
2 5.67 None or Minimal 9 (None or Minimal) 
4 12.83 Mild-Moderate 18 (Mild-Moderate) 
7 7.25 None or Minimal 22 (Moderate-Severe) 
14 11.75 Mild-Moderate 17 (Mild-Moderate) 
18 6.50 None or Minimal 9 (None or Minimal) 
3 5.17 None or Minimal 7 (None or Minimal) 
5 4.33 None or Minimal 7 (None or Minimal) 
6 19.25 Moderate-Severe 25 (Moderate-Severe) 
8 0.00 None or Minimal 0 (None or Minimal) 
9 4.00 None or Minimal 7 (None or Minimal) 
10 2.25 None or Minimal 7 (None or Minimal) 
11 4.00 None or Minimal 5 (None or Minimal) 
13 1.60 None or Minimal 4 (None or Minimal) 
15 2.50 None or Minimal 4 (None or Minimal) 
16 4.14 None or Minimal 8 (None or Minimal) 
17 7.67 None or Minimal 12 (Mild-Moderate) 
19 5.00 None or Minimal 8 (None or Minimal) 
20 2.63 None or Minimal 3 (None or Minimal) 
21 4.25 None or Minimal 6 (None or Minimal) 
22 4.25 None or Minimal 11 (Mild-Moderate) 
23 8.88 None or Minimal 12 (Mild-Moderate) 
24 8.25 None or Minimal 15 (Mild-Moderate) 
25 1.25 None or Minimal 2 (None or Minimal) 
26 11.50 Mild-Moderate 13 (Mild-Moderate) 
All Patients 6.45 None or Minimal 10.08 (Mild-Moderate) 
ANV 10.06 Mild-Moderate 16.00 (Mild-Moderate) 
Non-ANV 5.54 None or Minimal 8.21 (None or Minimal) 
E) EDI Physiological Subscale and Cognitive/Affective Subscale Scores 
When the Beck Depression Inventory scores were divided into the physiological 
subscale (items 14-21) and the cognitive/affective subscale (items 1-13) the differences 
between the two groups were evident more in the affective/cognitive subscale than in 
the physiological subscale. The two subscales of the BDI were very highly correlated 
(r=0.93), so that a patient who scored high on the physiological symptoms also tended to 
score high on the affective/cognitive symptoms and vice versa. 
The average BDI-PS score for the ANY group was higher than for the patients in the 
non-ANY group but this difference did not reach a significant level (t(23)=1.5745, ns). 
The average BDI-PS score for the ANY group was 6 (SD:4.12), 50% higher than the 
average for the non-ANY group of 4 (SD:3.15). As Table 23 shows, the difference was 
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recorded over all of the six cycles compared and was found to be statistically significant 
on the first two cycles; with the ANY group scoring 0.79 standard deviations higher at 
cycle one (t(23)=2.2008, P<0.05), 0.95 SDs higher at cycle two (t(23)=2.2091, P<0.05), 
but only 0.87 SDs higher at cycle three (t(23)=1.6519, ns), 0.47 SDs higher at cycle four 
(t(22)=0.8038, ns), 0.59 SDs higher at cycle five (t(9)=L1268, ns), and 0.45 SDs higher 
at cycle six (t(8)=0.8785, ns). The highest BDI-PS scores on average were recorded by 
the ANY group, 61 % higher than those of the non-ANY group (t(23)=1.8930, ns); 
whereas the lowest BDI-PS scores were recorded by the non-ANY group, 46% lower 
than those of the ANY group (t(23)= 1.3960, ns). So, the ANY and non-ANY groups did 
not score significantly higher or lower than each other on the physiological subscale of 
the BDI. 
The regression lines in Figure 14 show that there was a downward trend in the scores 
for the BDI physiological subscale in both groups (ANY: slope=-0.51, non-ANY: 
slope=-0.37). These lines are an accurate representation of the relationship between the 
BDI-PS scores and the cycle number (ANY: r=-0.92, non-ANY: r=-0.88). 
Table 23. 
Beck Depression Inventory Physiological Subscale Averages 
All Patients ANV Non-ANV 
Cycle 1 4.66 6.83 (n=6) 3.97 (n=19) 
Cycle 2 4.22 6.83 (n=6) 3.39 (n=l9) 
Cycle 3 4.62 7.00 (n=6) 3.87 (n=19) 
Cycle4 4.31 5.58 (n=6) 3.89 (n=18) 
Cycle 5 3.64 5.00 (n=4) 2.86 (n=7) 
Cycle6 3.65 4.63 (n=4) 3.00 (n=6) 
Cycle 7 2.00 * 2.00 (n=2) 
Cycle 8 1.00 * 1.00 (n=l) 
Average 4.24 5.99 3.69 
S.D. 3.61 4.12 3.15 
Highest 6.42 9.00 5.61 
Lowest 2.18 3.33 1.82 
*no patients who developed ANY were followed for more than six cycles. 
The patients in the ANY group recorded BDI-C/AS scores significantly higher than 
those who did not develop ANY (t(23)=3.0386, P<0.01). The average BDI-C/AS score 
in the ANY group was 4 (SD:3.22), twice as high as the average score of 2 (SD:2.01) in 
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the non-ANY group. Table 24 shows that the ANY group scored consistently higher 
than the non-ANY group, with significant differences on the first three cycles. The ANY 
group scored 1.34 standard deviations higher at cycle one (t(23)=3.1647, P<0.01), 1.05 
SDs higher at cycle two (t(23)=2.6458, P<0.05) and 1.00 SDs higher at cycle three 
(t(23)=2.3953, P<0.05), but only 0.56 SDs higher at cycle four (t(22)=1.2033, ns), 1.43 
SDs higher at cycle five (t(9)=2. l 932, ns) and 1.34 SDs higher at cycle six (t(8)=2.2094, 
ns). On average, the highest scores recorded by the ANY group were 190% higher than 
those recorded by the non-ANY group (t(23)=3.9888, P<0.01); whereas the lowest 
scores recorded by the non-ANY group were 60% lower than those of the ANY group 
(t(23)=1.6606, ns). So the highest scores recorded by the ANY group were significantly 
higher than those recorded by the non-ANY group, but there was no significant 
difference between the lowest scores recorded by the two groups. 
The regression lines in Figure 15 show that both group maintained relatively stable 
BDI affective/cognitive subscale scores (ANY: slope=-0.09, non-ANY: slope=-0.21). 
The scores for the non-ANY group were very stable (r=-0.83) but the scores for the non-
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Figure 14. Beck Depression Inventory Physiological Subscale Averages 
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Table 24. 
Beck Depression Inventory Affective/Cognitive Subscale Averages 
All Patients ANV Non-ANV 
Cycle 1 2.84 5.58 (n=6) 1.97 (n=l9) 
Cycle 2 1.92 4.08 (n=6) 1.24 (n=l9) 
Cycle 3 2.36 4.42 (n=6) 1.71 (n=19) 
Cycle 4 2.21 3.33 (n=6) 1.83 (n=l8) 
Cycle 5 2.55 5.00 (n=4) 1.14 (n=7) 
Cycle 6 2.45 4.63 (n=4) 1.00 (n=6) 
Cycle7 1.00 * 1.00 (n=2) 
Cycle 8 0.00 * 0.00 (n=l) 
Average 2.30 4.44 1.62 
S.D. 2.70 3.22 2.01 
Highest 4.22 8.42 2.89 
Lowest 1.06 2.00 0.76 
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Figure 15. Beck Depression Inventory Affective/Cognitive Subscale Averages 
C) BDI Profiles 
Although the ANV group scored higher on the BDI, they did not score significantly 
higher on all of the items of the BDI. Table 25 and Figure 16 show that the patients who 
developed ANV only scored significantly higher on items 2 (Pessimism; t(23)=3.1653, 
P<0.01), 4 (Lack of satisfaction; t(23)=2.1618, P<0.05), 18 (Loss of Appetite; 
t(23)=2.63 l 6, P<0.05) and 21 (Loss of Libido; t(23)=2.0937, P<0.05); but there was no 
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significant difference between the two groups on items 1 (Mood), 3 (Sense of failure), 5 
(Guilt Feelings), 6 (Sense of punishment), 7 (Self-dislike), 8 (Self-accusation), 9 
(Suicidal Wishes), 10 (Crying), 11 (Irritability), 12 (Social withdrawal), 13 
(Indecisiveness), 14 (Distortion of Body Image), 15 (Work Inhibition), 16 (Sleep 
Disturbance), 17 (Fatigability), 19 (Weight Loss) and 20 (Somatic Preoccupation). The 
patients who developed ANV were significantly more pessimistic, less satisfied, lost 
more weight, and experienced a larger decline in their libido. 
Table 25. 
Beck Deeression Inventory Individual Item Averages 
Item Number Average All Pats AverageANV Average Non ANV 
1 0.19 0.29 0.15 
2 0.13 0.38 0.05 
3 0.08 0.17 0.05 
4 0.29 0.57 0.20 
5 0.07 0.10 0.07 
6 0.21 0.49 0.13 
7 0.09 0.14 0.07 
8 0.18 0.36 0.13 
9 0.03 0.00 0.04 
10 0.12 0.24 0.08 
11 0.49 0.78 0.39 
12 0.16 0.32 0.10 
13 0.15 0.26 0.11 
14 0.18 0.24 0.16 
15 0.74 1.00 0.66 
16 0.58 0.74 0.54 
17 0.96 1.08 0.92 
18 0.35 0.75 0.22 
19 0.47 0.81 0.37 
20 0.57 0.72 0.52 
21 0.36 0.69 0.25 
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Figure 16. BDI Individual Item Averages 
D) Depression mm Scores 
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The levels of depression reported by the patients in the ANV group, when measured 
using the 10cm visual analogue scale, were significantly higher than the levels of 
depression reported by those in the non-ANV group (t(23)=2.3416, P<0.05). The 
average depression mm score for the ANV group was 17 (SD:17.46), 113% higher than 
the average of 8 (SD:9.50) for the non-ANV group. Table 26 shows that the ANV group 
scored higher on average at five out of the six cycles compared, with significantly higher 
average scores on the second and third cycles. The ANV group scored 1.43 SDs higher 
at cycle two (t(23)=3.0008, P<0.01) and 1.62 SDs higher at cycle three (t(23)=3.0556, 
P<0.01), but only 0.75 standard deviations higher at cycle one (t(21)=1.6738, ns), 0.34 
SDs higher at cycle four (t(22)=1.0512, ns), 0.21 SDs lower at cycle five (t(9)=-0.9941, 
ns) and 0.52 SDs higher at cycle six (t(8)=0.6991, ns). The highest scores on average 
were recorded by those in the ANV group, 120% higher than those of the non-ANV 
group (t(23)=2.7019, P<0.05). The lowest scores on average were recorded by the non-
ANV group, 61 % lower than those of the ANV group (t(23)=1.2192, ns). So, the highest 
scores recorded by the ANV group were significantly higher than the highest scores 
recorded by the non-ANV group, but the two groups did not have significantly different 
low scores. 
Figure 17 shows that the depression mm scores for the non-ANV group were 
relatively stable over time (slope=-0.37) but the scores for the ANV group were quite 
varied and not well represented by a straight line. 
Table 26. 
Depression 10cm Visual Analogue Scale Averages 
All Patients ANV Non-ANV 
Cycle 1 8.70 16.63 (n=6) 7.03 (n=19) 
Cycle 2 11.96 25.83 (n=6) 7.58 (n=19) 
Cycle 3 13.98 29.67 (n=6) 9.03 (n=l9) 
Cycle4 8.40 11.67 (n=6) 7.31 (n=l8) 
Cycle 5 4.32 2.63 (n=4) 5.29 (n=7) 
Cycle 6 8.50 12.50 (n=4) 5.83 (n=6) 
Cycle 7 13.50 * 13.50 (n=2) 
Cycle 8 0.00 * 0.00 (n=l) 
Average 9.89 17.21 7.58 
S.D. 12.76 17.46 9.50 
Highest 19.88 33.92 15.45 
Lowest 2.22 4.08 1.63 
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A) SEEO Totals 
Table 27 and Figure 18 show that those patients who developed ANV did not expect 
to experience significantly more side effects from their chemotherapy than those who 
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Figure 18. Average Total Scores on the Side Effect Expectancy Questionnaire 
B) Nausea and Vomiting Expectancy 
Table 27 and Figure 19 show that the patients who developed ANV generally started 
their chemotherapy expecting to experience nausea and vomiting as a side effect of their 
treatment and that the patients who did not develop ANV generally did not expect to 
nausea and vomiting to be a side effect of their treatment (Nausea:t(20)=2.5424, P<0.05; 
Vomiting:t(20)=2.5885, P<0.05). The results of the SEEQ also show that patients 
usually expected to experience nausea more than they expected vomiting as a side effect 
of their chemotherapy. 
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Table 27. 
Side Effect Exp_ectancy Questionnaire Results 
Patient Total Nausea Vomiting Rated>3 
1 60 4 4 Tiredness, Hairloss, Change in taste/appetite, 
Nausea, Vomiting, Nervousness, Weakness, 
Problems with sex, Constipation 
2 * * * * 
3 36 3 4 Tiredness, Hairloss, Nervousness, Vomiting, Skin 
itching 
4 47 4 4 Weight loss, Nausea, Vomiting, Tiredness, Hair loss, 
Change in taste/appetite, Sleep problems, Chills 
5 59 3 3 Tiredness, Hairloss, Nervousness, Weakness, 
Diarrhoea, Chills 
6 40 3 3 Sleep problems 
7 47 5 4 Nausea, Tiredness, Weakness, Vomiting, Chills 
8 36 3 3 None 
9 41 1 1 Nervousness 
10 44 4 2 Nausea, Tiredness, Weakness 
11 24 2 2 None 
12 35 4 4 Nausea, Vomiting, Change in taste/appetite 
13 16 1 None 
14 49 4 3 Hairloss, Nausea 
15 51 3 3 Tiredness, Hairloss, Change in taste/appetite, 
Nervousness, Pain, Diarrhoea, Sleep problems 
16 16 1 1 None 
17 31 3 1 None 
18 40 3 2 Tiredness 
19 * * * * 
20 50 1 1 Hairloss, Skin itching, Nervousness, Weight loss, 
Sleep problems 
21 46 4 3 Tiredness, Hairloss, Weakness, Nausea 
22 * * * * 
23 55 3 3 Sleep problems, Hairloss, Nervousness, Weight loss, 
Pain, Weakness, Chills 
24 37 2 2 Skin itching 
25 19 4 I Nausea 
26 51 4 2 Tiredness, Nausea, Weakness, Diarrhoea 
All 40.43 (12.71) 3.00 (1.17) 2.48 (1.12) 
ANV 48.60 (7.23) 4.00 (0.71) 3.40 (0.89) 
Non-ANV 38.17 (13.10) 2.72 (1.13) 2.22 (1.06) 














Figure 19. Average Expectation Ratings for the Nausea and Vomiting Items 
110 
There was a high correlation between the SEEQ-Total scores and the expected 
nausea frequency (maximum estimate r=0.71, mean estimate r=0.69) and severity 
(maximum estimate r=0.69, mean estimate r=0.68). This means that the patients with 
the most emetogenic chemotherapy protocols were expecting more side effects from 
their treatment. SEEQ-Nausea scores were reasonably well correlated with anticipatory 
nausea severity (r=0.46) and frequency (r=0.48), as was SEEQ-Vomiting correlated with 
anticipatory nausea severity (r=0.44) and frequency (r=0.49). This shows that the 
patients who were expecting nausea as a side effect of their treatment were also the 




The primary aims of this study were to assess the prevalence of anticipatory nausea 
and vomiting in cancer patients who are receiving their chemotherapy in a setting where 
the new 5-HT3 receptor antagonists are being used for antiemetic therapy, and to identify 
any relationships that may exist between the development of anticipatory symptoms and 
various demographic, clinical and psychological variables. 
Summary of Results 
This study has produced a number of interesting results. The prevalence of 
anticipatory nausea and vomiting in this study is similar to the prevalence rate reported 
in studies where less effective antiemetics have been used. 
The patients who developed ANV reported higher levels of state anxiety, trait anxiety 
and depression than the patients who did not develop ANV. The difference in anxiety 
and depression was more evident prior to the first few chemotherapy cycles. The 
anticipatory patients were expecting nausea and vomiting as a side effect of their 
chemotherapy more than the patients who did not develop ANV. 
The ANV patients were younger than the non-ANV patients; tending to be under 
forty years of age. The anticipatory patients were receiving more emetogenic 
chemotherapy protocols and experienced more frequent and severe posttreatment nausea 
and vomiting than those who did not develop ANV. 
The Prevalence of ANV and the Introduction of 
5-HT3 Receptor Antagonists 
If the introduction of 5-HT3 receptor antagonists has decreased chemotherapy-
induced nausea and vomiting, and the classical conditioning model of acquisition is 
correct, then there should be a decreased incidence of anticipatory nausea and vomiting 
in an environment where 5-HT3 receptor antagonists are provided for patients who are 
likely to experience nausea and vomiting as a side effect of their treatment. The patients 
in this study did receive 5-HT3 receptor antagonists if they were expected to experience 
nausea and vomiting with their chemotherapy, so it follows that the prevalence of ANV 
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in this study should be less than the 20-40% prevalence rate reported in studies where 5-
HT 3 receptor antagonists have not been available (Bernstein, 1991). 
Contrary to this hypothesis, the prevalence rate of ANV for the patients in this study 
was 24% - within the range reported for populations where 5-HT3 receptor antagonists 
have not been used. In fact, all of the patients who developed ANV were given 5-HT3 
receptor antagonists for their nausea and vomiting. Also, there were two patients who 
were not recorded as having anticipatory nausea but who had experienced an 
anticipatory loss of appetite and a general feeling of anxiousness a day or two before 
receiving their chemotherapy, perhaps indicating that they may have been close to 
developing ANV. 
There are a number of possible explanations for the unexpectedly high prevalence 
rate in this study. If the group of patients in this study included an unusually large 
proportion of highly emetogenic protocols then the high prevalence of ANV could have 
been attributed to the biased sample. The protocols used in this study were 
predominantly in the moderate to severe range for their emetogenicity, suggesting that 
this may have some influence on the prevalence of ANV in this sample of patients. The 
prevalence rate of ANV in this study was remarkably similar to the prevalence rate of 
23% reported by Watson et al. (1992), which also contained a large percentage of 
patients receiving moderate to severely emetic chemotherapy regimens. The only 
discernible difference between the current study and the Watson et al. (1992) study is 
the use of 5-HT3 receptor antagonists as the main antiemetics. Therefore, it would seem 
that the introduction of 5-HT3 receptor antagonists has had little effect on the incidence 
of ANV in patients receiving moderate to severely emetic protocols. Additionally, the 
prevalence of anticipatory vomiting in this study and in the Watson et al. (1992) study 
are both 4%. 
Another explanation may be found in the small sample size. Each patient who 
developed ANV added 4% to the prevalence rate, whereas with a larger sample the 
influence of individuals on the overall prevalence rate would have been much less. 
However, even with the prevalence at 24%, the severity of the anticipatory nausea 
and vomiting was considerably lower than in studies where 5-HT3 antagonists have not 
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been used. The average level of anticipatory nausea in this study was 'very mild' whereas 
the average level of nausea and vomiting reported by Dunne et al. ( 1992) was in the 
'moderate' to 'severe' range, using the same measure of nausea and vomiting (MANE) 
but using metoclopramide and prochlorperazine for antiemetic therapy. Also, Boakes 
and colleagues (1993) reported that 24% of their patients experienced 'moderate' to 
'severe' anticipatory nausea. Therefore, it would appear that although the introduction of 
5-HT3 receptor antagonists may not have reduced the incidence of ANV greatly, there 
has been an apparent reduction in the severity of the anticipatory symptoms experienced. 
The Role of Anxiety and Depression in the 
Development of ANV 
STATE ANXIETY 
The results of this study replicate one of the findings which has been consistently 
reported in most research on anticipatory nausea and vomiting - that higher levels of 
state anxiety are present in patients who develop anticipatory nausea and vomiting 
(Morrow & Dobkin, 1988; Andrykowski, 1990). The relationship which exists between 
the development of ANV and the patient's level of state anxiety has often been 
discussed, as to whether the ANV patients are more anxious as a result of experiencing 
more nausea and vomiting (both posttreatment and pretreatment) or whether these 
patients are more anxious right from the start of their chemotherapy. What has been 
demonstrated here is that the ANV patients scored significantly higher than the non-
ANY patients on the ST AI-State anxiety items before their first three cycles of 
chemotherapy but there was no significant difference prior to the fourth, fifth, and sixth 
cycles. On the visual analogue scale for state anxiety, the ANV patients only scored 
significantly higher than the non-ANV patients before their first cycle of chemotherapy. 
However, neither posttreatment nor pretreatment nausea and vomiting reached a peak in 
either group until after the third and fourth cycles of chemotherapy. Therefore, the 
differences in state anxiety levels were present prior to the development of the highest 
levels of posttreatment and pretreatment nausea and vomiting. The level of state anxiety 
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reported by the patients prior to their first cycle of chemotherapy was found to be highly 
correlated with anticipatory nausea severity before their second and third cycles. All of 
these findings suggest that patients who are more anxious before their first few 
chemotherapy cycles, and especially prior to receiving their first treatment, are more 
susceptible to developing anticipatory nausea and vomiting, as well as experiencing 
more posttreatment nausea and vomiting. More evidence for the importance of the first 
few treatments in the development of ANV comes from the observation that state 
anxiety (STAI-S and state mm) decreased over time and this was especially true for the 
ANV patients. This explains why the difference between the two groups decreased to an 
insignificant level, as the ANV patients became less anxious over time but the non-
ANV patients remained relatively stable. This suggests that the ANV patients were 
initially very upset by the chemotherapy process but were less distressed as they became 
accustomed to their treatment; whereas the non-ANV patients did not react as strongly 
to their chemotherapy treatment right from the start. 
A more detailed look at the ST AI-S scores revealed that the ANV group did not score 
significantly higher on all of the twenty items in this self-report questionnaire. The 
patients who developed ANV were feeling less at ease, less relaxed, less secure, less 
steady, less pleasant and less content than the patients who did not develop ANV; and 
were feeling more jittery, more tense, and more confused than the non-ANV patients 
before their chemotherapy cycles began. These results must, however, be treated with 
some caution, as the ST AI was not designed to be analysed item by item in this manner. 
It is possible to perceive that any attempts to make the patient more at ease, more 
relaxed, more secure, more steady, more pleasant, less jittery, less tense, and less 
confused could decrease that patients likelihood of developing ANV and also decrease 
the posttreatment nausea and vomiting as well. The proposed modes of action for the 
psychological treatment of ANV generally support this suggestion - as these treatments 
allow the patient to feel more relaxed, less concerned with their situation, and more in 
control of themselves. The high levels of state anxiety prior to the first few 




Trait anxiety refers to relatively stable individual differences in anxiety proneness, 
that is, to differences between people in the tendency to perceive stressful situations as 
dangerous or threatening and to respond to such situations with elevations in the 
intensity of their state anxiety. The significance of trait anxiety in relation to the 
development of anticipatory nausea and vomiting has not previously shown any 
consistent trend, although whenever there has been a significant relationship it has 
always been that a higher level of trait anxiety is related to an increased incidence of 
ANV (Burish & Carey, 1986). 
This study has shown that higher levels of trait anxiety are evident in patients who 
develop ANV as compared to those who do not develop ANV. There appears to be a 
similar relationship between trait anxiety and the development of ANV as there was 
with state anxiety; so that significantly higher levels of trait anxiety, as measured using 
the STAI, were demonstrated before the first three chemotherapy cycles and that 
significantly higher levels of trait anxiety, as measured using the visual analogue scale, 
were demonstrated prior to the third and four cycles of chemotherapy. Therefore, these 
significantly higher levels of trait anxiety were present before most of the ANV patients 
experienced their first episode of anticipatory nausea or vomiting, and were also present 
before the highest levels of posttreatment nausea and vomiting were reported. Also, high 
levels of trait anxiety being reported prior to the first cycle of chemotherapy correlated 
with a higher level of anticipatory nausea prior to the third and fourth cycles. This 
implies that patients who see themselves as being more prone to perceiving stressful 
situations as dangerous or threatening, and especially feeling this way prior to receiving 
their first cycle of chemotherapy, are more likely to develop ANV. Also, the results 
show that the level of trait anxiety reported by the ANV patients decreased over time 
and that this was greater than the decrease observed in the non-ANV patients. This 
observation also supports the notion of some type of habituation process, so that the 
patient sees him or herself as more reactive before the first few treatment but decreases 
this opinion as their treatment progresses. 
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When the results of the STAI-Trait anxiety questionnaires were analysed in more 
detail, it was revealed that the ANV group did not score significantly higher on all of the 
twenty items. The patients who developed ANV saw themselves as being less 'cool, 
calm and collected', less steady, less secure, and less happy than the patients who did not 
develop ANV; and the ANV patients saw themselves as being more prone to taking 
disappointments keenly and being unable to forget them, and more likely to let 
difficulties pile up to the point where they can not overcome them. Again, these results 
must be viewed cautiously, as the ST AI was not designed to be analysed item by item in 
this manner. 
DEPRESSION 
When depression was measured using the Beck Depression Inventory and the 10cm 
visual analogue scale, both measures revealed that the patients who developed ANV 
were more depressed before their chemotherapy treatments began than the patients who 
did not develop ANV. The total BDI scores for the ANV group were significantly higher 
on the first three chemotherapy cycles, whereas the visual analogue scale had scores 
significantly higher on cycles two and three. When this is compared to the peaks for 
posttreatment and pretreatment nausea and vomiting following cycles three and four, it 
appears that a higher level of depression predisposes a patient to the development of 
anticipatory nausea and vomiting, as well as more frequent and severe posttreatment 
nausea and vomiting. 
The difference in the level of depression is not merely of statistical significance, but 
it is of clinical significance as well. The average level of depression reported by the 
ANV group was in the mild to moderate range, in comparison to an average level of 
depression for the non-ANV in the none to minimal range. Half of the ANV patients had 
average depression scores in the mild to moderate range, whereas only one out of the 
nineteen non-ANV patients had an average score in the mild to moderate range. 
One criticism which might be aimed at this finding is the influence which the 
physiological symptoms in the BDI might have on the scores of the two groups; with the 
possibility that the ANV patients merely experienced more of physiological symptoms 
than the non-ANV patients. However, it was shown that there was not a significant 
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difference between the ANV and non-ANV groups within this subscale of symptoms. 
However, there were two items in the physiological subscale, loss of appetite and loss of 
libido, which were significantly higher in the ANV patients. The largest difference was 
shown to be present in the affective/cognitive items of the BDI - the items which may be 
seen to be more relevant to the detection of depression in medical populations. The 
patients who developed ANV recorded significantly higher BDI-Affective/Cognitive 
subscale scores than the patients who did not develop ANV. Interestingly, there were 
only two items on the affective/cognitive subscale, pessimism and lack of satisfaction, 
which were significantly higher in the ANV patients. 
Expectancy and the Development of ANV 
The patients who experienced ANV displayed higher expectations about 
experiencing nausea and vomiting as a side effect of their chemotherapy. They were not 
generally more expectant about the side effects which might accompany their 
chemotherapy, with the greater expectancy restricted to nausea and vomiting only. There 
are two possible relationships which may exist between this increased expectancy and 
the development of ANV. Firstly, these patients were receiving chemotherapy regimens 
which were more emetogenic than the regimens of those patients who did not develop 
ANV; so their expectations were not unfounded. However, many of the non-ANV 
patients who were also receiving very emetogenic regimens, did not have expectations 
as high as the ANV patients. There is a second relationship which may exist between 
expectancy and ANV, where those patients who are expecting to experience nausea and 
vomiting are likely to experience more nausea and vomiting than those patients who do 
not expect nausea and vomiting, irrespective of the emetogenicity of their 
chemotherapy. 
The relationship between the expectations of the patient and the actual nausea and 
vomiting which occurs raises an interesting debate about the information which is given 
to the patient prior to starting their chemotherapy. In this age of 'informed consent' it 
would not be ethically correct for a patient to start an emetic chemotherapy treatment 
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without being warned about the possibility of experiencing nausea and vomiting as a 
side effect of their treatment. However, it may be beneficial for that patient to start their 
chemotherapy with understated expectations about the probability of them experiencing 
nausea and vomiting. 
Clinical Variables Related to the Development of 
ANV 
There were a number of clinical variables which were found to correlate with the 
development of ANV. The patients who developed ANV were considerably younger 
than the patients who did not develop ANV, with five of the six patients with ANV forty 
or under. This is consistent with much of the previous research in this area, with patients 
under fifty showing an increased incidence of ANV (Morrow & Dobkin, 1988; Burish & 
Carey, 1986). The shift from fifty to forty for the increased incidence may just be a 
result of the age distribution of the subjects in this study or it may indicate that there is a 
reduced incidence of ANV in patients between forty and fifty with the introduction of 
the 5-HT3 receptor antagonists. 
There was no relationship between gender and ANV, as similar percentages of the 
males and females in this study developed ANV. This supports other recent studies, 
which have also found no relationship between gender and the development of ANV 
(Boakes et al., 1993). There has been some suggestion that females report more 
anticipatory symptoms than males (Stefanek et al., 1988) but this was also not supported 
by this study. 
There was also no relationship between ANV and the patients' susceptibility to 
motion sickness. This result challenges previous studies which have found significant 
correlations between a patient's susceptibility to motion sickness and their likelihood of 
developing ANV (Morrow, 1985; Leventhal et al., 1988). The results of this study 
suggest that patients who are susceptible to motion sickness are not any more likely to 
develop ANV than patients who do not suffer from motion sickness, with just over half 
of the ANV group suffering from motion sickness and just under half of the non-ANV 
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group suffering from motion sickness. On the other hand, Leventhal et al. (1988) 
reported that 78% of the patients who reported motion sickness also reported developing 
ANV. Conceivably, it could be that the patients who were susceptible to motion 
sickness had their nausea and vomiting well controlled using 5-HT3 receptor antagonists 
and that this subgroup of patients no longer have an increased risk of developing ANV. 
The emetogenicity of the chemotherapy protocol which the patients received was 
correlated with ANV, so that protocols which were expected to induce more severe and 
frequent nausea and vomiting were also more likely to result in the patient developing 
ANV. Similarly, the patients who actually experienced more severe and frequent nausea 
and vomiting were more likely to develop ANV. The patients who did not develop ANV 
experienced posttreatment nausea after 56% of their chemotherapy infusions, whereas 
the patients with ANV experienced posttreatment nausea after 93% of their 
chemotherapy infusions. Likewise, the non-ANV patients experienced posttreatment 
vomiting after 23% of their infusions, whereas the ANV patients experienced 
posttreatment vomiting after 69% of their chemotherapy infusions. In addition, the non-
ANV patients rated the posttreatment nausea as 'very mild' on average, while the ANV 
patients rated their posttreatment nausea as 'moderate' on average. Similarly, the non-
ANV patients rated their posttreatment vomiting as less than 'very mild' on average and 
the patients who developed ANV rated their posttreatment vomiting as 'mild' on 
average. All of these findings are supported by previous research which has found a 
positive correlation between posttreatment nausea and vomiting, both frequency and 
severity, and the development of anticipatory nausea and vomiting (Watson et al., 1992; 
Kvale et al., 1991; Andrykowski & Redd, 1987; Cohen et al., 1986). 
The severity and frequency of posttreatment nausea and vomiting reported in this 
study can be compared to the prevalence rates of posttreatment nausea and vomiting 
reported in other studies where 5-HT3 receptor antagonists have not been used. 
Leventhal et al. ( 1986) reported that 86% of the patients in their study experienced 
posttreatment nausea and 47% experienced posttreatment vomiting, Lindley et al. 
(1989) reported that 50% of their sample of outpatients experienced posttreatment 
nausea and 27% experienced posttreatment vomiting, and Lindley and Hirsch (1992) 
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reported that over 90% of patients receiving high dose cisplatin experience some degree 
of nausea and/or vomiting. Therefore, the non-ANY patients experienced less nausea 
and vomiting than would generally be expected without the use of 5-HT3 receptor 
antagonists but the patients who did develop ANY experienced more posttreatment 
nausea and vomiting than would have been expected when 5-HT3 receptor antagonists 
were not used. This suggests that the patients who develop ANY are not benefiting as 
much as other patients from the use of these new and normally highly effective 
antiemetics. This is not to say that the introduction of 5-HT3 receptor antagonists has not 
helped these patients at all, as the severity of anticipatory nausea and vomiting in this 
study was considerably lower than in studies where 5-HT3 receptor antagonists have not 
been used. 
The Profile of a Patient Likely to Develop ANV 
If it is possible to identify specific clinical, demographic and psychological 
characteristics which predispose a patient to developing ANY then it should be possible 
to identify those at risk prior to starting their chemotherapy and provide them with the 
most effective antiemetics available (currently the 5-HT3 receptor antagonists), and also 
give them the option of learning techniques such as progressive muscle relaxation 
training which have been shown to reduce and/or prevent ANY in the past (Morrow & 
Dobkin, 1988). 
This study has essentially replicated the findings of other researchers, but in a New 
Zealand environment where the use of the new 5-HT3 receptor antagonists for the 
control of chemotherapy-induced nausea and vomiting was widespread. Using relatively 
quick and easy to administer questionnaires, such as the STAI, BDI and MANE, it has 
been possible to show significant differences in various characteristics between those 
patients who developed ANY and those patients who did not develop ANY. 
From the results of this study, and by synthesising these results with previous 
research findings, it is possible to put together a profile of a patient who is at risk of 
developing ANY. The patient could be male or female, under forty (or maybe fifty) 
years of age, and receiving a moderately or highly emetic chemotherapy protocol -
especially one containing cisplatin, adriamycin, dacarbazine or high-dose 
cyclophosphamide. 
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The psychological profile of the patient who is at risk of developing ANV is of a 
person who responds to stressful and threatening situations with relatively high levels of 
anxiety, as supported by other research on the relationship between anxiety and ANV 
(Andrykowski, 1990). If this person is also suffering from depression at the time of their 
treatment then they may also have a higher chance of developing ANV, although the 
relationship between depression and ANV has not been consistently reported. A person 
with high expectations about the possibility of experiencing nausea and vomiting as a 
side effect of their chemotherapy could also be more likely to develop ANV. This 
relationship was not particularly strong in this study, although this relationship between 
expectancy and ANV has been reported previously (Andrykowski & Redd, 1987). 
After receiving the first cycle of chemotherapy it is possible to identify other factors 
which put the patient at risk of developing ANV. Moderate to severe posttreatment 
nausea and vomiting after the first cycle of chemotherapy is a good indicator for the 
development of ANY and also of a continuing problem with emetic control. As already 
discussed, there is a general consensus about the relationship between posttreatment 
nausea and vomiting and the development of ANV (Morrow & Dobkin, 1988). 
Support for Which Model of Acquisition? 
Although it was not the aim of this study to provide support for any of the models of 
acquisition discussed in the introduction, the results do lend some support to the anxiety 
model, the autonomic reactivity model and especially strong support is provided for the 
learned model. 
Support for the anxiety model is provided by the observation that there were higher 
levels of state and trait anxiety in the patients who developed ANV, and that these 
differences were more apparent before the development of ANV. This is consistent with 
Andrykowski et al. ( 1985) who reported higher levels of state anxiety before the 
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occurrence of ANV. However, it seems paradoxical that the level of anxiety decreases 
as the incidence of ANV increases. 
This same observation may also provide evidence for the autonomic reactivity model, 
which suggests that people who are more reactive to external and internal stimuli 
develop conditioned responses more easily than people who are less reactive (Kvale et 
al., 1991; Ohman & Bohlin, 1973). According to the three-systems model of fear 
(Hugdahl, 1981; Lang, 1968; Rachman, 1977), anxiety is not an entity, but a set of 
loosely coupled components of self-reports, autonomic reactivity, and overt avoidance 
behaviour. Therefore, assuming that trait anxiety and state anxiety (in a stressful 
situation, such as before chemotherapy) are related to the autonomic reactivity of these 
patients in some way, then the increased levels of trait and state anxiety in the ANV 
patients may be consistent with this model. 
The majority of the support is provided for the learning model, which applies the 
laws of classical conditioning to the development of ANV. Firstly, the course of 
development fits the classical conditioning model, in that for all but one patient, who 
had experienced nausea and vomiting in response to radiotherapy a few years prior, 
anticipatory nausea did not develop until after at least two cycles of chemotherapy. Also, 
the ANV typically started out being very mild but increased over time in most of the 
patients with ANV. Under the classical conditioning paradigm, it takes a number of 
presentations of the unconditioned stimulus (chemotherapy) with the conditionable 
stimulus (any stimuli associated with chemotherapy) for the conditioning to take place 
and the strength of the conditioned response (ANV) increases with the number of 
conditioning trials (chemotherapy cycles). 
The anticipatory nausea experienced was highly correlated with the level of 
posttreatment nausea and there were no patients with ANV who had not experienced 
nausea and/or vomiting prior to the development of ANV; including the patient who had 
ANV before her first cycle, as she had experienced nausea and vomiting during a 
previous treatment for her cancer. This fits the classical conditioning model, which 
states that the conditioned response (ANV) closely resembles the unconditioned 
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response (posttreatment nausea and vomiting) and that conditioning will never occur in 
the absence of an unconditioned response (posttreatment nausea and vomiting). 
Furthermore, the increased incidence of ANV in those patients who experienced 
more frequent and severe posttreatment nausea and vomiting provides support for the 
classical conditioning model in that a more intense unconditioned response 
(posttreatment nausea and vomiting) enables the conditioned response (ANV) to be 
established more easily. 
The higher incidence of ANV in younger patients can also be explained using the 
classical conditioning model, in that more novel stimuli are more easily conditioned and 
it may be that the chemotherapy setting (i.e., hospital, doctors, needles, etc) is likely to 
contain more novel stimuli for younger patients, who are less likely to have come across 
these stimuli in the past. Another explanation for the higher incidence in younger 
patients, which also supports the learned model, is that younger patients may be more 
likely to receive more emetic chemotherapy protocols (unconditioned stimuli) than older 
patients and so will be more likely to experience more severe posttreatment nausea and 
vomiting (unconditioned responses). Under the classical conditioning model, the 
stronger unconditioned responses (posttreatment nausea and vomiting) make the 
acquisition of a conditioned response (anticipatory nausea and vomiting) more likely. 
The increased anxiety in the ANV patients may also be supportive of the classical 
conditioning model as it has been suggested that increased anxiety is related to increased 
conditionability (Jacobsen et al., 1993). 
However, there was an observation which challenges the application of the learning 
model to the development of ANV. There was no perceivable change in the 
environment in which the patient received his or her chemotherapy but they did not 
always experience ANV once it had occurred the first time. The chemotherapy was 
usually given in the same room, by the same people, and usually at around the same 
time of the day; yet this conditioned response (ANV) did not occur consistently in 
response to the chemotherapy environment - only occurring before about half of the 
ANY patients' chemotherapy cycles. 
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Putting ANV in Perspective 
There seems to be little argument about nausea and vomiting being the most 
traumatic side effect of chemotherapy. It would follow, therefore, that any increase in 
this nausea and vomiting may have wide ranging implications for the welfare of the 
patient undergoing chemotherapy. When the nausea and vomiting resulting from 
chemotherapy becomes too severe, the patient may require hospitalisation, they may 
require a reduction in the doses of his or her chemotherapy drugs, they may need longer 
intervals between treatments to recover, or they may even refuse further treatment. Any 
of these consequences are potentially life-threatening, so any outcome which increases 
the frequency and/or severity of nausea and vomiting in patients receiving 
chemotherapy, such as ANV, is of great concern to all those involved. 
Anticipatory nausea and vomiting seldom reaches levels which would affect the 
continued treatment of a patient, with the majority of the ANV patients in this study 
never having an episode of anticipatory nausea or vomiting above the 'moderate' level. 
Consequently, ANV is viewed by some cancer specialists as trivial and not of any major 
concern (Stefanek et al., 1988). However, the patients who develop ANV are noticeably 
distressed by the whole process of their treatment and any increase in their discomfort is 
of major concern to them and to many health professionals. So, although there may only 
be a small percentage of patients who develop ANV it is important that there be some 
additional support services available for these patients. 
In providing these extra services there may be both short and long-term benefits for 
the patients and the overall financial cost of their treatment. The ability of some 
psychological treatments to reduce both anticipatory and posttreatment nausea and 
vomiting may prevent a patient from having to be hospitalised during his or her 
chemotherapy, may reduce the quantity of expensive antiemetic drugs needed to control 
his or her nausea and vomiting, may decrease the number of times that patient comes in 
between treatments for additional consultations, and should generally make their 
experience with chemotherapy less traumatic. Therefore, the benefits of providing these 
extra services may greatly outweigh any expense involved. 
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Limitations of Current Research 
The major limitation of this study is that the small number of patients makes any 
statistical analysis less powerful and open to criticism. However, the small size of the 
sample has enabled a much more detailed assessment and analysis to be done. Each 
patient was followed through his or her chemotherapy by the same investigator, enabling 
the development of a good rapport for the exchange of information - which is difficult 
when there are a large number of patients in a study. The results which have been 
obtained here, may therefore be more accurate than in a study where the patient has little 
contact with the investigator or where they are interviewed by different investigators 
over the duration of the study. 
This study also contained a large proportion of patients receiving moderate to 
severely emetic chemotherapy regimens. Therefore, any application of these results to a 
general chemotherapy population is limited. This is not of any great significance, as it is 
the patients who are receiving these more emetic protocols who are of interest in a study 
on anticipatory nausea and vomiting. The inclusion of patients receiving mildly emetic 
regimens is not necessary, and in the future it may be more helpful to state separate 
prevalence rates for those receiving highly emetic chemotherapy regimens, moderately 
emetic regimens, and mildly emetic regimens. Also, the sample is fairly representative 
of the population of chemotherapy patients treated at the Christchurch Hospital 
Oncology Centre during the time of the study as a high percentage of the new 
chemotherapy patients treated during that time were included in the analysis. 
Another limitation is that this sample of patients consisted only of adult oncology 
patients, with all patients under eighteen being excluded. Therefore, the actual 
prevalence of ANV may be higher among all chemotherapy patients, as it has been 
consistently shown that younger patients experience more anticipatory symptoms than 
older patients. 
The results of the study may also have been affected by the use of progressive muscle 
relaxation training (PMRT) by two of the patients who did not develop ANV and one 
patient who did have ANV. It is possible that the use of PMRT may have prevented 
these two patients from developing ANV and may have reduced the severity and 
frequency of ANV in the other patient. 
Future Research 
There are many questions related to the development of anticipatory nausea and 
vomiting which remain unanswered and which deserve some attention in future 
research. 
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Given that this is one of the first studies on ANV in which 5-HT3 receptor antagonists 
have been used in the majority of patients, there is a need for replications of this study to 
confirm whether the prevalence of ANV has remained constant despite the introduction 
of these highly effective antiemetics or if there has been a decrease in the prevalence 
which the small number of patients in this study was unable to detect. Confirmation is 
also needed for the observation that the severity of anticipatory nausea and vomiting has 
decreased with the introduction of these new antiemetics. 
There needs to be more research into the relationship between anxiety and ANV, 
especially with an aim towards finding ways to predict the development of ANV by 
measuring anxiety levels before starting chemotherapy. There have been no studies to 
date which have reported a decrease in anxiety over time in patients with ANV as was 
shown in this study, so more research is needed to determine if this is a consistent 
phenomenon. 
The relationship between expectancy and ANV is one which has not been examined 
in great detail as yet. Research into the effects of providing patients with different 
expectations, irrespective of the emetogenicity of their chemotherapy, should help to 
clarify the relationship between a patients expectations of experiencing nausea and 
vomiting and the actual occurrence of nausea and vomiting. 
The low prevalence of ANV in patients between forty and fifty suggests that there 
has been a shift in the age of susceptibility from under fifty to under forty. More 
research in settings where 5-HT3 receptor antagonists are used would be helpful in 
determining the accuracy of this hypothesis. 
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This study's inability to confirm that patients who are susceptible to motion sickness 
are more likely to develop ANV may indicate that these patients are no longer at greater 
risk of developing ANV with the introduction of the 5-HT3 receptor antagonists. 
Replications of this study should confirm or deny this hypothesis. 
Most importantly, there is a great deal which can be done to reduce or prevent ANV 
using various psychological treatment methods, but there is no current consensus about 
which treatment modalities work most effectively and efficiently. Therefore, there is a 
need for research which compares the effectiveness of various treatment methods and 
the cost involved in providing these services, both with patients who already have ANV 




The main conclusion to come from this study is that the prevalence of anticipatory 
nausea and vomiting has not been dramatically reduced with the introduction of 5-HT3 
receptor antagonists as the mainstay of antiemetic treatment. Indeed, it appears that 
ANV still occurs in approximately one quarter of patients receiving chemotherapy. 
However, there is a strong indication that the severity of the anticipatory nausea and 
vomiting has been reduced substantially. 
Another major finding is the relationship between state anxiety, trait anxiety and the 
development of ANV. Patients who are more anxious at the start of their chemotherapy 
are more likely to develop nausea and vomiting, and this is true for both state and trait 
anxiety. Similarly, patients who are more depressed at the start of their treatment are 
also more likely to develop ANV. It seems that the difference between the ANV patients 
and non-ANV patients decreases over time with respect to anxiety and depression 
levels, further implicating the importance of the first few chemotherapy cycles in the 
subsequent development of ANV. 
The patients' expectations about the occurrence of nausea and vomiting as a side 
effect of their chemotherapy also seem to influence the development of ANV. Patients 
who are more expectant of nausea and vomiting are more likely to develop ANV and 
also more likely to experience more severe posttreatmcnt nausea and vomiting. 
Younger patients have an increased risk of developing ANV and it seems that 
patients under forty are particularly susceptible. More emetogenic chemotherapy 
protocols also put a patient at risk of developing ANV, as well as patients who 
experience more severe posttreatment nausea and vomiting. 
The results tend to provide the most support for the learned model of acquisition, 
following the classical conditioning model's guidelines for the course of development; 
including the relationship between the conditioned response (ANV) and unconditioned 
response (posttreatment nausea and vomiting), the intensity of unconditioned response 
(posttreatment nausea and vomiting) and ease of acquisition, anxiety and 
conditionability, and novel stimuli being more easily conditioned. 
Finally, it does seem possible to identify patients at risk of developing ANV before, 
or soon after, they start their chemotherapy and providing additional support services for 
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these patients may considerably reduce the likelihood of them developing ANV during 
their chemotherapy. Furthermore, this extra support may produce other benefits which 
greatly outweigh the cost of providing these services. 
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Chemotherapy Emetogenicity Questionnaire 
Chemotherapy Drug Toxicity: 
This questionnaire has been designed to assess the perceived toxicity ( emetogenicity) 
of the chemotherapy drugs currently being used for the treatment of cancer. Estimates of 
how frequent and severe the episodes of vomiting are with these drugs is required. Each 
drug is being assessed individually despite the fact that they are often given in 
combination with each other. Any comments about specific drugs or any general 
comments you wish to make can be written in the available space below. The results 
from this questionnaire will be used in the Anticipatory Nausea and Vomiting study 
which is currently being conducted. It would be appreciated if you could complete this 
questionnaire and return it to Robert McNeill in Clinic 4 of the Oncology Department. 
Comments: 
151 
Position held: Doctor I Nurse / Radiographer (Circle one) 
How long have you worked in oncology?: Years Months 
Please circle the appropriate numbers which you think correspond to both the 
frequency and severity of vomiting elicited by the following chemotherapy drugs. If you 
are unsure about a drug leave it blank. 
Freguency: Severity: 
O=Never induces vomiting. l=Mild 
l=Rarely induces vomiting. 2=Moderate 
2=Induces vomiting about half the time. 3=Severe 
3=Frequently induces vomiting. 
4=Always induces vomiting. 
5-Fluorouracil 0 1 2 3 4 1 2 3 
Folinic Acid 0 1 2 3 4 1 2 3 
Adriamycin 0 1 2 3 4 1 2 3 
BCNU 0 1 2 3 4 1 2 3 
Cyclophosphamide 0 1 2 3 4 1 2 3 
Melphalan 0 1 2 3 4 1 2 3 
Bleomycin 0 1 2 3 4 1 2 3 
Vinblastine 0 1 2 3 4 1 2 3 
Dacarbazine (DTIC) 0 1 2 3 4 1 2 3 
Cisplatin 0 1 2 3 4 1 2 3 
Etoposide 0 1 2 3 4 1 2 3 
Prednisone 0 1 2 3 4 1 2 3 
Carboplatin (JM8) 0 1 2 3 4 1 2 3 
Lomustine (CCNU) 0 1 2 3 4 1 2 3 
Chlorambucil 0 1 2 3 4 1 2 3 
Procarbazine 0 1 2 3 4 1 2 3 
Methotrexate 0 1 2 3 4 1 2 3 
Vincristine 0 1 2 3 4 1 2 3 
Actinomycin D 0 1 2 3 4 1 2 3 
Ifosfamide 0 1 2 3 4 1 2 3 
Mesna 0 1 2 3 4 1 2 3 
Mustine 0 1 2 3 4 1 2 3 
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There are two aims of this project: Firstly, to determine the efficacy of ondansetron in 
the prevention and treatment of anticipatory nausea and vomiting; and secondly, to 
compare the frequency of anticipatory nausea and vomiting in patients who have good 
or bad control of their sickness. 
Background: 
The nausea and vomiting that accompanies chemotherapy occurs in two different 
contexts; before the chemotherapy drugs are administered (anticipatory nausea and 
vomiting, ANV), and during or after the drugs have been administered (posttreatment 
nausea and vomiting, PNV). Various things seem to make people more likely to 
experience nausea and vomiting, including being younger, higher doses of 
chemotherapy, the kind of drugs given, and also how they are feeling and their life 
situation. The recent introduction of ondansetron antiemetic therapy has produced a lot 
of studies which indicate that this new drug is very effective in reducing posttreatment 
nausea and vomiting without many of the side effects that accompany most other 
antiemetics. However, it has not yet been established whether ondansetron affects 
anticipatory nausea and vomiting. 
Patients Eligible to Participate: 
Patients must be older than 17 years, be receiving intravenous chemotherapy, have 
had no other chemotherapy in the past and be able to give consent. 
Patients are not eligible if they have pre-existing nausea and/or vomiting due to brain 
metastases or gastrointestinal involvement by cancer. 
Outline of Study: 
After deciding they wish to participate and signing the informed consent form the 
patients will be divided into two antiemetic groups depending on whether their doctor 
prescribes metoclopramide (maxolon) or ondansetron for their first course of 
chemotherapy. Patients who receive maxolon for their first treatment and experience 
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severe posttreatment nausea and vomiting (>5 emetic incidences/day) will usually be 
transferred to ondansetron for their next chemotherapy treatment. Some patients may 
also be prescribed dexamethasone as well as ondansetron if their nausea and vomiting is 
severe. Patients will be followed for at least four cycles of chemotherapy. Some patients 
may develop anticipatory nausea and vomiting. If this occurs they will be offered a 
relaxation therapy called progressive muscle relaxation training (PRT) which may help 
the patient with his/her nausea and vomiting. 
The patients in the study will be interviewed before their first chemotherapy 
treatment and with each subsequent course, to check things which might influence their 
nausea and vomiting. In addition, patients will be asked to complete an assessment of 
their nausea and vomiting after the cycle is completed. 
Progressive Muscle Relaxation Training: 
Patients who experience anticipatory nausea and vomiting will be offered training in 
progressive muscle relaxation. In addition, other patients will be able to have this 
training if they wish to. This procedure consists of learning to tense and then relax 
various muscle groups throughout the body, while at the same time paying very close 
attention to the feelings associated with both tension and relaxation. In addition to 
focusing on tension and relaxation in the various muscle groups, it helps the patient to 
learn to recognise tension as it occurs in various situations. The procedure has two basic 
objectives: first, to help the patient become aware of tension levels before they are so 
high that they cause problems or discomfort; and second, to be able to reduce tension 
completely and on their own. Progressive relaxation training has been used to 
successfully treat anticipatory nausea and vomiting in the past and has also been used to 
treat a variety of other problems such as insomnia and anxiety. 
Inconveniences: 
The interviews should take no longer than 20 minutes, except the first interview 
which may take up to 30 minutes. It will take approximately 5 minutes to complete the 
nausea and vomiting assessment questionnaire after each cycle is completed. Those who 
attend the progressive relaxation training sessions will find the first session takes about 
30 minutes but the subsequent sessions take only about 20 minutes. 
Benefits: 
Patients will benefit from close attention to their nausea and vomiting, and those who 
develop anticipatory nausea and vomiting will be able to have progressive relaxation 
training, not formerly available in the Oncology Department. 
Confidentiality: 
Patients' names will not appear on any data sheets, interview sheets or in any 
publications - all patients will be numbered and this number will appear in place of their 
name. We hope the study results will be able to be analysed and presented as a paper or 
published. 
Compensation: 
Patients will be covered for any injuries associated with participating in this study by 
the Depaitment of Health. 
Informed Consent: 
You will be told about this study and given this information sheet at the same time 
that you are learning about the need for chemotherapy for your cancer. You will be 
given the opportunity to discuss both your chemotherapy and this study with a doctor or 
other person of your choice and to have all your questions answered by your doctor. 
Unless the patient objects, their general practitioner will be notified about their 
chemotherapy, its likely side effects and their participation in this study. 
You are free to decline to participate, without giving reasons, and to withdraw your 
consent at any time. In either case, you will receive the best antiemetic medication, and 
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will not prejudice your ongoing medical care. Furthermore, your doctor may recommend 
you withdraw from the trial if it is no longer in your best interest to continue. If you 
agree to participate you need to sign the attached consent form. 
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APPENDIX 3. 
Progressive Muscle Relaxation Training Patient Results 
Table 28 shows that this patient O 17 never developed anticipatory nausea and 
vomiting. This patient received training before her first two cycles and then stopped 
PMRT due to a neck injury which made the exercises uncomfortable. Figure 21 shows 
that the worst posttreatment nausea that she experienced was 'moderate' following cycle 
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53 40 40 
39 35 35 
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4 2 3 
0 6 26 
2 2 2 
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Figure 20. Patient 017 - Posttreatment Nausea and Vomiting 
6 
156 
Patient 007 received progressive muscle relaxation training before starting her fourth 
cycle of chemotherapy and was shown through the procedure before three consecutive 
cycles. Figure 22 and Table 29 show that this patient experienced 'severe' anticipatory 
nausea prior to receiving her fourth cycle of chemotherapy and after that there were no 
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1a lb 2a 2b 3a 3b 4a 4b Sa Sb 
No No No No No No Yes Yes Yes No 
60 29 35 20 49 33 22 23 25 26 
60 51 62 45 40 56 32 37 27 25 
82 11 21 0 2 31 9 3 12 14 
69 48 59 61 43 66 33 34 46 32 
22 9 19 12 3 14 2 3 0 0 
12 6 7 3 0 4 0 1 0 0 
10 3 12 9 3 10 2 2 0 0 
17 12 26 0 2 2 0 2 0 l 
5 5 2 5 6 5 4 4 0 3 
5 2 0 0 5 0 0 0 0 0 
0 0 0 2 3 3 4 0 0 0 
0 0 0 0 0 0 0 0 0 0 
la lb 2a 2b 3a 3b 4a 4b Sa Sb 6a 6b 
Cycle Nmroer 
i~PN -11-PV ---ANI 
















Patient 020 was shown the PMRT procedure before his first two chemotherapy 
cycles. Figure 23 and Table 30 show that this patient never developed any anticipatory 
symptoms and never experienced any posttreatment nausea above the 'moderate' level, 
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2a 2b 3a 3b 
No No No No 
30 28 32 35 
28 30 28 28 
2 6 8 10 
4 0 2 10 
3 2 3 3 
3 2 3 2 
0 0 0 1 
3 0 3 0 
3 3 0 0 
0 0 0 0 
0 0 0 0 
0 0 0 0 
2a 2b 3a 3b 4a 
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Side Effect Expectancy Questionnaire 
Patient No.: Date: ----- ---------
Here is a list of side effects that some patients have with some chemotherapies. For 
each side effect, please circle one number that best indicates your feelings. 
Nausea I am certain I am certain 
I will not 1 2 3 4 5 Iwill 
have this have this 
Vomiting I am certain I am certain 
I will not 1 2 3 4 5 Iwill 
have this have this 
Feeling tired I am certain I am certain 
I will not 1 2 3 4 5 Iwill 
have this have this 
Hair loss I am certain I am certain 
I will not 1 2 3 4 5 Iwill 
have this have this 
Nervousness I am certain I am certain 
I will not 1 2 3 4 5 Iwill 
have this have this 
Change in taste I am certain I am certain 
or appetite I will not 1 2 3 4 5 Iwill 
have this have this 
Weight loss I am certain I am certain 
I will not 1 2 3 4 5 Iwill 
have this have this 
Weight gain I am certain I am certain 
I will not 1 2 3 4 5 Iwill 
have this have this 
Skin itching I am certain I am certain 
I will not 1 2 3 4 5 lwill 
have this have this 
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Pain I am certain I am certain 
I will not 1 2 3 4 5 I will 
have this have this 
Weakness I am certain I am certain 
I will not 1 2 3 4 5 I will 
have this have this 
Diarrhoea I am certain I am certain 
I will not 1 2 3 4 5 !will 
have this have this 
Sleep problems I am certain I am certain 
I will not 1 2 3 4 5 Iwill 
have this have this 
Chills I am certain I am certain 
I will not 1 2 3 4 5 I will 
have this have this 
Problems with sex I am certain I am certain 
I will not 1 2 3 4 5 I will 
have this have this 
Constipation I am certain I am certain 
I will not 1 2 3 4 5 !will 
have this have this 
Do you suffer from motion sickness (Car, Boat, Plane, Train etc.) ? 




State Anxiety, Trait Anxiety, and Depression 10cm Visual Analogue Scales 
Patient No.: Date: ---- -----
Are you feeling anxious at the moment? 
Notatall ------------------- Very 
Anxious Anxious 
Are you an anxious person generally? 
Notatall ------------------- Very 
Anxious Anxious 
Are you feeling depressed? 






Patient Chemotherapy Protocol 
1 Day 1: Adriamycin 50mg IV; Day 2: Adriamycin 60mg IV 
2 Day 1: Cyclophosphamide 1000mg IV, Methotrexate 70mg IV, 5-FU 1000mg IV 
3 Day 1: Cyclophosphamide 1500mg IV, Etoposide 200mg IV, Vincristine 2mg IV; Day 2: 
Etoposide 200mg IV; Days 3-6: Prednisone 60mg PO 
4 Day 1: Cyclophosphamide lOmg/kg IV, Adriamycin lmg/kg IV; Days 2-5: Prednisone 
lmg/kgPO 
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5 Day 1: Cyclophosphamide 750mg/m' IV, Adriamycin 50mg/m' IV, Vincristine l.4mg/m' IV; 
Days 2-5: Prednisone 40mg PO 
6 Day 1: Cyclophosphamide 750mg/m' IV, Adriamycin 50mg/m' IV, Vincristine l.4mg/m' IV, 
Methotrexate 12.5mg IT; Days 2-5: Prednisone 40mg PO 
7 Day 1: Adriamycin 25mg/m' IV, Bleomycin lOmg/m' IV, Vinblastine 6mg/m' IV, 
Dacarbazine 375mg/m' IV 
8 Day l: Carboplatin 670mg IV 
9 Day 1: Carboplatin 650mg IV 
10 Cycle 1: Daily 5-FU* 450mg/m' IV for 5 days, then six months of: Weekly 5-FU 450mg/m' 
IV + Fortnightly Levamisole 50mg PO 
11 Day 1: Cyclophosphamide 1000mg IV, Methotrexate 70mg IV, 5-FU 1000mg IV 
12 Day 1: Cyclophosphamide 1000mg IV 
13 Cycle 1: Daily 5-FU 450mg/m' IV for 5 days, then six months of: Weekly 5-FU* 450mg/m' 
IV + Fortnightly Levamisole 50mg PO 
14 Day 1-2: Cisplatin 50mg/m' IV; Days 1-3: Etoposide 120mg/m' IV; Day 3: Bleomycin 30mg 
IV 
15 Day 1-2: Cisplatin 50mg/m' IV; Days 1-3: Etoposide 120mg/m' IV; Day 3: Bleomycin 30mg 
IV 
16 Cycle 1: Daily 5-FU 450mg/m' IV for 5 days, then six months of: Weekly 5-FU* 450mg/m' 
IV + Fortnightly Levamisole 50mg PO 
17 Day 1: Cyclophosphamide 600mg/m' IV, Methotrexate 40mg/m' IV, 5-FU 600mg/m'IV 
18 Day 1-2: Cisplatin 50mg/m' IV; Days 1-3: Etoposide 120mg/m' IV; Day 3: Bleomycin 30mg 
IV 
19 Chlorambucil 6mg/m' PO, Vinblastine 6mg/m2 IV, Procarbazine lOOmg/m' PO, Prednisone 
40mg/m2 PO 
20 Day 1: Adriamycin 25mg/m' IV, Bleomycin lOmg/m' IV, Vinblastine 6mg/m2 IV, 
Dacarbazine 375mg/m' IV 
21 Day 1-2: Cisplatin 50mg/m' IV; Days 1-3: Etoposide l20mg/m' IV; Day 3: Bleomycin 30mg 
IV 
22 Day 1: Cyclophosphamide 1000mg IV 
23 Day 1: Adriamycin 25mg/m' IV, Bleomycin lOmg/m' IV, Vinblastine 6mg/m' IV, 
Dacarbazine 375mg/m' IV 
24 Day 1: Cyclophosphamide 750mg/m' IV, Adriamycin 50mg/m' IV, Vincristine l.4mg/m' IV, 
Methotrexate 12.5mg IT; Days 2-5: Prednisone 40mg PO 
25 Cycle 1: Daily 5-FU 450mg/m' IV for 5 days, then six months of: Weekly 5-FU* 450mg/m' 
IV + Fortnightly Levamisole 50mg PO 
26 Day 1: Cyclophosphamide 600mg/m' IV, Methotrexate 40mg/m' IV, 5-FU 600mg/m' IV 
